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 Three decades have passed since the discovery of HIV and still no viable vaccine 
technologies exist to prevent the spread of the virus. The concept of interrupting HIV 
transmission with oral or topical antiretroviral drugs (ARV), also known as pre-exposure 
prophylaxis (PrEP), has been proven in several clinical efficacy trials. One PrEP strategy 
has been to formulate the ARV tenofovir (TFV) into topically applied vaginal gels. 
However, the vaginal gel approach has met with mixed results, likely due to poor user 
adherence. Globally, high incidence of HIV infection correlates with high incidence of 
unintended pregnancy, especially in resource-poor regions. Combining HIV PrEP with 
contraception into a single, easy-to-use product could have a synergistic effect, further 
motivating women to protect themselves against HIV infection. Thus, a concerted effort 
is underway to develop long-acting multipurpose prevention technologies (MPT) capable 
of simultaneously preventing sexual HIV transmission and pregnancy.  
 The nearly half-century-old technology of the intravaginal ring (IVR) has 
undergone a renaissance in the past decade due to the potential of IVR to leverage both 
the principles of topical HIV PrEP and of long-acting controlled drug release systems. 
This dissertation details several new observations and innovations regarding drug 
delivery from intravaginal rings (IVR). First, an injection-molded, hydrophilic poly(ether 
urethane) (HPEU) matrix IVR capable of sustained release of milligram-per-day 
quantities of TFV over 90 days is described. In the final two chapters, a second-
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generation reservoir TFV IVR is combined with a reservoir poly(ether urethane) segment 
that releases microdoses of the contraceptive progestin levonorgestrel (LNG), in a 
multisegment IVR design, concluding with assessments of product stability and in vivo 
pharmacokinetics in order to confirm the suitability of the IVR for clinical investigation. 
This dissertation represents an engineer's approach to designing and testing IVR, which 
are most commonly considered a pharmaceutical product rather than a medical device. 
Accordingly, much attention is given to the development and usage of mathematical 
models for drug release and mechanical properties from IVR, and in general to a 
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1.1 HIV/AIDS Pandemic and ARV Therapy 
 The human immunodeficiency virus (HIV) was clinically identified as the 
causative agent of acquired immunodeficiency syndrome (AIDS) in 1983. Primarily by 
sexual transmission, HIV propagated rapidly both in the developed and developing 
world, eventually resulting in the classification of HIV/AIDS as a global pandemic.  HIV 
is a retrovirus that causes a loss in cell-mediated immunity by attacking CD4+ T cells. 
The virus is notoriously difficult to eradicate from the body due to its high genetic 
variability and highly glycosylated envelope that protects genetically conserved receptor 
sites [1], as well as its ability to lie latent in cellular reservoirs [2]. Three decades 
following its discovery, no efficacious vaccine strategies have been identified to prevent 
infection. The WHO estimates that approximately 70 million people have been infected 
with HIV since the beginning of the epidemic, half of whom (35 million) have died due 
to AIDS-related complications. 
 Through the diligent use of antiretroviral (ARV) drug therapy, HIV infection is no 
longer universally fatal. Over two dozen ARV drugs have been approved by the FDA to 
date [3]. ARV are generally classified by their mechanisms of action, with reverse 
transcriptase inhibitors (RTI) being among the earliest and most common. These RTI act 
by inhibiting HIV reverse transcriptase (RT) and preventing DNA transcription of the 
viral RNA genome. RTI are further subdivided into three main categories: nucleoside 
analogs (NRTI), nucleotide analogs (NtRTI), and nonnucleosides (NNRTI). NtRTI and 
NRTI are phosphorylated two or three times intracellularly, respectively, to their active 
forms which compete with deoxyribonucleotide triphosphate binding to prevent 
transcription of the viral genome [4]. In contrast, NNRTI are delivered in their active 





dissertation will focus on RTI, there are several other classes of ARV utilized for HIV 
treatment, including protease inhibitors, integrase inhibitors, and cell entry inhibitors. 
Even with the advent of ARV therapy, HIV/AIDS remains a global pandemic, with 35 
million living with HIV infection, 2.3 million new infections per year, and 1.6 million 
annual deaths resulting from AIDS-related complications [5]. HIV/AIDS 
disproportionately affects resource-poor settings, such as sub-Saharan Africa, where 
nearly 5% of the population (age 15-49) is infected, compared to less than 1% in most 
other parts of the world. National prevalence is even more staggering in specific Southern 
African countries; more than 15% of the population (age 15-49) lives with HIV in South 
Africa (18%), Botswana and Lesotho (23%), and Swaziland (27%, the highest observed 
globally) [5]. 
 
1.2 HIV Pre-Exposure Prophylaxis 
 The continued absence of an HIV vaccine has motivated the investigation of 
woman-controlled strategies that can interrupt the early events of male-to-female sexual 
transmission. Early studies employed vaginal gels formulated with nonspecific polymeric 
agents (e.g. carrageenan, cellulose sulfate) designed to prevent infection and were 
categorically unsuccessful [6]. More recent efforts have proven the concept of pre-
exposure prophylaxis (PrEP), whereby ARV drugs are administered prior to sexual 
exposure. To date, HIV PrEP has met with mixed results. In the CAPRISA 004 study, 
women were instructed to use a hydroxyethylcellulose (HEC) vaginal gel containing the 
NtRTI tenofovir (TFV) up to 12 hours before and after sexual intercourse (twice per act 
of intercourse, often referred to as BAT24 dosing). Use of this TFV 1% gel resulted in a 





TFV gel prevented transmission more effectively (54%) in women who reported at least 
80% adherence to the trial protocol. Furthermore, the gel was 74% effective in women 
who exhibited vaginal fluid concentrations of TFV greater than 1000 ng/g [8]. 
Unfortunately, once-daily, coitally-independent administration of the same TFV 1% gel 
failed to demonstrate a statistically significant reduction in male-to-female transmission 
in the VOICE study [9]. Another PrEP strategy, also met with mixed results, has been 
once-daily oral administration of the existing HIV therapy Truvada, a fixed dose 
combination of tenofovir disoproxil fumarate (TDF, an oral prodrug of TFV) and the 
NRTI emtricitabine (FTC). In the Partners PrEP study, oral Truvada was 75% effective in 
preventing HIV-negative men and women from becoming infected by their seropositive 
partner [10]. This result was confirmed in another study termed TDF2, where a general 
population of men and women were 62% less likely to become infected when using 
Truvada. These results contributed to the FDA approval of oral Truvada as the first 
clinical PrEP intervention [11]. However, oral Truvada was unsuccessful in the 
aforementioned VOICE study and in the FEM-PrEP study that was discontinued due to 
low user-reported adherence [12]; also likely contributing to the failure of VOICE. In 
total, these results demonstrate that PrEP has great promise to impact the pandemic, but 
that products need to be developed that women are highly motivated to use. It is 
impossible to demonstrate clinical efficacy if a majority of participants do not use the 
product as instructed.   
 Although it has been difficult to show effectiveness in human PrEP studies to-
date, the promise of PrEP has been strengthened by several demonstrations of HIV 





measure of HIV PrEP efficacy, NHP (generally pig-tailed or rhesus macaques) are 
repeatedly exposed to the recombinant simian-human immunodeficiency virus (SHIV) 
during the implementation of a PrEP dosing strategy. Dobard et al. challenged pig-tailed 
macaques twice-weekly for 10 weeks during once-weekly 1% TFV gel dosing (SHIV 
exposure both 30 minutes and 72 hours after exposure) and demonstrated 74% efficacy of 
TFV gel in preventing SHIV infection [13]. ARV-releasing intravaginal rings (IVR, 
which will be the focus of this manuscript and are introduced in detail below) have also 
shown high rates of efficacy in NHP challenge studies. An IVR releasing the NNRTI 
MIV-150 demonstrated 80% efficacy in preventing SHIV infection in rhesus macaques 
[14], while another IVR releasing TDF was 100% effective (no infections in the active 
IVR group) in preventing SHIV infection in pig-tailed macaques challenged weekly for 4 
months during continuous IVR use [15]. 
 
1.3 Contraception and Modern Contraceptive Methods 
 Nearly inseparable from a discussion of the HIV/AIDS pandemic is the staggering 
global incidence of unintended pregnancy (UP). Over 50 years after the advent of daily 
hormonal contraception and with several highly-effective contraceptive options available 
worldwide, nearly half of all pregnancies worldwide are still unintended, equating to 
approximately 80 million pregnancies per year that result in nearly 100,000 maternal 
deaths due to unsafe abortions and pregnancy- or delivery-related complications [16]. 
These statistics are startling considering the wide variety of contraceptive options 
available to women. Contraceptive methods are typically classified as either modern or 
traditional, where "traditional methods" include lower effectiveness user interventions 





be either reversible or nonreversible (e.g. sterilization). Most reversible methods can be 
further subdivided into two main categories: barrier methods, such as the male and 
female condom that employ a physical polymeric barrier to prevent the transport of 
sperm through the cervix, and hormonal methods that employ the periodic or continuous 
administration of various hormone analogs to prevent ovulation and/or fertilization. With 
the exception of the male condom and male sterilization, all modern methods are woman-
controlled. No approved drug products exist for male contraception, although several 
compounds with various mechanisms of action are under investigation. In daily combined 
oral contraceptive (COC) strategies (colloquially known as "the pill"), a fixed-dose 
combination pill containing a synthetic progestogen (progestin) and an estrogen analog is 
taken once-daily in a 21 day on, 7 day off cycle that simultaneously prevents ovulation 
and regulates the menstrual cycle. COC is still the most popular modern method in the 
U.S. [17] and the most popular reversible modern method in some regions around the 
world [18]. Progestin-only pills (POP) are also available that may or may not inhibit 
ovulation, depending on the dose, but also may rely on the thickening of cervical mucus 
to inhibit sperm transport and prevent fertilization [19].  
 As with any periodic interventions, daily oral contraception is subject to varying 
degrees of user adherence which may ultimately reduce effectiveness. Several highly-
effective alternative drug delivery systems exist which can provide reliable contraception 
for extended durations with little or no user intervention. As discussed below, NuvaRing 
is a 99% effective combined contraceptive IVR applied once every 28 days and follows 
COC pattern of 21 days in, 7 days out to regulate the menstrual cycle [20]. Other, even 





injection (effective for 3 months), progestin-releasing subcutaneous implants (i.e. 
Norplant and Jadelle, effective for up to 3-5 years), and progestin-releasing intrauterine 
systems (IUS). The Mirena and Skyla IUS both deliver very small doses (up to 14 and 20 
µg/d, respectively) of the progestin levonorgestrel (LNG) in the uterus for up to 3 and 5 
years, respectively, and achieve contraception largely through local effects (e.g. cervical 
mucus thickening and inhibition of sperm function) [21]. Both Mirena and Skyla are over 
99% effective in preventing pregnancy [22, 23]. The one product perhaps not classified 
as either a barrier or hormonal method is Paragard, a copper-releasing IUS that is also 
over 99% effective and can remain in place for up to 10 years [24]. 
 UN models estimate that worldwide prevalence of modern contraception among 
married or in-union women between the ages of 15 and 49 was 57% in 2013. As with the 
HIV statistics presented above, a large regional disparity exists in the use of modern 
methods, with the same models predicting 71% and 74% use in North America and 
Northern Europe, respectively, but only 21% use throughout Sub-Saharan Africa [25]. 
 
1.4 Multipurpose Prevention Technologies 
 Through the statistics presented thus far, the reader will recognize the 
simultaneous need for HIV prevention technologies and reliable contraception in 
resource-poor settings, such as the often-discussed Sub-Saharan Africa. Biomedical 
interventions designed to simultaneously address multiple reproductive health needs are 
commonly termed multipurpose prevention technologies (MPT) [16]. MPT can include 
products that protect against multiple sexually transmitted infections (STI) or 
contraception and an STI. The only existing commercially available MPT are the barrier 





efficacy in providing a barrier to both agents of infection (i.e. viruses and bacteria) and 
sperm cells, but are prone to misuse and inconsistent use. Condoms are particularly 
problematic in developing areas with high HIV prevalence, in part due to men's 
unwillingness to comply with a woman's desire for their use [26].   
 A single product that combines HIV PrEP and contraception has been identified 
as an urgently needed MPT by the global health community [27]. It has been 
hypothesized that the inclusion of a contraceptive into an HIV PrEP  could increase user 
demand for PrEP products, due to the familiarity of contraceptive products whereas HIV 
PrEP is a relatively new concept. Combination of the two indications could also provide 
significant cost amortization, greatly needed in the development of publically-funded 
developing world products. 
 
1.5 History of Intravaginal Rings 
 Intravaginal rings (IVR) have taken center stage in the PrEP discussion as an 
alternative to the inconvenient and undesirable once-daily application of ARV using oral 
tablets or vaginal gels. IVR are promising as they can directly deliver ARV to the 
potential site of HIV infection in a sustained or controlled fashion for months or even 
years from a single device [28]. Similarly, IVR have been identified as one of the two 
most viable options for a long-acting MPT platform along with injectable depot 
formulations [16].  
 IVR were among the first in the class now referred to as "combination devices" or 
"drug/device combinations". Combination devices can either be regulated as drugs or 
medical devices by the FDA, depending on the primary mechanism of action. All IVR to 





the vaginal tract, and their secondary function is to remain in place in the upper vaginal 
tract via a mechanical force balance between the IVR and the vaginal musculature. IVR 
were first investigated for the sustained delivery of contraceptive hormones to systemic 
circulation in the late 1960s [29, 30], exploiting the effective systemic absorption of 
small molecules through the vaginal mucosa, a phenomenon discovered nearly a century 
ago [31]. Mishell et al. were the first to clinically demonstrate the potential of 
contraception via IVR by testing a silicone IVR impregnated with the progestin 
medroxyprogesterone acetate, the same active ingredient as in the commonly used Depo-
Provera contraceptive injection, in a small PK/PD pilot trial [32]. In a series of seminal 
papers, Chien et al. used similar silicone IVR as a case study for the discussion of 
controlled drug release in the context of vaginal delivery, describing methods for in vitro 
release testing [33], mechanisms of drug release [34], and in vivo evaluation of vaginal 
devices using the rabbit model [35]. The WHO developed a "microdose" progestin IVR 
that released approximately 20 µg/d LNG for up to 3 months [36-39]. This LNG IVR was 
tested in a large clinical multicenter clinical trial and was shown to be over 95% effective 
in preventing pregnancy. This IVR showed promise, but development was discontinued 
for multiple reasons, one being that use of the IVR was associated with formation of 
vaginal lesions, potentially due to excessive device stiffness [40] (IVR mechanical 
properties are discussed in detail in Section 1.9). The first contraceptive IVR to market 
was the progestin/estrogen NuvaRing, a poly(ethylene-co-vinyl acetate) (EVA) ring that 
releases the progestin etonogestrel (ENG) and ethinyl estradiol (EE) at near constant rates 
over 21 days. The inclusion of EE and the 3 week in/1 week out cycle generally results in 





similar 3 week/1 week cycle. Several important insights to IVR design and development 
gained from the NuvaRing work were published by van Laarhoven and colleagues in the 
early 2000s [41-43].  Four silicone-based IVR are currently available worldwide for 
various indications other than general contraception. Estring and Femring, both available 
in the US, deliver estrogen analogs (estradiol and estradiol acetate, respectively) for 
postmenopausal hormone replacement. Progering and Fertiring both release natural 
progesterone and are approved only in select Central and South American countries. 
Progering is indicated for contraception in lactating women, while Fertiring is indicated 
for hormone supplementation and pregnancy maintenance during in vitro fertilization 
[44]. 
 IVR for HIV PrEP can be traced back to the nonoxynol-9 (N9) releasing silicone 
IVR reported by Malcolm and Woolfson at Queen's University Belfast in the early 2000s 
[45]. N9 is a nonionic surfactant that was indicated for use as a spermicide and 
investigated for use as anti-HIV ("microbicide") agent. However, all hope of using N9 as 
a microbicide ceased with observations that N9 use could result in higher risk for HIV 
infection, regardless of its potential anti-HIV activity. This group went on to formulate 
the NNRTI dapivirine (DPV, often referred to by its laboratory designation, TMC120) 
into silicone IVRs [46, 47], research that ultimately led to clinical testing [48-50] and an 
ongoing Phase III clinical trial, the first of its kind to test the efficacy of an IVR for HIV 
PrEP. In the mid-to-late 2000s, Kiser et al. at the University of Utah published several 
papers reporting the in vitro and in vivo investigation of polyurethane IVR for the 
delivery of several ARV [15, 51-55], including an innovative multisegment IVR for the 





detail the continuation of this work, including the incorporation of a contraceptive-
releasing component in what will likely become the first clinically-viable MPT IVR. 
 
1.6 IVR Dimensions, Design, Materials, and Manufacturing 
 IVR are flexible torus-shaped devices typically classified by two characteristic 
dimensions: outer diameter (OD), or the overall maximum width of the entire ring, and 
cross-sectional diameter (XD), the width of the ring forming strand. IVR OD are 
somewhat constrained by the width of the vaginal canal, observed to vary from 48 to 63 
mm in one study [57], although the fit and comfort of IVR are truly constrained by the 
overall balance of elastic properties between the compressible ring and the vaginal 
musculature (see Section 1.9). Clinical IVR OD do not vary greatly, ranging from 54 mm 
(NuvaRing) to 56 mm (Femring); however, sizes of 50 to 61 mm are thought to be well- 
tolerated based on clinical investigation [29]. Interestingly, the first silicone IVR tested 
by Mishell had OD of up to 80 mm [32]. Clinical IVR XD vary more significantly than 
OD, ranging from 4 mm (NuvaRing) to 9 mm (Estring).   
 Most IVR fall into two design classes, matrix and reservoir. Matrix IVR are 
simple, monolithic devices where drug is dissolved and/or dispersed evenly throughout 
the polymer matrix, whereas reservoir IVRs employ a rate-controlling membrane (RCM) 
to control the rate of drug release. Drug release from matrix IVR usually decreases 
significantly with time, due to an increase in the effective diffusion path length following 
progressive inward drug depletion. Drug release rates from reservoir IVR are linearly 
dependent on the dissolved core drug concentration, and thus can be constant (if an 
excess of undissolved drug is present), or can decay in a first-order exponential fashion 





from IVR are a focus of this dissertation, and are given a detailed introduction in Section 
1.7. Most clinical IVR are reservoirs, but matrix IVR have seen significant investigation 
by the HIV PrEP field, likely due to their potential manufacturing simplicity and reduced 
cost. More advanced designs have been investigated which ease the challenge of 
delivering multiple drugs simultaneously, although this was achieved in the standard 
reservoir NuvaRing, likely due to the chemical similarity of the two molecules delivered. 
These advanced designs include the segmented or multisegment IVR (discussed in 
Chapters 3 and 4) which theoretically can incorporate both matrix and reservoir 
components, and the pod-insert IVR wherein a placebo injection molded ring is fitted 
with several reservoir-type controlled release inserts [58]. 
 When designing an IVR for drug delivery, one must first estimate the desired 
daily drug dose and duration, the product of which results in the minimum necessary drug 
load, although a significant overage would be required for matrix IVR that exhibit time-
dependent drug release behavior. The total drug load in an IVR (M0) is calculated as 
follows: 
ܯ଴ ൌ 2்߱ߩߨଶݎ௢ଶሺܴ െ ݎ௢ሻ (1.1) 
where ωT is the drug weight fraction loaded in the matrix, ρ is the matrix density and R 
and ro are the IVR outer and cross-sectional radii, respectively (or half of the outer and 
cross-sectional diameters). In cases where drug is only loaded into the core of a reservoir 
IVR, the first instance (but not the second) of ro is replaced with ri, or the core cross-
sectional radius. 
 In theory, any elastomer that proves biocompatible in contact with the vaginal 





must not erode or degrade on relevant time-scales for IVR drug delivery (i.e. weeks to 
months, depending on the specific system), and second, it must possess appropriate 
continuum-scale properties, namely compatible values of effective drug-polymer 
diffusivity (Deff, used interchangeably with D in this dissertation) and elastic modulus (E). 
The interdependence of Deff and E is further explored in Chapter 2. As detailed in the 
previous section, 4 of the 5 commercially-available IVR are fabricated from 
thermosetting silicone elastomers, with the one exception (NuvaRing) being fabricated 
from the thermoplastic poly(ethylene-co-vinyl acetate) (EVA). The DPV IVR under 
clinical investigation for HIV PrEP is also synthesized from a silicone elastomer. Kiser 
and colleagues have extensively investigated thermoplastic polyurethane elastomers as 
IVR matrices, particularly poly(ether urethanes) (PEU), which are synthesized from the 
condensation polymerization of isocyanates and oligomeric poly(ether diols), typically 
poly(tetramethylene oxide) (PTMO). These PEU can be synthesized in water-swellable 
and nonswellable variants, with the former, referred to as hydrophilic PEU (HPEU), 
achieving tunable hydrophilicity through the modulation of the ratio between PTMO and 
poly(ethylene oxide) (PEO). Use of HPEU and PEU in segmented IVR has proven useful 
as the two types are chemically very similar on the microscopic scale, and thus can easily 
be welded together to form mechanically sound IVR, while the HPEU ring components 
allow for delivery of hydrophilic drugs which do not possess sufficient solubility and/or 
permeability in the nonswellable elastomers. Most IVR designs are limited to the delivery 
of small molecule drugs due to similar solubility/permeability constraints; however, 
several designs have been investigated, including the aforementioned pod-insert ring, that 





biodegradable hydrogel IVR formed from a co-polymer of 2-hydroxyethyl methacrylate 
and acrylic acid, although not much is known about the practicality or acceptability of 
such a device [60, 61].   
 IVR manufacturing is usually limited to reaction injection molding as most IVR 
are comprised of thermosetting silicones. NuvaRing manufacturing leverages the 
thermoplastic nature of EVA by using a continuous co-axial hot melt extrusion process to 
manufacture a drug-loaded reservoir strand that is cut to length and welded to form a ring 
by induction welding. The PEU IVR designed by Kiser et al. are also typically made by 
hot-melt extrusion and melt-welding. The use of extrusion and injection molding are 
described in Chapter 2, and use of co-axial extrusion and induction welding are described 
in Chapter 3. 
 Sections 1.7, 1.8, and 1.9 contain excerpts from "State of the Art in Intravaginal 
Ring Technology for Topical Prophylaxis of HIV Infection", authored by Patrick F. 
Kiser, Todd J. Johnson, and Justin T. Clark, and published in AIDS Reviews Volume 14 
(2012) (pages 62-77). 
 
1.7 Drug Release from IVR 
 The release rates of drugs from IVR can be limited by one or more physical 
processes. Assuming a physiological sink condition exists for the drug in the vaginal 
tract, drug release is limited by diffusional flux away from the surface of the IVR. As 
described above, this flux can be steady-state in the case of a reservoir ring, or unsteady 
in the case of a matrix ring. Models describing these types of release mechanisms 
generally assume that a “sink” boundary condition is maintained at the outer surface of 





low with respect to its solubility. Most in vitro IVR drug-release studies are performed 
under sink conditions, where the volume and stirring of the release medium is sufficient 
to prevent the local and/or overall drug concentration from approaching the drug 
solubility in the medium. It is unclear, however, whether a sink is maintained for some 
hydrophobic antiviral compounds in vivo. It may be that zero-order release would be 
possible in vivo for certain devices that exhibited diffusion/dissolution limited kinetics in 
vitro if the vaginal fluid concentration remains saturated or supersaturated at a value 
limited by its solubility [34]. Illustrating this phenomena, a study comparing drug release 
behavior of matrix-type UC781-containing IVR segments from various polymeric 
matrices showed large differences in release rates between formulations under sink 
conditions in the lab, yet very few pharmacokinetic differences in a rabbit model, with 
UC781 release rates significantly less in vivo as compared to in vitro [51, 62]. 
 Drug release from IVR can be mechanistically described by solutions to diffusion 
equations. Since axial diffusion can generally be neglected, IVR diffusion problems can 
be reduced to one dimension by transforming to polar coordinates. For matrix IVR, the 
mathematical approach depends on the physical nature of the drug inside the polymer 
matrix. When the entirety of the drug load is dissolved, Fick's Second Law can be solved 
on the circular IVR cross-section with a sink outer boundary and uniform initial 
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where M is the cumulative release of drug as a function of time, and D is the effective 





0.2-0.3, the first term is sufficiently accurate and the remaining terms may be neglected. 
Equation 1.2 can also be used if a saturation equilibrium is reached outside the ring by 
replacing M0 with the total mass released when equilibrium is reached. If the majority of 
drug molecules are undissolved, meaning that the drug loading far exceeds the solubility 
in the polymer matrix, a pseudo-steady-state moving diffusion boundary approach leads 
to an implicit solution for cumulative release [64-66]: 
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where ωs is the mass fraction solubility of the drug in the polymer matrix. Equation 1.3 is 
derived by a similar approach used by T. Higuchi to arrive at the classic equation for thin 
films [67], and is further discussed in Chapter 2. For long-acting systems, including IVR, 
it is more useful to express results as release rates (dM/dt) than as a cumulative release 
quantity. Instantaneous release rates can be obtained by a simple time-derivative of M(t), 
or often-used daily release rates can be obtained by subtracting M(t) across a 24-hour 
interval. Although Equation 1.3 is simplified in that it neglects the change in the amount 
of dissolved drug with time outside the diffusion front (appropriate for some systems), 
Helbling and Cabrera corrected for this by integrating the concentration profile outside 
the diffusion front in their more comprehensive analytical model [68].  
 For reservoir-type IVR, the steady-state form of Fick's Second Law can be solved 
on the rate-controlling membrane (RCM), and applying Fick's First Law at the outer 
boundary reveals a simple formula for instantaneous drug release rate as a function of 










It should be noted that D (or Deff) refers to a macroscopic Fickian approximation of 
diffusivity. Also, the derivation of Equation 1.4 assumes that no drug partitioning exists 
between the core and RCM polymers at their interface, which should be appropriate if 
drug solubility is the same in the two materials. When this is not the case, a linear 
partition coefficient K (equal to the ratio of  drug solubilities between the membrane and 
core) is applied to the boundary condition and ultimately appears in the numerator of 
Equation 1.4. This model is further discussed in Chapter 3. 
 
1.8 Biotransport Description of HIV Pre-Exposure Prophylaxis 
 Although the characterization of drug release from an IVR into an in vitro release 
media sink condition is a critical step in the design and optimization process, 
understanding drug transport through vaginal tissue is of equal practical importance. 
There are three basic compartments of importance when considering spatial drug 
distributions following PrEP administration in women: vaginal fluid, vaginal tissue, and 
blood circulation. For topical delivery (e.g. from IVR), vaginal fluid is the dissolution 
medium, and acts as a relay from dosage form to tissue. Fluid can be a sink-type 
boundary in the case of water-soluble drugs, or can become a saturated (or partially-
saturated) rate-controlling impediment for release in the case of less water-soluble drugs 
[34, 51]. In either case, the fluid serves as a source for drug transport throughout the 
tissues. It is thought that fluid convection in the vaginal tract serves to effectively spread 
drugs longitudinally from the device to the introitus [69], which is particularly 





vaginal tract (such as an IVR). It is likely that a fraction of any dose delivered vaginally 
remains dissolved in the fluid and is lost through the introitus [70], which could lead to a 
reduction in dose availability for bolus-type doses (such as gels). It has also been 
suggested that drugs can partition directly into the epithelial layer from an IVR, thus 
bypassing the fluid compartment completely [29]. However, a fraction of the surface area 
is not in direct contact with the tissue, so only a fraction of the total flux from the ring 
would be described by this phenomenon. The vaginal tissue compartment can be further 
stratified into various sub-compartments. When considering continuum-scale drug 
transport, the tissue can be divided into the epithelium (nonvascularized), and the lamina 
propria (vascularized). For vaginal delivery, a linear concentration reduction in drug 
concentration can be expected across the epithelium (by Fick's laws, approximating the 
epithelium as a thin plane), while combined diffusion and elimination to the bloodstream 
should result in an exponential decay of drug concentration throughout the vascularized 
tissues [71]. Any vaginal PrEP delivery strategy must ensure that a sufficient drug source 
is maintained in the fluid compartment to ensure an effective drug level surrounding 
infectable cells at various depths in the tissue [72]. For drugs that are activated 
intracellularly (NtRTI and NRTI), the tissue can be further stratified at the cellular level 
and chemical reactions must be considered along with diffusion and elimination. 
 The plasma compartment acts as a sink for vaginal delivery, in contrast to its 
function as a source for oral delivery. In either case, drugs or their byproducts will likely 
be eliminated by renal or hepatic clearance mechanisms. For oral delivery of 
antiretrovirals, local tissue protection is likely achieved by the same mechanism 





loaded with drug, which can then diffuse into the epithelial layers and vaginal fluid. 
However, it is likely that large temporal fluctuations in local tissue drug concentrations 
are experienced in the tissue compartment with intermittent oral dosing, leading to the 
same drawbacks experienced with intermittent gel dosing. Through this analysis, it is 
readily apparent, as with many local drug delivery schemes, that vaginal delivery of PrEP 
agents can have two advantages over oral delivery: 1) Greatly reduced systemic drug 
concentrations are required to deliver the tissue a protective level; and 2) The potential 
for establishing constant vaginal tissue levels through controlled-release dosage forms 
(e.g. an IVR), which would be impossible to achieve through intermittent oral dosing 
[73]. 
 When considering the mass transport of PrEP agents, several physicochemical 
properties are of interest including aqueous solubility, tissue permeability, and 
hydrophobicity. Aqueous solubility is important since the concentration dissolved in the 
vaginal fluid will ultimately serve as the boundary condition for transport across the 
tissue compartment. Compounds also must have sufficient diffusivity in the tissue 
compartment for them to reach their potential sites of action (inside and surrounding 
target immune cells). Although hydrophobic compounds generally have better 
permeability across epithelial cell membranes, small hydrophilic compounds can rapidly 
diffuse in the extracellular space, quickly reaching continuum-level steady state 
concentrations. The extracellular concentration at any point then serves as a drug source 
across individual cell membranes. Aqueous solubility is potentially more important for 
long-term delivery from an IVR because local tissue concentrations should be directly 





 Several models of local PK for vaginal delivery have been reported. Kuo et al. 
used a steady-state solution to a one-dimensional diffusion-elimination model to predict 
the vaginal transport of 125I-labeled IgG antibodies released from EVA discs [71], but 
measured the concentration as a function of distance experimentally. This treats the 
vaginal fluid as a thin conducting surface with constant API concentration. However, this 
model neglects the advective transport of drugs longitudinally through the vaginal tract. 
Saltzman later published an improved, compartmental, vaginal pharmacokinetic model 
that also considered vaginal fluid advection [74]. Geonnotti and Katz constructed a finite-
element model of a two-dimensional cross-section of an IVR and the vaginal tract and 
surrounding tissues [69]. Although this 2D model is not fully representative of vaginal 
anatomy, it was the first in silico attempt to assess the spatial pharmacokinetics of drugs 
released from an IVR. The results of the model indicate that the thickness and fluid 
velocity of the vaginal fluid boundary layer has much greater impact on drug distribution 
through tissue than the effective diffusivity of the drug through the tissue. A proposed 
three-dimensional PK model to describe IVR drug transport is discussed in Appendix A. 
 Another variable often not considered is the effect of menstrual cycle variation 
and sexual intercourse on drug release from an IVR. In cases where the flux of a drug 
from the IVR surface is limited by its solubility in the surrounding fluid, it is conceivable 
that changes in the vaginal environment could affect drug release. For instance, drug 
release could be reduced in the case of peri-menopausal vaginal dryness, or increased 
upon the introduction of semen to the insertion site due to changes in the available 
dilution volume. The increase in vaginal pH following intercourse could also result in a 





solubility. Some IVR dosing regimens currently under consideration involve the user 
leaving the ring in place for one or more menstrual cycles. During this time, drug release 
rates could be modulated by the composition of the vaginal fluid, which may contain 
various drug-solubilizing factors, such as hemoglobin, as well as by an increase in the 
vaginal fluid volume, as already mentioned. A full analytical treatment of vaginal 
transport through the tissue, where both bulk diffusion and surface convection are 
considered along with first-order elimination, is not likely feasible, but finite-element or 
other numerical approximations could aid in the design of IVR or other topical 
microbicide sustained-delivery systems, provided that they can be sufficiently validated 
by correlation to experimental data. 
 
1.9 Mechanical Properties of IVR 
 In general, the efficacy of long-term controlled release drug-device combinations 
is dependent on their ability to remain in place for the duration of use. IVR differ from 
other long-term delivery systems in that they are not surgically implanted and are 
designed to be inserted and removed by the user. An elastic IVR under compression will 
be in a force balance with the vaginal wall, the magnitude of which is determined by ring 
geometry and matrix material properties and the biomechanical environment provided by 
the underlying musculature. Provided the force applied on the tissue as a result of ring 
relaxation is of sufficient magnitude, the ring will remain in place. Under normal 
physiological conditions, the vaginal tract is a low-friction environment due to the 
presence of vaginal fluid and cervicovaginal mucus. If an IVR is too easily deformed, the 
ring may be expelled as a result of day-to-day activities of the user that apply force to the 





great, it may be difficult for the user to compress the ring prior to insertion or it may 
cause damage to the vaginal epithelium proximal to the ring site [40]. Logically, there 
exists an optimum range of compressibility for an IVR of given dimensions, keeping in 
mind that there will be a wide range of vaginal shapes and sizes among the user 
population [57, 75, 76]. A mechanical model for the point compression of thin elastic 
rings is derived in engineering literature [77]. The most interesting feature of the model 
result is the fourth-power dependence of compressive load on the cross-sectional 
diameter of the ring. Thus, increasing the cross-sectional diameter of an IVR from 5 to 6 
mm will result in a 107% increase in the force required to deform the ring by a given 
amount. Also, IVR compression force is linearly related to the elastic modulus of the IVR 
matrix, which can be affected by the incorporation of drugs and/or other excipients. This 
mechanical model is discussed in further detail in Chapter 2. The addition of 
nondissolved solids to the matrix can greatly increase the elastic modulus [78], whereas 
dissolution of polymer-soluble compounds can cause a plasticizing effect, effectively 
reducing the elastic modulus of the material [79]. Although this mechanical model 
assumes linear stress-strain behavior, which is invalid for high ring deformations such as 
during ring insertion, the model can still be a useful tool for ring design, especially when 
considering small ring deformations such as those seen in an MRI assessment of 
NuvaRing retention in vivo [80]. Complete mechanical analysis of complex IVR designs, 
such as the dual-segmented polyurethane IVR described by Johnson et al. [56] or pod-
insert-type IVR [58], would most likely require a numerical approximation or finite-
element simulation. An even larger difficulty in designing new IVR products is the 





side-by-side comparison tests with existing clinical IVR which have shown high user 
acceptability, there is no quantitative model to directly determine the ideal range for 
mechanical IVR acceptability. Recent studies have begun to quantitatively examine the 
vaginal musculature [81, 82]. Developing a model which couples ring elastic mechanics 
with vaginal biomechanics could prove useful in future IVR design and in the design of 
dosage forms with shapes other than the symmetric torus, such as the SILCS diaphragm. 
 
1.10 Dissertation Chapter Overview 
 Chapters 2, 3, and 4 of this dissertation are separate manuscripts in various stages 
of publication. Chapters 2 and 3 are published, peer-reviewed articles, and Chapter 4 is a 
manuscript in preparation for publication. 
 
1.10.1 Chapter 2 Overview 
 Chapter 2 describes an injection-molded hydrophilic polyether urethane (HPEU) 
matrix intravaginal ring (IVR) for the sustained delivery of tenofovir (TFV) for up to 90 
days, as well as mathematical models for in vitro release and mechanical properties. The 
drug release model is an explicit solution of implicit model for limited-solubility 
cylindrical dosage forms originally derived by Roseman and W. Higuchi [64, 65]. An 
explicit solution was obtained by use of the Lambert-W (product log) function, the first 
such use in the drug delivery literature. Described is the first device capable of the 
sustained vaginal delivery of milligram per day quantities of TFV, a molecule that proved 
effective in early HIV prevention studies as detailed above. This article also established a 
foundation for the prediction of IVR mechanical properties using a model that had not yet 





Publication:  Clark JT, Johnson TJ, Clark MR, Nebeker JS, Fabian J, Tuitupou AL, 
Ponnapalli S, Smith EM, Friend DR, Kiser PF. Quantitative evaluation of a hydrophilic 
matrix intravaginal ring for the sustained delivery of tenofovir. Journal of Controlled 
Release, 2012, 163(2), pages 240-248. 
 
1.10.2 Chapter 3 Overview 
 Chapter 3 describes the design and in silico, in vitro, and in vivo evaluation of a 
two-segment, dual-reservoir polyurethane IVR which delivers TFV and the contraceptive 
progestin levonorgestrel (LNG) at near-constant rates for 90 days. Several aspects of the 
work are presented, including a new diffusion model for drug release, in vitro release 
testing, in vivo pharmacokinetic testing in a rabbit model, manufacturing methods, and 
mechanical testing. This article presents a novel solution for the delivery of two 
physicochemically different drugs at up to 700-fold different rates through the use of the 
chemically diverse PEU/HPEU platform. The IVR described is one of the first devices in 
its class designed for simultaneous long-acting HIV prevention and contraception. The 
mathematical model presented is an improvement over those existing in the literature and 
is useful in the design of cylindrical reservoir devices, including IVR. This chapter 
focuses primarily on the design and testing of a solid, co-axially extruded 1 to 2 cm 
length PEU reservoir for the delivery of LNG and its incorporation into a two-segment 
ring that also delivers TFV. The TFV delivery system is a hollow-tube HPEU reservoir 
and represents the "second generation" of the technology presented in Chapter 2, but is 





the reader is referred to the Ph.D. dissertation of Todd Johnson, also of the University of 
Utah Department of Bioengineering.  
Publication:  Clark JT, Clark MR, Shelke NB, Johnson TJ, Smith EM, Andreasen AK, 
Nebeker JS, Fabian J, Friend DR, Kiser PF. Engineering a segmented dual-reservoir 
polyurethane intravaginal ring for simultaneous prevention of HIV transmission and 
unwanted pregnancy. PLoS ONE 2014; 9(3): e88509.  
 
 
1.10.3 Chapter 4 Overview 
 Chapter 4 continues in the description of the TFV/LNG dual-reservoir IVR 
presented in Chapter 3. In this manuscript, the physical and chemical stability of the 
system are evaluated, as well as the pharmacokinetics of TFV and LNG in the sheep 
model.     
Publication: Clark JT, Shelke NS, Clark MR, Johnson TJ, McCabe RT, Meidell KZ, 
Fabian J, Friend DR, Kiser PF. Preclinical evaluation of a multipurpose prevention 
intravaginal ring: Assessments of stability and in vivo performance. In preparation for 
submission to the European Journal of Pharmaceutics and Biopharmaceutics. 
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Microbicides for HIV prevention
Tenofovir
In vitro testing and quantitative analysis of a matrix, hydrophilic polyether urethane (HPEU) intravaginal ring
(IVR) for sustained delivery of the anti-HIV agent tenofovir (TFV) are described. To aid in device design, we
employed a pseudo-steady-state diffusion model to describe drug release, as well as an elastic mechanical
model for ring compression to predict mechanical properties. TFV-HPEU IVRs of varying sizes and drug load-
ings were fabricated by hot-melt extrusion and injection molding. In vitro release rates of TFV were measured
at 37 °C and pH 4.2 for 30 or 90 days, during which times IVR mechanical properties and swelling kinetics
were monitored. Experimental data for drug release andmechanical properties were compared to model pre-
dictions. IVRs loaded with 21% TFV (w/w) released greater than 2 mg TFV per day for 90 days. The diffusion
model predicted 90 day release data by extrapolating forward from the ﬁrst 7 days of data. Mechanical prop-
erties of IVRs were similar to NuvaRing®, although the matrix elastic modulus decreased up to three-fold fol-
lowing hydration. This is the ﬁrst vaginal dosage form to provide sustained delivery of milligram quantities of
TFV for 90 days. Drug release and mechanical properties were approximated by analytical models, which
may prove useful for the continuing development of IVRs for HIV prevention or other women's health
indications.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The use of pre-exposure prophylaxis (PrEP) as a tool to combat
the global HIV/AIDS pandemic is evolving from theory to practice
with the successful completion of several clinical trials [1] and the
recent FDA panel recommendation for approval of preventative
oral administration of anti-HIV drugs [2]. All efﬁcacious HIV PrEP
strategies to date utilized either topical (i.e., microbicides) or oral
prodrug formulations of tenofovir (TFV), an HIV-1 nucleotide re-
verse transcriptase inhibitor. The CAPRISA 004 trial tested a vaginal
gel containing 1% TFV in a “before and after sex” dosing regimen.
Overall, the trial showed a 39% reduction in the rate of HIV acquisi-
tion when compared to a placebo gel, and a 54% reduction among
self-reported high-adherers (at least 80% use) [3]. This trial mea-
sured the ﬁrst reduction in HIV infection rates in women using a top-
ically applied dosage form [4]. Unfortunately, the once-daily TFV gel
arm of the VOICE trial (MTN-003) did not show a reduction in transmis-
sion [5]. Together, these results indicate that HIV chemopreventionmay
be achieved with topical TFV administration, but that dosing regimen
can largely impact trial outcomes. They also highlight the need to devel-
op alternative drug delivery systems for TFV and other antiretroviral
agents.
Intravaginal rings (IVRs) provide several beneﬁts over gels in-
cluding sustained drug delivery and coitally independent use. IVRs
are torus-shaped elastomeric devices commonly used for vaginal
drug delivery in reproductive health applications [6–8], and are cur-
rently under investigation as HIV PrEP agents [9–12]. IVR systems
may be capable of antiviral delivery for months or potentially years
from a single device. Sustained, long-term delivery of TFV from an
IVR may provide three substantial improvements over pericoital de-
livery systems. First, the high user acceptability observed with
existing clinical IVRs [13] may translate to higher user adherence in
IVR PrEP trials. Second, sustained delivery should provide more fa-
vorable pharmacokinetics than those provided by pericoital delivery
systems [14]. Finally, as HIV PrEP likely will be implemented in
low-income populations, the potential to spread IVR cost over
weeks or months attracts interest in the public health community.
The hydrophilicity of TFV [15] presents a challenge for achieving
sustained release from hydrophobic elastomers typically used to
Journal of Controlled Release 163 (2012) 240–248
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manufacture IVRs (i.e., poly(ethylene-co-vinyl acetate), silicones) due to
low drug-polymer solubility. Our previous article [16] describes a seg-
mented, hydrophilic poly(ether urethane) (HPEU) IVR prototype which
released TFV over 30 days. HPEUs differ from conventional
poly(ether urethanes) by exhibiting moderate water swellability,
owing to covalently incorporated polyethylene oxide segments [R.
Ward, patent application 27959-WO-PCT]. When HPEUs are hydrat-
ed, hydrophilic small molecules can dissolve into the aqueous phase,
allowing for their passive diffusion through the matrix.
Quantitative analysis of drug release mechanisms can yield useful
tools for the design and development of drug delivery systems, espe-
cially those designed to release drugs for weeks ormonths. However,
mathematical description of drug delivery systems may increase in
complexity when both drug dissolution and matrix swelling are re-
quired for drug release due to potential time-dependent drug diffu-
sivity [17–19].
In addition to drug release, one also must study mechanical prop-
erties when considering IVRs as drug delivery vehicles. Excessively
inﬂexible IVRs may cause user discomfort or epithelial barrier dam-
age, while excessively compressible IVRs may be expelled during
use [20–22]. These problems are compounded in swellable systems
as polymer properties will likely vary during swelling and drug
dissolution.
In this article we describe the design and characterization of a
monolithic, injection-molded, HPEU IVR that releases milligram-per-day
quantities of TFV for up to 90 days in vitro. We also apply a simple
pseudo-steady-state model that effectively describes TFV release from
this IVR, and perform the ﬁrst application of a solid mechanical model
that provides a quantitative foundation for the description of IVRmechan-
ical properties.
2. Theory
2.1. Model for drug release
Mathematical description of drug release from a swellable IVR
with limited drug solubility requires consideration of three-
dimensional drug diffusion and drug dissolution, both of which are
affected by the spatially dependent kinetics of polymer matrix swell-
ing. For this system, swelling has a minimal impact on long-term
drug release modeling as HPEU IVRs typically reach equilibrium
swelling within the ﬁrst 2 to 3 days of drug release. In an IVR, diffu-
sion should only occur in the radial direction, meaning that any con-
stitutive equations can be solved on a circular cross-section (if the
cross-sectional radius is small with respect to the outer radius),
which is reduced to one-dimension in polar coordinates (Fig. 1).
We assume an outer zero-concentration boundary (sink condition),
and deﬁne two dimensionless weight fractions: the solubility of
drug in the hydrated polymer matrix (ωs), and the total IVR drug
loading (ωT). We also assume that an excess of undissolved drug
will maintain the dissolved concentration at ωs inside the diffusion
front (rd), resulting in a constant-value moving boundary. Our ap-
proach follows the pseudo-steady-state method used by Higuchi
when considering drug release from spheres with limited drug solu-
bility [23]. Ifωs≪ωT, this model setup is identical to that of Roseman
and W. Higuchi for matrix-controlled drug release from cylindrical
dosage forms with no axial drug transport [24,25]. Their solution to
the model, which is achieved via the steady-state solution of Fick's
second law [8] on the annular drug depletion zone (rdbrbro) and ap-
plication of Fick's ﬁrst law at the outer radius (r=ro), results in an
implicit solution for cumulative release (M) drug release as a func-












whereM0 is the initial drug load (assuming all drug is eventually re-
leased from the device) and Deff is the effective diffusivity of the drug
in the hydrated, depleted polymer matrix (outside the diffusion
front). For further simpliﬁcation and analysis, we will revert Eq. (1)
to an earlier point in its derivation by replacingM/M0 by the fraction-
al residual drug mass (Mr/M0, equal to ‘1−(M/M0)’) which yields













We refer to the left-hand-side of Eq. (2a) as the product-
log-difference (PLDT) of cumulative release. Further analysis reveals
that the right-hand-side of Eq. (2a) represents dimensionless time









It should be noted that this model is only valid when undissolved
drug still remains in the device. However, whenωs≪ωT, the amount
of dissolved drug at total depletion is very small with respect to M0
and negligible error should result from this simpliﬁcation. An explic-
it solution for cumulative drug release can be computed using the
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where β is as deﬁned above. Eq. (4) was computed algebraically
using Maple 13 (Maplesoft, Waterloo, Ontario). By comparison of
the input domains and output values of the two real-valued branches
of W (W0 and W−1), it is obvious that using W−1 in Eq. (4) lends a
physical solution to Eq. (2a) while W0 does not. The W-function,
also called the product log function, was ﬁrst discussed by Euler
and Lambert in the 18th century, but did not see much practical
use by physicists until the 1990s. To our knowledge this is the ﬁrst
Fig. 1. Drug release model. Pseudo-steady-state, sink diffusion model setup for a circu-
lar IVR cross-section. Dots inside the diffusion front (rd) represent undissolved drug
loaded at ωT, resulting in constant dissolved drug concentration ωs for r≤rd. Drug
ﬂux at the device boundary (ro) decreases with inward movement of rd.


















use of the W-function in a drug delivery application. Eqs. (2a)–(4)
should apply to drug release from any IVR (whether swellable or
not) where ωs≪ωT. For systems where the ωs≪ωT assumption
does not hold, the reader is referred to the analysis of Helbling et
al. [28], which accounts for the change in dissolved drug mass with
movement of the diffusion front. In Roseman's initial analysis [25],
it was noted that use of a planar (Higuchi-style) approximation for
cylindrical drug release was accurate to within 10% for the ﬁrst 50%
of cumulative release (M/M0≤0.5), which may explain any refer-
ences to the Higuchi Equation for thin ﬁlms when discussing drug re-
lease from matrix IVRs.
2.2. Model for IVR deformation
An expression for the point deﬂection Y of a thin elastic torus with







where E is the Young's modulus of the ring-forming material and I is
the area moment of inertia of the ring-forming beam (πro4/4 for a cir-
cular cross-section of radius ro). Since Eq. (5) only considers the
cross-section as a massless beam, R′ represents the distance to the
beam's center and can be replaced by ‘R− ro’ for an IVRwith outer ra-
dius R. Solving for F we obtain an expression for IVR compression







There are limitations to the utility of this model in IVR design.
First, the model considers only the stresses from bending, and thus
is most accurate for low values of ro/R. Also, themodel assumes linear
elasticity, and is therefore only accurate for small values of Y when
considering viscoelastic polymers, such as HPEUs.
3. Materials and methods
3.1. Materials
A custom-designed HPEU (HPEU 20) (Fig. 2A) was provided by DSM
Biomedical (formerly DSM-PTG) (Berkeley, CA) [R.Ward, patent applica-
tion 27959-WO-PCT]. TFV (Fig. 2B) was provided by CONRAD (Arlington,
VA). NuvaRing® was obtained from a local pharmacy. Dimethyl acet-
amide (HPLC grade) was obtained from Honeywell Burdick & Jackson
(Morristown, NJ). Acetonitrile (HPLC grade) was obtained from EMD
Chemicals (Gibbstown, NJ). DDI or USP grade water was used to prepare
all aqueous stock solutions. All other reagents used were ACS or USP
grade.
3.2. IVR fabrication
TFV was ground using an M20 universal mill (IKA Works,
Wilmington, NC) and passed through a 425 μm U.S. standard brass
sieve to remove large aggregates (VWR International, Radnor, PA).
Milled TFV and HPEU 20 pellets were fed into a HAAKE MiniLab
twin-screw extruder (Thermo Scientiﬁc, Newington, NH) at varying
ratios to achieve a range of drug loadings. Prior to extrusion, HPEU 20
was placed in a CAFM series compressed air dryer (Dri-Air Industries,
East Windsor, CT) overnight at 66 °C to remove excess moisture.
Batch sizes ranged from 150 to 500 g. The extruder barrel tempera-
ture and screw speed were set to 147 °C and 50 rpm, respectively.
Each mixture was extruded and then pelletized using a variable-
speed pelletizer (Randcastle Extrusion Systems, Cedar Grove, NJ).
To ensure batch homogeneity, the pelletized sample was then
re-extruded (147 °C, 70 rpm) and re-pelletized. The pelletized
extrudate was molded into rings using a Babyplast 6/10P micro-
injection molding system (ALBA Enterprises, Rancho Cucamonga,
CA) using custom-fabricated, water-cooled, torus-shaped aluminum
molds (Sorenson Mold, Inc., Midvale, UT). Target IVR dimensions
were 55 mm outer diameter (OD) with 5.0, 5.5 or 6.0 mm cross-
sectional diameter (XD). Injection-molding temperatures ranged
from 130 °C to 135 °C and mold temperatures ranged from 12 °C to
14 °C. The XD and OD of each ring were measured with digital cali-
pers and the mass of each ring was measured using an analytical bal-
ance. HPEU 20 pellets were also injection-molded to produce
placebo IVRs.
3.3. TFV quantiﬁcation by HPLC
TFV was quantiﬁed in extraction and release media samples by
HPLC analysis using methods similar to those reported previously
[16]. Detailed methods are described in the supplementary data
section.
3.4. Determination of drug loading in IVRs
The TFV mass fraction (ωT) in each IVR batch was determined by
performing drug extractions similar to those reported previously
[16]. Detailed methods are described in the supplementary data
section.
3.5. IVR swelling
Both placebo and TFV-loaded IVRs were incubated for 7 days in
25 mM sodium acetate buffer (pH 4.2) in a MaxQ 6000 shaker cabi-
net set to 37 °C and 80 rpm (Thermo Scientiﬁc, Asheville, NC).
Masses were measured using a digital balance.
3.6. Estimation of TFV solubility in hydrated HPEU
A slurry of TFV was prepared at 20% (w/w) in 50 mL of 25 mM so-
dium acetate buffer (pH 4.2), and incubated at 37 °C and 80 rpm for
approximately 24 h to allow for TFV dissolution, at which time it was
passed through an Express PLUS 0.22 μm ﬁlter (Millipore, Billerica,
MA), resulting in a saturated TFV solution. In a separate container,
5 g of HPEU 20 pellets were hydrated in 25 mM sodium acetate buff-
er (pH 4.2) for 24 h, and the pellets were removed and added to the
saturated TFV solution described above and returned to the shaker at
Fig. 2. IVR composition. Structural formulae for HPEU 20 (A) and tenofovir (TFV) (B),
along with a photograph of an example injection molded 21% TFV, HPEU 20 IVR (C)
(scale in cm).































37 °C and 80 rpm. Approximately 100 mg HPEU 20 were removed
daily and massed directly into a tared 10 mL volumetric ﬂask on an
analytical balance, which subsequently was ﬁlled with approxi-
mately 7 mL of buffer. Flasks were shaken on a large capacity mixer
(Glas-Col®, Terre Haute, IN) for 24 h to leach all TFV from the pellets,
at which time the pellets were removed, ﬂasks were ﬁlled to volume
with buffer, and the solution was analyzed by HPLC for TFV content.
After steady-state TFV concentration had been achieved, similar
leaching was repeated with replicates to estimate ωs. In a separate
experiment, it was determined that 24 h incubation was sufﬁcient
to reach TFV saturation in HPEU 20. To determine the aqueous solu-
bility of TFV in 25 mM sodium acetate buffer, another TFV slurry
(20% w/w in 25 mM sodium acetate buffer, pH 4.2) was prepared
in parallel. Aliquots were drawn into plastic syringes and passed
through 0.2 μm nylon syringe ﬁlters daily and analyzed by HPLC.
Again, the solubility was measured with replicates after steady-state
had been reached. Since placebo pellets were used to estimate ωs,
porosity-adjusted solubility values (ωs⁎) were calculated using the frac-






3.7. In vitro release testing of IVRs
IVRs were incubated for either 30 or 90 days in 25 mM sodium
acetate buffer (pH 4.2) in a MaxQ 6000 shaker set to 37 °C and
80 rpm. Sink conditions (TFV concentrations below 10% of solubili-
ty) were maintained throughout. Release media were changed
daily, aliquots of which were collected at various times throughout
the study (following approximately 24 h incubation) and analyzed
by HPLC for TFV content. Cumulative release was estimated by linear
interpolation of daily release rate proﬁles (see supplementary data
section). To observe the inwardmovement of the diffusion front dur-
ing release testing, photomicrographs of IVR cross-sections were
obtained with a Stemi 2000-C Stereo Microscope with a Stereo CL
1500 ECO light source (Carl Zeiss Microimaging, Thornwood, NY)
and CFW-1312C color digital camera (Scion Corporation, Frederick,
MD).
3.8. Drug release prediction
For each TFV release test a linear interpolation of product-
log-difference transform (PLDT) versus time data from day 3 to day
7 was used to compute the time constant (β) in Eqs. (2a) and (2b). Ef-
fective lag-time (caused by matrix hydration) was calculated by





A modiﬁed form of Eq. (4), obtained by replacing 't' with 't− tlag'
(see supplementary data section) was then evaluated using the
MATLAB 2011b Symbolic Math Toolbox (MathWorks, Natick, MA) to
predict cumulative release (MATLAB code can be found in the supple-
mentary section). The expected daily release rate proﬁle Q(t), calcu-
lated by sequentially subtracting the cumulative proﬁle, was then
compared to experimental data. Coefﬁcients of determination (R2)
were calculated by comparing measured and predicted data from
day 10 onward. The mean error in model prediction (μ(ε)) also was
calculated from day 10 onward by computing the arithmetic mean
of percentage discrepancies between experimental and theoretical
release rates. R2 values were also used to assess the linearity of
PLDT versus time from day 3 onward. Time constants (β) and
porosity-adjusted solubility values (ωs⁎) were used to estimate the








3.9. Compression testing of IVRs
Before and during drug release testing, the force required to com-
press TFV-loaded and placebo HPEU IVRs to up to 25% of their ODwas
measured using an Instron 3342 materials testing system, with
500 N load cell and Bluehill Lite software (Instron, Norwood, MA)
using methods similar to those previously described [16,30]. IVRs
were positioned in a rectangular aluminum cradle (6 mm in
width), and a cylindrical aluminum probe (6 mm diameter) was
placed directly above the IVR. The probe was moved downward at
a velocity of 1 mm/s, during which time load and displacement
values were measured. F10was deﬁned as the applied load following
displacement by 10% of OD, which approximates in situ compression
for NuvaRing® [31]. An F10 value alsowas determined for NuvaRing®
by a similar test. To calculate elastic moduli for both dry and hydrat-
ed matrices, linear regressions of force vs. compression data were
performed for the ﬁrst 1 mm of compression. By rearranging Eq. (6),
the elastic modulus for each IVR was then calculated using the slope







3.10. Mechanical model validation
To experimentally validate Eq. (6), the elastic modulus of TFV-
loaded HPEU was ﬁrst estimated by uniaxial tensile testing. Rod seg-
ments cut from 21% TFV IVRswere then annealed at 150 °C in a cylin-
drical aluminum mold, rolled ﬂat with a stainless-steel cylinder and
clamped between two aluminum plates to produce ﬁlms with 1 mm
thickness. Films were cut into strips approximately 11 mm in width
and exact dimensions were measured using digital calipers. The
Instron system was outﬁtted with 2710–203 screw-side action
clamps at an initial vertical spacing of 10 mm. Films were extended
by 1 mm at 1 mm/s. Elastic modulus values were derived by com-
puting the slope of linear regressions (R2≥0.999) of the stress versus
strain plots for extension values of 0.04 to 0.15 mm. The average
modulus value was used in Eq. (6) to predict the required force for
1% compression (of initial OD) of an IVR with 53 mm OD. This
model function was compared to compression data from IVR batches
containing 21% TFV (w/w). R2 values were calculated to assess model
accuracy.
4. Results and discussion
4.1. IVR fabrication
We compounded up to 0.5 kg TFV-HPEU batches using hot-melt
extrusion and fabricated IVRs using lab-scale injection molding.
Five batches of TFV-loaded, injection-molded HPEU IVRs were pro-
duced (an example can be seen in Fig. 2C). Three batches had an av-
erage XD of 5.0 mmwith varying TFV loadings (2%, 11% or 21% w/w).
The two remaining batches had an average XD of 5.6 mm and
6.0 mm and were loaded with 21% (w/w) TFV. All batches had an av-
erage OD of 52 or 53 mm. All IVRs produced were opaque and white
to off-white. The processing methods described herein represent a
marked improvement from those reported previously [11,16]. The































weakness of many innovative drug delivery systems, particularly
those intended for the developing world, is the lack of attention to
cost and scalability. With this in mind, we developed a two-step process
utilizing hot-melt extrusion and high-throughput injection-molding [32]
technologies commonly used in high-throughput plastics production.
4.2. IVR swelling
As shown in Fig. 3A, TFV-HPEU IVRs reached equilibrium swelling
within 48 h, indicating that the swelling front reaches the center of
the IVR within the ﬁrst two days of drug release, validating the
rapid swelling assumption discussed above. Equilibrium swelling ra-
tios, averaged from day 2 to day 7, were 20%, 22% and 25% of initial
IVRmass for placebo (no TFV), 11% TFV and 21% TFV IVRs, respective-
ly. A potential concern with use of a water-swellable IVR is the initial
size change upon insertion. The dry and hydrated dimensions of var-
ious IVR batches tested are shown in Table 1. The outer diameter of
these IVRs increased between 6% and 9% upon initial hydration,
resulting in rings with OD of up to 57 mm, which is in the range of
ODs for IVRs currently in clinical use [33].
4.3. TFV solubility
Using HPLC analysis of TFV slurry ﬁltrates, we determined that
TFV solubility in 25 mM sodium acetate buffer was 0.66±0.01%
(w/w) (22.9±0.2 mM) (N=5, mean±SD). The TFV solubility in
HPEU 20 pellets was assessed by 24 h leaching following storage in
a saturated TFV solution for 1, 2, 3, 4, 6 or 7 days, during which solu-
bility varied from 0.015% to 0.021% (w/w), with no discernible up-
ward trend. On day 8, HPEU 20 pellets were removed from the
saturated TFV solution and subjected to the same test. The TFV solu-
bility in hydrated HPEU 20 pellets (ωs) was determined to be
0.020±0.003% (w/w) (N=5, mean±SD); considerably less than
the 0.1% (w/w) obtained by scaling TFV solubility by aqueous mass
fraction. This suggests that TFV has limited solubility in the polymer
phase of this HPEU, and furthermore supports that only a fraction of
water molecules in the hydrated HPEU are free to solubilize TFV [34].
Porosity-adjusted TFV solubility values (ωs⁎) were calculated for each
IVR batch using Eq. (7) (shown in Table 1). It should be noted that
solubility measurements do not take into account the possibility for
TFV dissolution into the polymer phase during the high tempera-
tures experienced in melt processing, which could result in a
meta-stable, supersaturated TFV dispersion in HPEU 20 at 37 °C [8],
thus increasing ωs⁎ and decreasing Deff.
4.4. IVR mechanical characterization
An evaluation of TFV-HPEU IVR mechanical properties is pre-
sented in Fig. 4. Load varied non-linearly with compression distance,
as shown in Fig. 4A. Elastic moduli (Fig. 4B) were calculated using the
linear low-displacement (~1 mm) region of load versus displace-
ment curves and Eq. (6). For dry TFV-HPEU matrices, increasing the
TFV loading from 2% to 21% resulted in an increase of the mean elas-
tic modulus from 10 MPa to 26 MPa. Following hydration, the mod-
ulus of the 2% TFV-loaded matrix decreased to 7 MPa, while the
modulus of the 21% TFV-loaded matrix decreased to 12 MPa. Using
ring compression, the dry and hydrated elastic moduli of placebo
HPEU 20 were determined to be 11 and 8 MPa, respectively. In gen-
eral, the elastic moduli of the dry and hydrated HPEU matrices in-
creased with incorporation of undissolved TFV particles, but the
magnitude of this effect was markedly reduced following polymer
hydration. Assuming no adhesion occurs between undissolved TFV
aggregates and HPEU molecules, the particles are likely disengaged
from the polymer matrix upon hydration [35]. If TFV aggregate sur-
faces are well-hydrated, the resulting TFV slurry formed within the
porous matrix should likely have little-to-no effect on matrix elastic-
ity, which would explain the results shown in Fig. 4B–D.
The force required to compress IVRs to 10% of OD (F10) [31] was
evaluated as a function of time during release testing (Fig. 4C and
D). Nearly a two-fold drop in F10 was observed following matrix hy-
dration, except for in 2% TFV (w/w) loaded IVRs, where the average
F10 only dropped from 0.75 N to 0.64 N over the ﬁrst three days.
For 21% TFV IVRs, a gradual decrease in the F10 was observed over
90 days, which is likely due to continued depletion of undissolved
TFV. The F10 increased by 82% (averaged over all measurements dur-
ing release testing) when the XD of 21% TFV IVRs was increased from
5.0 mm to 5.6 mm (only a 12% increase). For the 5.0 mm, 21% TFV
IVR group, the average F10 ranged from 1.6 N at t=0, to hydrated
values of 0.9 N on day 2, 0.6 N on day 20, and 0.5 N on day 90. The
F10 of the contraceptive IVR NuvaRing® tested under the same con-
ditions (dry) was 0.7 N.
While the non-linear stress–strain behavior observed is unre-
markable given the viscoelasticity inherent to such elastomers [36],
the mechanical model presented in Eq. (6) does not account for
such viscoelastic effects, as it is derived from a linear elastic constitu-
tive model. Accordingly, 1% IVR compression force (F1) values, rather
than F10 values, were used for mechanical model validation (Fig. 4E).
The elastic modulus value for HPEU 20 loaded with 21% TFV (w/w)
was determined to be 24.9±1.7 MPa (N=3, mean±SD) from uni-
axial tensile testing. 53 mm OD, 21% TFV-HPEU 20 IVRs with either
5.0 mm, 5.6 mm or 6.0 mm XD had 1% compression force values
which correlated to values calculated from Eq. (6) (R2=0.997).
Model predictions for F1 as a function of XD for both dry and hydrat-
ed HPEU loaded with 21% TFV are shown in Fig. 4F to further illus-
trate the impact of IVR geometry and hydration state on IVR
compressibility.
Table 1
Dimensions (dry/hydrated), TFV loading (ωT), porosity-adjusted solubility (ωs⁎) and ef-
fective TFV diffusivities (Deff) for TFV-HPEU IVRs. Loadings were determined by drug
extraction, solubilities using Eq. (7), and diffusivities using Eq. (9).
OD (mm) XD (mm) ωT (% w/w) ωs⁎ (% w/w) Deff (10−7 cm2/s)
52/55 5.0/5.4 2.3 0.022 4.9
53/56 5.0/5.4 11.1 0.029 4.8
53/57 5.0/5.4 20.6 0.038 6.7
53/57 5.6/6.1 20.6 0.038 5.6
Fig. 3. Movement of the swelling and diffusion front. Percentage mass increase of
TFV-HPEU 20 IVRs under aqueous sink conditions at 37 °C (A). Equilibrium swelling
is reached within 48 h. Mass loss due to drug release is not considered. Data represent
N=3, mean±SD. Photomicrographs of IVR cross-sections prior to (B) and following
(C) 30 day drug release testing illustrating the movement of the diffusion front (rd).































Despite the limitations of Eq. (6) in predicting behavior at high
deformations, it can be used to predict low-deformation behavior di-
rectly from elastic modulus and IVR dimensions. Furthermore, the
model can be used to generate ﬁrst-order estimations of appropriate
ring dimensions required to achieve targeted mechanical properties.
Themodel could be improved by replacing the linear elastic constitutive
modelwith a hyperelasticmodel (e.g.,Mooney–Rivlin) suitable for elas-
tomers. While an increase in drug loading will generally increase drug
release rates and duration (discussed below), it will result in in-
creased initial elastic modulus and a higher-magnitude drop in elas-
tic modulus following initial hydration and throughout the duration
of use. IVRs with 5.0 mm XD and 21% TFV loading had F10 values
more than twice those of NuvaRing® prior to release testing and
had F10 values approximately 30% less than NuvaRing® after release
testing. Various reports from clinical literature [20–22] indicate an
optimal range exists for IVR mechanical properties, however, there
is no consensus as to the appropriate metric for quantitatively deter-
mining mechanical IVR acceptability. If the load under compression
is insufﬁcient, an IVR may be displaced or expelled by the user. How-
ever, if the compression force is unnecessarily high, it may cause
user discomfort or even inﬂammation and/or damage to the vaginal
epithelium. We have introduced F10 as a metric for IVR acceptability
based on MRI observations of in vivo ring placement [31]. Even given
this metric, our approach for estimating mechanical acceptability
was still limited to comparing F10 values to a commercially available
IVR.
4.5. TFV release from HPEU IVRs
Release rates of TFV from HPEU IVRs, shown in Fig. 5, exhibited
the time dependence generally associated with diffusion-limited
matrices [12]. IVRs loaded with 21% TFV released greater than
2 mg/d for 90 days, although release rates decreased by more than
an order of magnitude over this time period. IVRs loaded with 2%,
11% or 21% TFV (5.0 mmXD) were tested for 30 days (Fig. 5A). By in-
terpolation, cumulative release was estimated to be 93%, 55% and
56% of the initial load from the 2%, 11% and 21% TFV-loaded IVRs, re-
spectively, after 30 days (Fig. 5B). The increase in 30 day cumulative
release from 2% to 11% TFV IVRs illustrates the correlation between
release duration and loading (Eq. (3)), although it appeared that lon-
ger experiments would be needed to show this relationship between
the 11% and 21% TFV groups, since linear loading-dependent release
was observed for 30 days.
Example photomicrographs of IVR cross-sections before and after
30 day release testing (Fig. 3B and C) illustrate the movement of the
diffusion front (rd). IVRs containing 21% TFV with XD of either 5.0 or
5.6 mm were subjected to in vitro release testing for 90 days. It was
estimated that 87% and 76% of the initial TFV loading was released
from the 5.0 mm and 5.6 mm XD IVR groups, respectively, after
90 days (Fig. 5D). The product-log-difference transform (PLDT) of
cumulative release was calculated for each IVR group. As shown in
Fig. 6A, PLDT generally varies linearly with time, as predicted by
Eq. (2a), (R2>0.997).
Linear regressions of PLDT versus time data (Fig. 6B) were used to
calculate time constants (β), which were used in a modiﬁed form of
Eq. (4) (incorporating a lag time shift, see supplementary data) to
construct 30 and 90 day release rate predictions, as shown in
Fig. 6C and D. Coefﬁcients of determination (R2) from day 10 onward
were greater than 0.8 in all cases. The mean error in prediction was
less than 10% except for the 2% TFV IVR group, where the mean
error was 14%. As shown in Fig. 6B, PLDT versus time ﬁts, calculated
from d3–d7, intercept the positive time axis when extrapolated to
PLDT=0, indicating that lag-type behavior occurs at early times dur-
ing TFV release. Lag times, calculated by Eq. (8), ranged from 10 to
12 h. This suggests that, although 48 h were required for complete
IVR swelling, the swelling front moved sufﬁciently inward in the
ﬁrst 12 h to achieve constant TFV diffusivity outside the diffusion
front. Similar lag-time corrections have been employed to modify
the Higuchi equation when considering early unsteady interfacial
mass-transfer [37].
Porosity-adjusted matrix solubility values were used with time
constants to calculate the effective diffusivity of TFV for each IVR
batch using Eq. (9). All diffusivity values were between 5–7×10−
7 cm2/s, indicating the architecture of the porous aqueous phase is
similar regardless of drug loading. These effective diffusivities are
functions of TFV aqueous diffusivity, TFV-polymer hydrodynamic
interactions and pore tortuosity (neglecting any transport in the
polymer phase) [38]. Fig. 6D shows that Eq. (4) (modiﬁed form)
can be used to predict 90-day release from TFV HPEU IVRs given
data from a 7-day drug release test. Although precise ﬁts were not
achieved between theoretical and experimental data, the mean
error in model prediction across all model time points was less
than 15%. This model can be used to reduce signiﬁcantly the
time-scale and experimental workload for the development of
new IVR systems by eliminating the need to run full duration drug
release studies during the formulation screening process. This
model may prove useful for water-swellable IVRs with negligible
Fig. 4. Mechanical testing of IVRs. (A) Example load vs. compression proﬁles for 21%
TFV IVRs with varying XD. The nonlinearity deviates from the model shown in
Eq. (6). (B) HPEU 20 elastic moduli as a function of TFV loading estimated from IVR
compression testing (Eq. (10)) either dry or hydrated (following 2–3 day drug release
testing). (C,D) F10 values as a function of time during drug release testing showing both
effects of increasing TFV loading with constant XD (5.0 mm) (C) and effects of increas-
ing XD with constant TFV loading (21% TFV) (D). (E) Low-strain (compression by 1% of
initial XD), validation of the IVR compression model presented in Eq. (6); average (N=
3) low-strain IVR compression data is well-correlated (R2=0.997) to a model
low-strain load vs. cross-sectional diameter curve. (F) Predicted 1% compression forces
(F1) are shown as a function of XD for 53 mm OD HPEU IVRs with 21% TFV, both dry
and hydrated. Data represents N=3, mean±SD for panels B-D (except N=6 for 21%
TFV points in panel B).































drug-polymer solubility, such as presented here, as well as for
non-swellable matrix-type systems where the drug load far exceeds
polymer solubility.
The exact release rate of TFV from an IVR required to achieve pro-
tection against HIV transmission in women is unknown. Efforts in
the HIV prevention ﬁeld are focused on correlating effective suppres-
sion of viral replication in tissue to antiviral drug concentrations
measured in the vaginal vault using human trial data [39], as well
as through pharmacokinetic [40] and challenge [41] studies in
non-human primates. It is likely that when high bolus doses of TFV
are administered vaginally, the efﬁciency of uptake into the vaginal
tissue is low [14], meaning that the potential 80 mg TFV adminis-
tered within a 24-hour period in CAPRISA 004 may not provide a
dose metric on which to base long-duration delivery systems. Thus,
matrix systems with increasing diffusion lengths and corresponding
decreases in drug ﬂux may not provide sustained levels of anti-
retrovirals to prevent viral invasion of the mucosa across multiple
episodes of exposure at later time points. Furthermore, the high re-
lease rates (as high as ~50 mg/d) seen in the early part of the release
proﬁle may provide a loading dose but also could result in toxicity
and potential loss of mucosal barrier function.
When testing this IVR in the pig-tailed macaque model, we have
observed that similar milligram-per-day release rates of TFV can be
replicated in vivo (unpublished data). While the 21% TFV IVR is capa-
ble of releasing greater than 2 mg/day for 90 days, there is a large
drop in the release rate from day 1 to day 90. Depending on the re-
lease rate required for effective tissue protection, this IVR may not
be effective over the complete 90 day proﬁle, but could provide ade-
quate protection for shorter durations (e.g., 30 days). To achieve the
goal of developing an IVR which remains efﬁcacious for longer dura-
tions, we are developing a reservoir-type IVR system for 90 day,
zero-order TFV delivery [42].
Our theoretical and experimental presentation illustrates that
co-optimization of drug release rates and IVR compressibility in a
swellable matrix system containing a high weight fraction of
undissolved drug is challenging. Drug release rates and IVR stiffness
Fig. 6. Analysis of drug release. (A) Product-log-difference transforms (PLDT) of cumu-
lative release data, as deﬁned in Eq. (2a), are generally linear with time (R2>0.997).
(B) Linear regressions of early-time PLDT (calculated from d3-d7 and extrapolated to
the x-axis) used to derive release time constants (β) (R2>0.999). (C,D) Accuracy of
the model presented in Eq. (4) in predicting TFV release rates from 5.0 mm XD IVRs
using time constants extracted from regressions shown in panel B. The 5.6 mm, 21%
TFV group (not shown) had R2 and mean error (μ(ε)) values of 0.879 and 9.3%,
respectively.
Fig. 5. Drug release testing. (A) Daily release rates measured by HPLC and (B) cumulative release estimated by linear interpolation from 5.0 mm XD IVRs with various TFV loadings
(% w/w) for 30 days. (C) Daily release rates measured by HPLC and (D) cumulative release estimated by linear interpolation from 21% TFV IVRs with differing cross-sectional di-
ameter (XD) for 90 days. All experiments were performed in 25 mM sodium acetate buffer (pH 4.2) at 37 °C and 80 rpm. Sink conditions were maintained throughout testing.
Data represent N=3, mean±SD in panels A and C.































are both positively correlated with initial drug loading and XD. This
indicates that a very narrow design space of ring dimensions and
drug loadings capable of yielding an IVR that performs within design
speciﬁcations may exist, which may necessitate the investigation of
different polymer systems and/or different IVR designs. Nonetheless,
this work illustrates that a deep, quantitative understanding of rele-
vant physical mechanisms is required to effectively design and de-
velop long-acting dosage forms.
5. Conclusion
Here we present an HPEU intravaginal ring capable of sustained
release of TFV, an inhibitor of HIV-1 reverse transcriptase, whose
simple design may allow for easy scale-up to clinical production.
However, there are several limitations to this IVR design that reduce
its potential usefulness as a clinical product; notably the large de-
crease in TFV release with time, as well as the change in mechanical
properties upon ring hydration. We also have presented drug release
and solid mechanical models that can be used to optimize such an
IVR system with minimal experimental work given inputs of desired
mechanical properties and minimum release rates. Our model and
simple resulting formulae should be extendable to any IVR system
where the drug loading far exceeds polymer solubility.
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Abstract
The HIV/AIDS pandemic and its impact on women prompt the investigation of prevention strategies to interrupt sexual
transmission of HIV. Long-acting drug delivery systems that simultaneously protect womenfrom sexual transmission of HIV
and unwanted pregnancy could be important tools in combating the pandemic. We describe the design, in silico, in vitro
and in vivo evaluation of a dual-reservoir intravaginal ring that delivers the HIV-1 reverse transcriptase inhibitor tenofovir
and the contraceptive levonorgestrel for 90 days. Two polyether urethanes with two different hard segment volume
fractions were used to make coaxial extruded reservoir segments with a 100 mm thick rate controlling membrane and a
diameter of 5.5 mm that contain 1.3 wt% levonorgestrel. A new mechanistic diffusion model accurately described the
levonorgestrel burst release in early time points and pseudo-steady state behavior at later time points. As previously
described, tenofovir was formulated as a glycerol paste and filled into a hydrophilic polyurethane, hollow tube reservoir that
was melt-sealed by induction welding. These tenofovir-eluting segments and 2 cm long coaxially extruded levonorgestrel
eluting segments were joined by induction welding to form rings that released an average of 7.5 mg tenofovir and 21 mg
levonorgestrel per day in vitro for 90 days. Levonorgestrel segments placed intravaginally in rabbits resulted in sustained,
dose-dependent levels of levonorgestrel in plasma and cervical tissue for 90 days. Polyurethane caps placed between
segments successfully prevented diffusion of levonorgestrel into the tenofovir-releasing segment during storage.Hydrated
rings endured between 152 N and 354 N tensile load before failure during uniaxial extension testing. In summary, this
system represents a significant advance in vaginal drug delivery technology, and is the first in a new class of long-acting
multipurpose prevention drug delivery systems.
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Introduction
The global HIV/AIDS pandemic continues to drive advances
in biomedical technologies designed to quell the spread of the virus
[1]. The recent USFDA approval of oral TruvadaH for HIV pre-
exposure prophylaxis (PrEP) in discordant couples is a major
biomedical advance [2]. But clinicians have encountered difficulty
in consistently demonstrating PrEP efficacy in prevention trials. In
the CAPRISA 004 trial, topical vaginal application of the
tenofovir (TFV) 1% gel used episodically before and after
intercourse resulted in a 39% reduction in HIV infection in
women [3]. But the same TFV gel did not reduce transmission
rates when used once daily [4]. The variability in trial outcomes
has caused consternation and several thoughtful reviews
[5,6,7,8,9]. Yet the progress is evident when simultaneously
considering the success of oral Truvada, the modest effect in
CAPRISA 004, and alongside the accumulating evidence of the
protective effect of TFV from non-human primate studies
[10,11,12]. It is now conceptually clear that using oral and topical
antiretroviral (ARV) drugs to interrupt the early events of sexual
HIV transmission and dissemination is biologically and biomed-
ically possible. The poor clinical outcomes result from confound-
ing factors that span across behavioral, biological and pharmaco-
logical causes. Since the discovery of low rates of adherence in the
Carraguard trial [13] and subsequently in the VOICE trial [4] it
has been clear that infrequent use of gels by women likely has been
a significant factor contributing to the low rates of effectiveness
observed in most gel PrEP trials to date. For many reasons, trial
participants are not sufficiently motivated to use the prevention
products as instructed. Therefore, if PrEP is to be a technological
success, new PrEP modalities are desperately needed that are
easier to use and more desirable to women, and are supported by
high user demand.
There are two main approaches being explored to increase user
demand for PrEP, to either increase device duration or to make
devices that are multifunctional and satisfy more than one user
need. It is observed across many types of pharmaceutical products



























that user adherence and dose duration are positively correlated
[14,15]. To this end much effort has been directed toward long-
acting injectable ARV [16] and ARV eluting intravaginal rings
(IVR) [17,18] for PrEP. Adding multiple functions, indications or
purposes is also receiving attention as a method for improving user
demand. Hormonal contraception is a well established technology
in many low income countries impacted by the HIV pandemic.
This has motivated the development of biomedical devices, and in
particular long-acting IVR [19,20,21] that elute both contracep-
tive hormones and ARV. The development of multipurpose
prevention technologies (MPT) could be ground breaking as there
are no approved products that use two drugs to simultaneously
address multiple indications. Yet the literature and the drug store
shelf are replete with examples of fixed dose drug combinations
designed to treat a single indication that were developed to
improve ease of use, patient compliance and outcomes [22,23].
As one might expect, there are a host of contraceptive agents
and ARV under evaluation for use in MPT. The progestin
levonorgestrel (LNG) is a leading contraceptive agent with a long
history of clinical use in topical and oral administration. The
MirenaH intrauterine system releases up to 20 mg LNG per day for
5 years. The WHO also developed a silicone reservoir IVR that
released approximately 20 mg LNG per day for 90 days [24]. In a
large multi-center clinical trial, the LNG IVR was over 95%
effective in preventing unintended pregnancy. Tenofovir (TFV) is
the leading ARV for many reasons including its approval for PrEP,
its long clinical safety record (tenofovir prodrug formulations are
currently used by 3.5 million people), extended duration of cellular
levels following dosing and stability. But simultaneous dosing of
TFV and LNG at relevant levels from simple, monolithic IVR is a
challenge due to differences in their properties and target release
rates, mandating the investigation of customized IVR designs.
We recently demonstrated the three-month zero-order delivery
of TFV from a hydrophilic polyether urethane (HPEU) reservoir
IVR [25]. In this report we describe the engineering and design of
a segmented dual-reservoir IVR for the controlled delivery of TFV
and LNG for 90 days. This manuscript illustrates the challenges of
designing and integrating a solid, non-swellable LNG-releasing
polyether urethane (PEU) reservoir into the existing swellable
HPEU reservoir technology. We used a combination of in silico, in
vitro and in vivo methodologies to study, engineer and evaluate the
combination IVR. We present new insights regarding the use of
the chemically diverse class of elastomeric PEU in reservoir-type
dosage forms to deliver chemically diverse molecules at greatly
divergent release rates. The work resulted in an IVR that gives
nearly time-independent vaginal delivery of TFV and LNG for
three months.
Design
All clinically-used IVR in the U.S. employ reservoir technol-
ogies, however HIV prevention researchers have often investigated
simpler matrix IVR designs to reduce manufacturing complexity
and cost [26,27,28,29]. Reservoir IVR are more attractive from a
pharmacokinetic perspective as they can provide constant drug
levels in the reproductive tract over extended durations [25].
Matrix IVR intrinsically provide high initial release rates, followed
by continuously attenuated rates over time [17]. This is generally
undesirable for PrEP applications, because the maintenance of
preventative ARV levels for the intended IVR duration will
require an excess of ARV exposure at early times during the
release profile, presenting potential safety concerns. Furthermore,
design limitations hindering the attainment of sufficient drug
release rates can render it impossible to achieve high drug levels
throughout the release profile and may result in increased
probability of HIV acquisition late in the release profile of a
matrix ARV-eluting IVR. These pharmacological limitations drive
the investigation of reservoir IVR technologies that have the
potential to provide precise and tunable control over the drug
release rates for as long as several months.
TFV and LNG exhibit approximately 7-log and 4-log
differences in their partition/distribution coefficients and aqueous
solubilities, respectively (Figure 1A and 1B), precluding their
simultaneous solubilization and controlled release from a single
polymeric compartment. To address these differences in molecular
properties, we utilized chemically diverse polyether urethanes
(PEU) capable of solubilizing and delivering TFV and other ARVs
with varying physicochemical properties [30,31,32,33]; an ability
not generally afforded by the traditionally used silicone and
poly(ethylene-co-vinyl-acetate) elastomers. Poly(ethylene oxide)
can be added alongside the poly(tetramethylene oxide) soft
segment typically used in PEU to create hydrophilic poly(ether
urethanes) (HPEU) that swell in aqueous solution and can
solubilize hydrophilic drugs when hydrated. Furthermore, PEU
and HPEU are otherwise chemically identical and can be readily
melt-welded to form mechanically sound IVR.
In addition to their disparate chemical properties, TFV and
LNG also require vastly different release rates for their respective
pharmacological effects. Our group designed an HPEU hollow-
tube reservoir IVR to release 10 mg TFV per day [25], which we
similarly targeted for the TFV/LNG IVR. However, as described
above much lower release rates of LNG are employed for topical
microdose contraception. We chose targets of 10 and 20 mg LNG
per day, similar to the MirenaH intrauterine system and WHO’s
silicone LNG IVR. To address the challenge of delivering these
diverse molecules at divergent release rates we designed a two-
segment reservoir IVR system [31] containing an analogous TFV
reservoir segment [25] and a PEU reservoir segment containing
dissolved LNG. We desired to create a platform technology from
which three devices, all with the same overall size (5.5 mm and
55 mm cross-sectional and outer diameters, respectively), could be
fabricated to deliver ,10 mg TFV per day with LNG daily doses
of either 0 (TFV-only), 10 or 20 mg.
Generally, drug release rates (dM/dt) from end-capped cylin-
drical reservoir devices, like IVR or IVR segments can be varied
by changing the segment length (l), core drug concentration (cin) or
the outer, rate controlling membrane (RCM) thickness (represent-
ed by the subtraction of outer and inner cross-sectional radii,
ro2ri). A steady-state description, assuming constant cin, is easily










where D is the effective diffusivity of the drug in the RCM
material. To achieve the membrane-controlled release described
in Equation 1, the drug-loaded core must be well-mixed so that the
drug concentration remains uniform throughout the core and at
the core/membrane boundary. For a solid polymer system, like
the LNG segment, this is achieved by choosing a core polymer
with much higher drug diffusivity than that of the RCM polymer.
Specifically for PEU, drug flux can be hindered by increasing the
volume fraction of crystalline hard segments. This is also easily
maintained for a hollow-tube system like the TFV segment [25],
because of the large differences in diffusivity between the liquid
core and the porous membrane of the wall.
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We chose to modify LNG release rates by changing the length
of the LNG-segment. We desired to minimize LNG segment
length to allow for minimal change in TFV dose between devices,
but also sought to minimize the core LNG concentration because
of potential physical stability issues of supersaturation and re-
crystallization on the IVR surface [36]. Thus, we arrived at a
target release rate 1 mg/mm/day for the LNG segment, leading to
two IVR prototypes with segments of 10 and 20 mm length to
deliver 10 mg and 20 mg LNG per day, respectively. A diagram of
the 20 mm configuration is shown in Figure 1C, and a photograph
showing both IVR configurations (with either 10 mm or 20 mm
LNG segments) is shown in Figure 1D. We also added diffusion-
limiting end-caps between the two segments (Figure 1C, shown in
blue) to prevent circumferential diffusion of LNG from the solid
PEU reservoir (green/red) to the HPEU tubing in the TFV-
releasing segment (gray). The end-caps are composed of the same
PEU used to create the RCM.
Theory
Mathematical models of drug transport can aid the in silico
design of drug delivery systems [37] including IVR [26,38]. TFV
release occurs at a constant rate as predicted by Equation 1, due to
an excess of un-dissolved drug which maintains a constant TFV
core concentration [25]. For the LNG segment in the TFV/LNG
Figure 1. IVR Design Overview. Structural formulae of (A) the HIV-1 nucleotide reverse transcriptase inhibitor tenofovir (TFV) and (B) the progestin
contraceptive levonorgestrel (LNG). (C) A design schematic of the full TFV/LNG IVR, shown in the 20 mm LNG segment configuration illustrating the
LNG-loaded core (green), the rate-controlling membrane (RCM, red), diffusion-limiting end-caps (blue) and the hollow HPEU tube containing TFV-
loaded paste (gray). (D) Photographs of TFV/LNG IVR in the 10 mm (left) and 20 mm (right) LNG segment configurations. (E) Illustration of a reservoir
cross-section with outer and inner radii ro and ri, and core drug concentration cin. (F) Photomicrograph of the LNG segment cross-section showing
microscopic measurement of RCM thickness. (G) Component parts of the TFV/LNG IVR: a TFV paste-filled HPEU tube (bottom), a co-axially extruded
LNG-loaded reservoir segment (top) and two diffusion-limiting end-caps (left and right).
doi:10.1371/journal.pone.0088509.g001
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IVR, two issues confound the simple description of drug release
presented in Equation 1. First, if LNG is equally distributed
throughout the cross-section (core and membrane) at t = 0, then
the device will initially behave as a matrix device, resulting in a
period of burst release, which we refer to as the ‘burst regime’,
prior to the onset of steady-state release [34]. Second, as LNG is
completely dissolved in the PEU core, the drug source (cin)
diminishes with time as drug is released, even after steady-state is
achieved. We refer to this pseudo-steady-state (PSS) period as the
‘steady state regime’. We derived a comprehensive model which
addresses both of these issues. Throughout, we assume the drug is
completely dissolved at equal concentration in both the core and
outer membrane at t = 0, and that equipartitioning exists between
the core and RCM polymer. Axial diffusion is neglected because
the loss of LNG to the end-caps occurs on a much longer time-
scale than that of drug release.
Radial drug release from cylindrical matrices. Diffusion-
limited drug release of a purely dissolved drug from a cylinder with
no axial diffusion is presented in the literature [39]. At early times
(up to ,20–30% of cumulative release), the following first-term











where M is cumulative release, M0 is the initial load of the device
(or the cumulative release at infinite time), D is the effective drug-
matrix diffusivity, and ro is the radius of the cylinder. Equation 2
will describe drug release in the burst regime for a solid reservoir
with initial homogeneous drug concentration.
Computation of burst duration. We compute the burst
regime duration assuming the device will proceed as a matrix until
its initial steady state profile is reached. The steady-state profile is
then integrated to obtain the mass loss required to complete the
burst. First we solve Fick’s Second Law in the steady-state form
with a c = c0 boundary at r = ri and a sink outer boundary (c = 0 at










We now integrate the right-hand-side of Equation 3 from ri to ro
and scale appropriately to determine the mass remaining in the



















To avoid confusion, in this manuscript a capital ‘‘M’’ will
represent to the cumulative drug mass released from the device,
while a lower-case ‘‘m’’ will represent the drug mass remaining in
various compartments of the device. By subtraction we compute














Combining Equation 5 with Equation 2 and solving for t, we

















There is some approximation in the computation of Equation 6, as
concentration profiles in a matrix device following release of Mb
and in a reservoir system at steady-state are likely not identical.
Some time is required for the system to adjust from the matrix to
the reservoir profile when the system becomes constrained by the
core boundary condition, during which additional drug is depleted
from the core. Depending on the relationship between outer
boundary flux during this transitional period and the predicted
reservoir flux at when c = c0, Equation 11 (below) will over- or
underestimate release rates during this period. This phenomenon
is discussed further in the Supporting Information (see Table S1
and Figures S1 and S2 in File S1)
Pseudo-steady-state adjustment for variable core
concentration. To effectively describe the attenuation of drug
release rates in the steady-state regime, we employ a PSS
technique which allows cin in Equation 1 to vary with time. First,
we must replace cin with an expression which depends on the mass
remaining in the device (which we denote as m) and the geometry
of the device. However m must represent the total system drug













Solving Equation 7 for cin and substituting into Equation 1 yields a
simple ODE, although we must first replace dM/dt, which
represents the rate of mass being released from the system, with







Solving the ODE, applying the initial condition c = c0 at tb gives an
expression for the mass remaining in the steady-state-regime.
Taking a time-derivative and applying the negative sign we obtain
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  1{e{a t{tbð Þ  ð10Þ
We now have a simple exponential time constant (‘a’) to describe
release rate attenuation. A PSS reservoir model was previously
described for cylinders [40], but was complicated by consideration
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of axial release from the device, and did not consider the error in
the depletion of drug from the outer membrane.
Complete two stage drug release model. We now have a
complete, piece-wise description of cumulative drug release from
the LNG segment, depending only on drug-polymer diffusivity in











  1{e{a t{tbð Þ  t§tb ð11bÞ
as described previously [26], daily release rates then are readily
computed by subtraction. It should be noted that, as Equation 2 is
a first-term approximation valid only at early times for a matrix
device, Equation 11 will lose accuracy for proportionally thicker
RCM (lower values of ri/ro). This is further discussed in the
Supporting Information (File S1).
Materials and Methods
Materials
Aliphatic polyether urethanes Tecoflex EG-85A, Tecoflex EG-
60D, Tecoflex EG-65D, Tecoflex EG-100A and the hydrophilic
Tecophilic HP-100A-60 were purchased from Lubrizol Advanced
Materials (Wickliffe, Ohio). Additionally, PEU-1 (73A-77A shore
hardness), PEU-2 (59D shore hardness) and HPEU-35 (78A shore
hardness, 37% equilibrium water absorption) were provided by
DSM-PTG (now a subsidiary of DSM Biomedical, Berkeley,
California). TFV was provided by Gilead Sciences (Foster City,
California), and micronized LNG was obtained from Industriale
Chemica (Saronno, Italy) or Haorui Pharma-Chem Inc. (Edison,
New Jersey). USP grade glycerol was purchased from Spectrum
Chemicals and Laboratory Products (New Brunswick, New
Jersey). Solutol HS 15 was obtained from BASF (Florham Park,
New Jersey). All water used was either USP grade or double de-
ionized (DDI) through an 18 mV*cm filtration system. All other
solvents were HPLC or ACS grade unless noted.
LNG and TFV quantification by HPLC analysis
TFV and LNG quantification were performed using a 1200
Series HPLC (Agilent Technologies, Santa Clara, California)
equipped with a diode array detector. TFV was quantified in in
vitro release samples by a 15-minute gradient method described
previously [25,26]. Various HPLC methods were used to quantify
LNG in unknown samples. In all cases a Zorbax ODS
4.66250 mm, 5 mm column was used and LNG was quantified
at 240 nm. For drug extraction samples a 5 minute isocratic run of
20:80 (v/v) DDI H2O:acetonitrile (ACN) was used, whereas a
gradient method was used to quantify LNG in in vitro release
samples. A longer gradient method was used to quantify LNG in
samples containing both TFV and LNG due to interference from
TFV elution. Both gradient methods are described in detail in the
Supporting Information (see Tables S2 and S3 in File S1).
Dissolution testing of matrix devices to determine LNG-
PEU diffusivities
Drug-polymer effective diffusivity was determined using matrix-
type PEU segments to aid in the design of the LNG segment and
evaluation of RCM polymers. LNG was compounded by roll-
coating and hot melt extrusion in each polymer using a Haake
Minilab extruder (Thermo Scientific, Tewksbury, Massachusetts)
to an approximate final diameter of 5 mm. Next, 2 mm length
segments were excised from the extrudate batch and subjected to
the extraction method below to determine the LNG loading for
each batch. Segments approximately 15 mm in length were then
cut and end-capped as described previously [27]. Before capping,
the exact length and diameter of each segment were measured
with digital calipers and the exact mass of each segment was
measured with an analytical balance. Segments were subjected to
release testing in sodium acetate buffer (pH 4.2) with 2% Solutol
HS 15 [30] for 7 days at either 23uC, 37uC or 50uC. Aliquots of
release media were collected daily and analyzed by HPLC. Daily
release data were summed sequentially to determine cumulative
release, which was normalized to the initial LNG mass in each
segment. Linear regressions of cumulative data against the square-
root-of-time were performed from day 3 to day 7 (some non-
linearity was observed on days 1 and 2).
As discussed above, diffusion-controlled release from a cylin-
drical matrix device wherein the drug is completely dissolved and
axial transport can be neglected can be approximated by a simple
relation at early-times (Equation 2). If the expected linearity of
fractional cumulative release (M/M0) against the square-root-of-
time is observed experimentally, Equation 1 can be re-arranged to






where ro is the cross-sectional radius of the device and k is the slope
of the linear regression of fractional cumulative release against the
square-root-of-time.
LNG Segment and IVR fabrication
A diagram detailing the TFV/LNG IVR manufacturing
scheme is shown in the Supporting Information (Figure S3 in
File S1). To fabricate LNG reservoir segments, LNG was first
dissolved in either PEU-1 or EG-85A by hot-melt extrusion. PEU-
1/EG-85A pellets were roll-coated with LNG powder (up to 2%
w/w) and flood-fed into a KETSE 12/36 twin-screw extruder
(TSE) (C.W. Brabender, South Hackensack, New Jersey) and cut
using a Micropelletizer (Randcastle Extrusion Systems Inc., Cedar
Grove, New Jersey). The pelletized extrudate was then subjected
to extractions and HPLC analysis to determine drug content as
described below. In some cases, LNG-loaded pellets were then
mixed with placebo pellets to the desired average LNG loading
(,1.3% w/w). LNG-containing reservoir strands were then
fabricated by co-axial extrusion. The TSE was connected to a
3/40 single screw extruder (SSE) w/advanced torque rheometer
drive (C.W. Brabender) at a 90u angle using a custom-designed
mandrel crosshead (Guill Tool, West Warwick, Rhode Island).
The LNG-loaded pellet mixture was starve-fed gravimetrically
into the TSE using a KCL-24-KQx4 loss-in-weight feeder (K-
Tron, Pitman, New Jersey) while PEU-2 or EG-65D pellets were
flood fed into the SSE to form an outer rate controlling membrane
(RCM) around the LNG-loaded PEU core. In some studies, EG-
60D was used as an RCM polymer in place of EG-65D. The
coated extrudate was passed through a water trough followed by
cold air drying using an Air Wipe cooling ring connected to a
Adjustable Spot Cooler vortexing tube (Exair, Cincinnati, Ohio)
and fed to a conveyor belt, from which coaxial strands
approximately 2–3 feet in length were manually cut. The feed
rate of PEU-1, the SSE screw speed and the conveying speed were
modulated to form a cylindrical reservoir extrudate with target
dimensions of 5.5 mm outer diameter and 5.3 mm inner diameter
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(0.1 mm RCM thickness). In some experiments the RCM
thickness was varied between 0.05 and 0.15 mm. To facilitate
LNG diffusion into the RCM, thus mitigating the lag-times
required to achieve steady-state release, strands were treated for 14
days at 40uC/75%RH prior to end-capping. In some cases heat
treatment was varied between 4 and 76 days at 40uC/75%RH to
assess the kinetic effects on lag/burst behavior during drug release.
If segments were fabricated for inclusion in full TFV/LNG IVR,
heat treatment was performed on the full IVR instead of the
parent co-axial strand as described below. Segments of either 10 or
20 mm length were cut from their parent strands. A process flow
diagram for LNG-loading co-axial extrusion is presented in the
Supporting Information (Figure S4 in File S1). Exact lengths and
diameters of LNG segments were measured by a digital caliper or
thickness gage. Exact RCM thicknesses were determined by
cutting thin slices of co-axial strand (either throughout the batch or
proximal to individual samples) and imaging by bright field
microscopy (Figure 1F). Four measurements per cross-section were
taken using cellSens Standard software (Olympus, Center Valley,
Pennsylvania) and averaged to determine a representative
thickness for a given sample or batch. To prevent significant
leakage of LNG into the TFV segment, LNG-loaded segments
were end-capped with 2 mm length, 5.5 mm diameter EG-65D or
PEU-2 caps using an HPS-EM induction welding system
(PlasticWeld Systems, Inc., Newfane, NY). End-caps were cut
from circular 5.5 mm EG-65D strands extruded using the SSE.
End-sealed TFV segments were fabricated by filling hollow hot-
melt extruded HPEU-35 or HP-100A-60 tubes (5.5 mm outer
diameter, 4.2 mm inner diameter, 145 or 155 mm length) with 2.1
to 2.3 g TFV/glycerol/water paste (62:36:2 w/w) and end-sealing
by induction welding, as described previously [25]. Component
parts of the TFV/LNG IVR (filled TFV segments, LNG segments
and end-caps) are shown in Figure 1G. To form TFV/LNG IVR,
capped LNG segments were welded to sealed TFV segments using
a HPS-20 induction welding system with a split-die configuration
(PlasticWeld Systems, Inc., Newfane, NY). TFV segments with
131 and 141 mm lengths (post-sealing) were paired with the
capped 20 and 10 mm LNG segments, respectively, to form IVR
with 55 mm outer ring diameter (Figure 1D). To form a more
circular ring shape, IVR were annealed in custom-fabricated
aluminum molds for approximately 15 minutes at 65uC. IVR
were heat-treated for 14 days at 40uC/75%RH in sealed
aluminum pouches prior to in vitro release testing.
Prior to any melt processing, all PEU or HPEU resins were
dried overnight in a CAFM series compressed air dryer (Dri-Air,
East Windsor, Connecticut) to less than 0.05% H2O (w/w) as
determined using a C30 Coulometric Karl Fischer Titrator
(Mettler-Toledo, Columbus, Ohio).
Drug extractions to estimate LNG content and in vivo
release
LNG was extracted from polymer segments to determine the
LNG loading in each batch of co-axial extrudate. Several 2 mm
long pieces were cut from various locations throughout the batch.
Each piece was placed in a 5 mL volumetric flask, which was filled
with 3 mL dichloromethane (DCM). Flasks were agitated on a
High Capacity Mixer (Glas-Col, Terre Haute, Indiana) overnight
to dissolve the PEU and LNG. Following dissolution, flasks were
filled to volume with DCM. Flasks inverted several times to ensure
good mixing. To precipitate PEU from the solution, 1.00 mL of
the DCM solution was transferred to a 10 mL volumetric flask
using a calibrated glass syringe. The 10 mL flask was then filled to
volume with acetonitrile (ACN) and vortexed for 5 seconds.
Aliquots of the resulting supernatants were then passed through a
0.2 mm PTFE syringe filter into HPLC vials for analysis. The same
extraction procedure was also performed on 50 mg samples of
LNG-loaded PEU-1/EG-85A pellets to assess the drug loading
prior to co-axial extrusion.
The same procedure was also used to determine the average
LNG mass loaded per device used in the rabbit PK study (see
methods below), except that a 25 mL volumetric flask was used in
place of a 5 mL flask for the first dissolution step. When full
segments with end-caps were extracted, it was necessary to further
cut the segment into 2–3 mm pieces before dissolution. These
extractions were also performed after in vivo testing to estimate
average LNG release rates.
In vitro release testing of LNG segments and TFV/LNG IVR
LNG-containing PEU segments and TFV/LNG IVR were
subjected to in vitro drug release testing. Samples were immersed in
aqueous buffer sink for up to 90 days in 250 mL or 500 mL I-
Chem glass jars (Thermo Scientific, Rockwood, Tennessee) in an
incubated shaker cabinet set to 37uC and 80 rpm. Media were
changed daily and media volumes were adjusted throughout the
studies to ensure a sufficient sink for both TFV and LNG. TFV
and LNG concentrations were not allowed to exceed 20% of their
solubility in the release media. Typically, 25 mM sodium acetate
buffer (pH 4.2) was used as the testing media, although Gibco (Life
Technologies, Carlsbad California) 16 phosphate buffered saline
(pH 7.4) was used for parallel in vitro release studies in the rabbit
PK study to approximate the neutral vaginal pH typically
observed in rabbits. Aliquots of release media were collected 23–
25 hours from the previous media change and analyzed by HPLC
at several points throughout each study to determine daily TFV
and LNG release rates. To assess the validity of the model
presented above, release rate profiles were compared to predic-
tions from Equation 11. Some TFV/LNG IVR were also evaluate
at an 200 rpm shaking speed to assess the adequacy of the
standard 80 rpm in maintaining sink conditions. For in vitro-in vivo
comparison, numerical integrations of in vitro release profiles were
performed by trapezoidal approximation to generate time-
averaged release rates.
Evaluation of LNG containment by PEU end-caps
To evaluate the potential effectiveness of PEU end-caps in
preventing LNG transport into the TFV segment, the full TFV/
LNG IVR was rendered in COMSOL Multiphysics 4 and Fickian
diffusion simulations were performed using the ‘‘Transport of
Diluted Species’’ package. A diffusivity of 7.3610211 cm2/s was
applied to the RCM and end-cap compartments based on an
experimental measurement of LNG diffusivity in PEU-2. An LNG
diffusivity of 3.061029 cm2/s was applied to the core compart-
ment and the tubing compartment of the TFV segment
representing a typical softer PEU at 37uC (see Table 1), as the
exact diffusivity in these compartments should not affect diffusion
provided that the value is sufficiently high in the core for LNG to
be well-mixed and sufficiently high in the tubing wall so that it acts
as a sink. End-cap lengths of 1, 2 and 3 mm were evaluated, while
the LNG segment length was fixed at 20 mm and the overall
dimensions were fixed at 5.5655 mm (cross-sectional and outer
ring diameters). The RCM thickness was set to 100 mm, and was
not loaded with LNG. An initial LNG loading of 42 mol/m3
(,1.3%w/w, assuming a matrix density of 1.05 g/cm3), was
applied to the core compartment. A free tetrahedral mesh was
applied throughout the IVR, with higher node resolution in and
near the RCM and near the segment/end-cap interface. Time-
dependent effective diffusivity simulations, governed solely by
Fick’s 2nd Law, were carried out for approximately 5 years.
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Volume integrals of the end-cap and TFV segment compartments
were performed every 7 days for the duration of the model and
normalized to the initial mass of LNG loaded in the system.
To experimentally validate the model presented above, TFV/
LNG IVR (HPEU-35/PEU-1/PEU-2) were stored at 40uC for
either 1, 3 or 6 months. IVR stored at 280uC were used as
controls. IVR were dissected, and separate LNG extractions, as
described above, were performed on the end-caps and TFV plug
sections (first ,5 mm of the TFV segment on either side of the
LNG segment). As can be seen in Figure 1D, it is difficult to
discern where the exact cap/segment interface is on the final IVR.
Masses of the dissected LNG segments were compared to the
initial segment mass before end-capping, and an adjustment was
made to the LNG mass extracted from the end-caps based on the
segment mass discrepancy and the initial LNG loading of the co-
axial extrudate batch.
Extension testing of TFV/LNG IVR
To assess mechanical robustness of the TFV/LNG IVR before
and after 31 day in vitro release testing, we performed destructive
extension tests to determine the tensile load and resulting
extension required to cause joint failure. IVR were tested using
an Instron 3342 with 500 N load cell and O-ring testing apparatus
with Bluehill Lite software control (Instron, Norwood, Massachu-
setts). IVR were placed on the testing apparatus with the LNG
segment oriented vertically and stretched at a rate of 5 mm/s until
failure was observed, at which point the net extension and net load
were recorded. The failure type of each IVR was also recorded.
Pharmacokinetic testing of LNG-loaded segments in
rabbits
Both 10 mm and 20 mm end-capped LNG-loaded PEU-1/
PEU-2 reservoir segments were implanted into New Zealand
white female rabbits (age 4–8 months) to assess in vivo device
performance and LNG pharmacokinetics. This study was carried
out in accordance with the U.S. Department of Agriculture’s
(USDA) Animal Welfare Act (9 CFR Parts 1, 2 and 3) and the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of MPI Research
(USDA Research License Number: 34-R-0031).
Preoperative and surgical procedures were performed as
described previously [41]. Briefly, LNG-loaded segments were
placed in the proximal, columnar epithelial region of the vagina,
such that the distal end of the segment was approximately 7 to
12 cm from the introitus. Up to three 3-0 or 5-0 Prolene sutures
were used to secure the segment to the outer ventral wall. All
surgery was performed under analgesia and anesthesia, and all
efforts were made to minimize suffering.
Animals weighed between 2.9 and 4.2 kg at implantation. Body
weights of test subjects were recorded periodically during
implantation. Groups of 6 animals were each administered either
10 or 20 mm segments, for either 28 or 90 days (4 groups total). In
the 28-day groups, plasma was collected at 4 hours, 8 hours, and
1, 2, 3, 7, 14, 21 and 28 days post-implantation. In the 90-day
groups, plasma was collected at 44, 60, 74 and 90 days post-
implantation. Approximately 1 mL blood was drawn from the
jugular vein of all animals at each time-point and stored in tubes
containing tripotassium EDTA. Tubes were stored on wet ice until
centrifuged under refrigeration, at which point samples were
aliquoted into cryovials and stored at 250uC to 290uC until
analysis could be performed. LNG was quantified in plasma
samples by a validated LC-MS/MS method (described in the
Supporting Information, see Tables S4 and S5 in File S1). To
assess total LNG plasma exposure and device dose dependence,
area under the curve (AUC) values were calculated from
individual plasma data using WinNonlin Phoenix (Pharsight, St.
Louis, Missouri). AUC was calculated from implantation to 28
days post-implantation (AUC0–28) for the 28 day groups and from
44 to 90 days post-implantation for the 90-day groups (AUC44–90).
All test subjects were euthanized at study’s end (either day 28 or
day 90) by an intravenous overdose of sodium pentobarbital
solution followed by exsanguination. Approximately 500 mg of
cervical tissue was collected from all animals during necropsy, snap
frozen in liquid nitrogen and stored at 250uC to 290uC until
LNG extractions could be performed. LNG was extracted from
tissue and again quantified by a validated LC-MS/MS method
(described in the Supporting Information, see Table S6 in File S1).
LNG segments were recovered post-study during necropsy.
Time-averaged in vivo LNG release rates were estimated by
subtracting the residual LNG mass recovered by extraction
(method described above) from the estimated initial LNG mass
loaded (batch average LNG loading multiplied by segment mass
prior to end-capping), and dividing the net mass by the study
duration. In addition, the average cumulative release values from
the 28 day and 90 day groups were subtracted to determine the
average release rate for the latter portion of the study.
Results and Discussion
LNG Diffusivity in PEUs
We measured effective diffusivities (D) for LNG in rate-
controlling PEU by analyzing LNG release from cylindrical
matrices and applying Equation 12. Figure 2A depicts examples of
linear regressions of release against the square-root-of-time for
PEU-1 and PEU-2 (R2.0.998). Diffusivity correlated negatively
with manufacturer-reported flexural modulus for Tecoflex PEUs
(Figure 2B). The mechanical properties of PEU can be controlled
by modulating the molar ratio of the macrodiol (e.g. poly(tetra-
methylene oxide)) to the chain extender (typically a monomeric
diol, e.g. 1,4-butanediol) [42]. Thus, the reduced diffusivity of a
dissolved molecule, like LNG, in stiffer PEU, e.g. Tecoflex EG-
60D and EG-65D, is likely a result of the lower volume fraction of
the amorphous soft segment domains that allow LNG transport
[43]. Figure 2C depicts the effect of temperature on LNG
diffusivity. Interestingly, diffusivity increased 15-fold in the higher-
modulus PEU-2 between 23uC to 50uC, but only 3-fold in PEU-1.
This could result from differences in phase transition behavior of
the crystalline hard segments between harder and softer PEU.
Table 1 contains a summary of LNG diffusivities in various PEU
tested. The lower diffusivity in PEU-2 at 23uC vs. 37uC
Table 1. Measured LNG effective diffusivities for various
PEUs, calculated using Equation 12. Data represents N
between 3 and 8, mean 6 SD.





































necessitated heat treatment to allow LNG to load into the RCM,
thus eliminating the undesirable lag time required to achieve
steady-state release.
Mathematical Modeling of LNG in vitro release
The model for drug release presented in Equation 11 proved
useful in the design of the LNG reservoir segment by allowing
accurate prediction of 90-day release rate profiles. Figure 3A
depicts the full two-stage model (Eqn. 11) result in comparison to
LNG release from PEU-1/PEU-2 segments stored at elevated
temperature to homogenize LNG concentration across the device
(as per the model assumption). The experimental in vitro release
data agreed with the full two stage model (R2= 0.74) with a mean
prediction error of 17%. This correlation confirmed that our
diffusivity measurements in rate-controlling PEU were sufficiently
accurate for release rate prediction in the device design process,
allowing us to screen potential RCM polymers for LNG diffusivity
using simple cylindrical matrices produced on a small-scale batch
extruder.
Use of the two-stage model has a practical limitation as the burst
regime of the model is only accurate when complete RCM loading
is achieved. Therefore, much of the remaining in vitro release data
presented herein does not demonstrate the full burst predicted by
the model. However, as demonstrated below the latter model
regime was still useful regardless of the burst magnitude. The burst
mass (Mb) is then practically regarded as the maximal burst release
that could be achieved from a given system.
Figures 3B and 3C depict the effects of RCM thickness and
drug-polymer diffusivity on steady-state regime LNG release,
predicted using Equation 11b, from 5.5 mm diameter solid
reservoirs. As shown in Equation 8, the release rate time constant
(a) varies with the ratio between diffusivity and RCM cross-
sectional area. At a fixed diameter, diffusivity or RCM thickness
are positively correlated with the magnitude of drug release, but
also with the rate of drug release attenuation, as any increase in
drug flux results in more rapid depletion of the core drug
concentration. The burst duration (tb, Eqn. 6), is also shown as a
function of RCM thickness and diffusivity in Figures 3D and 3E.
The burst duration is inversely proportional to diffusivity, while
the relationship between burst duration and RCM thickness is not
clear from Equation 6 as ro2ri is not readily factored. As expected,
the RCM thickness also correlates withMb (Figure 3F). Figures 3B–
3F illustrate the complex relationship between burst duration,
maximal burst mass and PSS release rate profile encountered
when designing reservoir systems.
In vitro release of LNG from end-capped segments
Experimentally, we evaluated the effects of several RCM design
inputs on the LNG release profile, including RCM polymer
selection, RCM thickness and duration of heat treatment required
to load the RCM with LNG. First, effect of heat treatment was
performed on segments fabricated from a LNG-loaded PEU-1
core and PEU-2 RCM by storing samples at 40uC for either 4, 14,
21, 28 and 76 days prior to in vitro release testing. As depicted in
Figure 4A, a 14-day heat treatment mitigated both burst and lag
behavior, and was thus incorporated into the manufacturing
process. Furthermore, it was necessary to include a 14-day
treatment at 40uC of the hydrophilic PEU used in the TFV
segment (manuscript in preparation). This allowed us to reduce
both procedures to a 14 day annealing of the final TFV/LNG
IVR to both stabilize the TFV release rate on subsequent storage
and eliminate the lag behavior in the LNG release profile [44].
Almost all reservoir devices will exhibit a drug burst that
increases with time as drug is allowed to diffuse into the RCM.
This phenomenon is acceptable if the amount of burst release does
not result in unsafe drug levels. LNG is given orally as an
emergency contraceptive at 1500 mg in a single dose, and our
maximum predicted burst (Mb) is over an order of magnitude
lower that this dose as shown in Figure 4D. Furthermore, a range
of release rates may be acceptable early in the release profile,
provided that the eventually PSS release rate in the reservoir-stage
is consistent and is consistently efficacious. If highly reproducible
burst release profiles are required for other drugs, it may be
necessary to manufacture devices with uniform concentration in
both compartments to ensure a kinetically stable release profile
during storage, either by compounding the drug in both polymers
before co-axial extrusion, or by extended heat treatment. This was
initially avoided to mitigate the potential for surface re-crystalli-
zation. However, in a recent stability study we discovered that
LNG does not re-crystallize on the surface of the TFV/LNG IVR
(to be reported in an upcoming manuscript).
Next, we evaluated the release of LNG from reservoir segments
fabricated with an 1.3% (w/w) LNG-loaded EG-85A core and
varying thickness of either EG-65D or EG-60D RCM (Figures 4B
and 4C) (all samples heat-treated for 14 days at 40uC). Based on
these data and the diffusion model, we selected an 80–85 mm thick
EG-65D RCM to target 20 mg/day release on day 45 (the middle
of the delivery profile), while also minimizing release rate
attenuation throughout the reservoir-stage. The batch with the
closest RCM (84 mm EG-65D) was tested for a full 90 days and
compared to the model in the steady-state regime (Figure 4D). The
reservoir-stage model (Equation 11b) and experimental data
Figure 2. Determination of LNG effective diffusivities in PEU. (A) Example square-root-of-time fitting for PEU-1 and PEU-2 used to estimate
LNG-PEU diffusivity values (Eqn. 12). (B) Log-log correlation between LNG diffusivity and reported flexural modulus for Tecoflex PEUs and (C) effect of
temperature on LNG diffusivity in PEU-1 and PEU-2.
doi:10.1371/journal.pone.0088509.g002
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Figure 3. Model for dissolved drug release from cylindrical reservoirs. (A) Accuracy of the two stage drug release model (Eqn. 11) for LNG
segments stored 76 days at 40uC to completely equilibrate LNG loading throughout the cross-section. Experimental data represent N=3, mean6 SD.
Effects of (B) EG-65D RCM thickness (in mm) and (C) diffusivity (in cm2/s) on the reservoir-stage model (Eqn. 11b) for 20 mm length segments with
5.5 mm diameter. Effects of (D) PEU-2 RCM thickness, and (E) diffusivity on the burst duration (tb) predicted by Equation 6. For panels C and E RCM
thickness was fixed at 100 mm. (F) Maximal burst amount (Mb) shown as a function of RCM thickness.
doi:10.1371/journal.pone.0088509.g003
Figure 4. In vitro release of LNG from reservoir segments. (A) Effect of partial LNG loadings in the RCM on lag/burst behavior in LNG in vitro
release kinetics for 10 mm length PEU-1/PEU-2 segments, achieved by 40uC storage for varying duration. In vitro LNG release from 20 mm length,
5.5 mm diameter co-axially extruded EG-85A segments with (B) EG-65D or (C) EG-60D RCMs of various thicknesses. (D) Full 90 day in vitro release
kinetics from the 84 mm EG-65D RCM group with model comparison (Eqn. 11). All data represent N= 5, mean 6 SD except panel A (N= 3). Segments
in panels B–D were all stored for 14 days at 40uC before testing.
doi:10.1371/journal.pone.0088509.g004
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exhibited excellent correlation (R2 = 0.987 from day 5 to day 90),
with mean error of 8.4%, or 0.8 experimental standard deviations.
In vitro release of TFV and LNG from full two-segment
IVR
In vitro release of TFV and LNG from full IVR for 90 days is
shown in Figures 5A and 5B. From day 2 to day 90, IVRs released
TFV and LNG at near-constant rates of approximately
7.560.1 mg TFV and 2162 mg LNG per day (N= 5 time-
averaged IVRs, mean 6 SD), a significant achievement given the
disparity in drug properties and release rates.
Based on our recent sheep study comparing pharmacokinetics
of the TFV-only IVR (similar in vitro release rate) and the TFV 1%
gel [25], we hypothesize that a device with this constant TFV dose
may protect women against HIV transmission. Also, based on
previous data from the WHO silicone LNG IVR [24], we
hypothesize that these LNG release rates can provide effective
contraception. Given our understanding of how to predict release
rates from this system, as well as the adaptability of the segmented
IVR design, the release rates of TFV and LNG could be modified
should human PK testing suggest different doses are needed.
TFV/LNG IVR evaluated at an increased shaking speed of
200 rpm released 2361 mg LNG per day over 14 days (N= 3
time-averaged IVRs, mean 6 SD), compared to 2062 mg LNG
per day at 80 rpm (N=5). This comparison suggests that an
80 rpm shake speed sufficiently disrupts the unstirred layer,
resulting in sink conditions appropriate for the model presented in
Equation 11.
Prevention of LNG diffusion between segments with PEU
end-caps
One of the design challenges with developing multi-segment
drug delivery systems is the potential for drug diffusion between
compartments during storage of the drug product. While diffusion
of TFV from the hollow core compartment is hindered by its poor
solubility in HPEU [26], LNG diffuses effectively through PEU
and thus its ‘‘leakage’’ into the TFV segment is expected.
Therefore, we designed end-caps to prevent LNG diffusion into
the TFV segment to maintain both LNG release rate magnitude
and control in the TFV/LNG IVR following product storage. We
evaluated the feasibility of using end-caps made from the same
polymers as the LNG-segment RCM (PEU-2 and 65D), but aimed
to minimize the end-cap length due to their mechanical rigidity
(EG-65D has a flexural modulus of 255 MPa) and the fact that a
large cap would eliminate additional length from the TFV
segment. We modeled the complex multi-compartment nature of
the problem by rendering a full TFV/LNG IVR performing finite-
element simulations of Fickian diffusion (Figures 6A–B). Simula-
tions were carried out for 5 years at 37uC, rather than the usual
40uC, due to availability of drug-polymer diffusivities at 37uC from
studies presented above. Volume integrals were performed in both
the end-cap and TFV segment compartments and normalized to
the initial drug load in the 20 mm LNG segment. As depicted in
Figures 6C and 6D, the 1 mm, 2 mm and 3 mm end-cap
simulations predicted full LNG containment (no LNG in the TFV
segment) for 203, 749 and 1484 days at 37uC, respectively. The
2 mm cap configuration ultimately was chosen because complete
LNG containment was achieved in the model for 2 years at 37uC,
at which time only 6% of the total LNG load had escaped into the
end-caps. In Figure 6D, we show that the subsequent leakage into
the whole TFV segment, proceeds at a linear but minimal rate
(approximately 1% of total LNG load per year for 2 mm caps),
suggesting that performance and chemical stability (depending on
the quantitative metric used) may be achieved for much longer
than 2 years in the 2 mm configuration. The end-caps also
function as RCM, where thickness can modulate LNG flux at the
TFV/LNG segment interface through the concentration gradient
across the segment. Encouragingly, EG-65D (used in our current
lead design) exhibits even lower LNG diffusivity than PEU-2
(Table 1), likely lengthening complete containment times from
those observed in these simulations.
In an attempt to experimentally approximate the diffusion
simulations, TFV/LNG IVR were stored for 6 months at 40uC
and the caps and TFV segment plugs were subjected to LNG
extractions at various times. The results are shown in Figure 6E.
Reasonable agreement was observed between the theoretical and
experimental LNG content in the caps, even with the temperature
disparity (37uC to 40uC from model to experiment). Trace
amounts of LNG (,5 mg total or ,0.1% of total load) were
detected in the TFV segment plugs, but this likely was not due to
leakage through the end-caps as no increase was observed in LNG
levels over time.
An ‘‘ideal’’ multi-segment IVR would be thermodynamically
stabilized by caps formed from a material miscible with the
polymers used and impermeable to all components in the
formulation. Here we have demonstrated a practical, kinetically-
stabilized system using a material already present in the IVR.
IVR extension testing
Mechanical integrity is an important design consideration for
any IVR. In this particular IVR design, we were faced with the
Figure 5. In vitro release of TFV and LNG from full two-segment IVR. In vitro release of (A) TFV and (B) LNG for 90 days from final TFV/LNG
(20 mm) IVR prototypes using Tecophilic and Tecoflex polymers (HP-100A-60 TFV reservoir tube, EG-85A LNG reservoir core and EG-65D LNG
reservoir RCM and end-caps). LNG reservoir RCM thicknesses were measured between 74 and 85 mm. All data represent N= 5, mean 6 SD.
doi:10.1371/journal.pone.0088509.g005
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additional challenge of welding swellable HPEU (TFV segment) to
rigid, non-swellable PEU (capped LNG segments) while main-
taining mechanical integrity both in dry and hydrated ring states.
To evaluate this, we performed O-ring extension tests (Figures 7A
and 7B) on full IVR after production (dry) and subsequent 31 day
in vitro release testing (hydrated). As shown in Figures 7C and 7D,
all IVR (N=15) in the dry group endured at least 190 mm
extension and 250 N (56.2 lbf) load before failure, and 9 of the 15
rings remained intact following extension to the limit of our
instrument (approximately 330 mm deformation). IVR in the wet
group exhibited extension and tensile load of 141647 mm and
239658 N (N=15, mean6 SD) at failure, with all IVRs enduring
at least 74 mm extension and 152 N (34.2 lbf) tensile load before
failure. Thus, a reduction in joint integrity was observed when
IVR were soaked in aqueous media, however these data
demonstrate that the IVR are still mechanically sound and would
require intentional and excessive user-applied stress to separate the
segments. In the dry group, all observed failures (6 of 15) occurred
between the cap and the LNG segment, whereas, in the hydrated
group, an equal number of joint failures occurred between the cap
and the LNG solid reservoir versus the cap and the TFV tube plug
(7 of each). The remaining hydrated ring experienced a HPEU
tubing rupture near the tube seal, but at the highest observed load
at failure in the hydrated group (354 N/79.6 lbf). Given the
mismatch in the HPEU tube, which exhibits 58% equilibrium
swelling by mass, and the non-swellable PEU assembly (caps and
LNG reservoir), the mechanical joint integrity observed in dry and
hydrated IVR is remarkable and illustrates the utility of the PEU/
HPEU platform in sophisticated drug delivery systems.
PK testing of the LNG segment in rabbits
Results from the rabbit pharmacokinetic study are shown in
Figure 8. Figure 8A depicts in vitro LNG release rates from the
same batch used in the rabbit study. On average, 10 and 20 mm
segments released 12.6 and 26.4 mg LNG per day in vitro,
respectively, over the 90 day study. Segments consistently released
more LNG in vivo than in vitro as shown in Figure 8B. Release rates
were higher in vivo for both the 10 and 20 mm segment groups,
however this disparity was diminished in the 90-day group with
respect to the 28-day group. In fact, when subtracting the average
in vivo cumulative LNG release of the 28-day group from the 90-
day group, the result was very similar to the time-averaged in vitro
release rate in both groups (10 mm: 13.5 in vivo vs. 12.0 mg/day in
vitro, 20 mm: 24.0 in vivo vs. 25.3 mg/day in vitro). This indicates
that a higher burst release of LNG occurred in vivo than in vitro, but
that the eventual steady-state regime profile was nearly identical.
In all cases, average release rates varied nearly two-fold in vivo
between the 10 mm and 20 mm segment groups.
LNG plasma results, presented in Figure 8C, strengthened the
observation of an additional burst not detected in vitro. An
approximately 3-fold drop was observed in plasma LNG
concentration from the 4 hour to the 7 day time point, while
levels remained relatively stable from day 7 to day 28. Plasma
levels also dropped markedly from day 28 to day 44 (25% in the
10 mm group and 37% in the 20 mm group), but this may be due
to anatomical differences in the two animal groups as plasma was
collected from the 28 day group for the first 28 days, and from the
90 day group from day 44 to day 90. Comparatively, plasma levels
stabilized from day 44 onward. It is worth noting that test subject
body masses increased 14% and 16% over 90 days in the 10 mm
and 20 mm test groups, respectively. This may have caused
additional attenuation of plasma profiles not expected from the in
vitro release rate profiles alone. Mean plasma AUC0–28 values of
110421 and 218315 pg*hr/mL (ratio: 1.98) and AUC44–90 values
of 154726 and 261354 pg*hr/mL (ratio: 1.69) were calculated for
the 10 mm and 20 mm segment groups, respectively, indicating a
dose dependent pharmacokinetic response. This and the agree-
ment of in vitro and in vivo release rates between day 28 and day 90
suggest that sink conditions exist for LNG in vivo, allowing for
Figure 6. Prevention of LNG diffusion between segments by PEU end-caps. An example (A) finite-element mesh and (B) outer surface
model result from the IVR storage diffusion model. The model result represents approximately 2 years storage at 37uC for an IVR with 2 mm length
PEU-2 end-caps, where red represents maximum scaled LNG concentration, and blue represents zero LNG. Quantitative results show LNG leakage
into the (C) end-caps and (D) entire hollow-tube in the TFV segment during storage by volume integrals of the COMSOL model. Shelf life was
determined as the last time-point of complete LNG containment (none detected in the TFV segment). (E) Experimental determination of LNG loss into
the caps as a function of TFV/LNG IVR (PEU-1/PEU-2 LNG segments) storage time at 40uC and comparison to the COMSOL result for 37uC storage.
doi:10.1371/journal.pone.0088509.g006
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direct control of LNG pharmacokinetics through polymer
selection and device geometry.
Since topical microdose progestin contraception is achieved
largely through local effects [45], the pharmacokinetic profile of
LNG concentration in the cervical tissue are a potentially more
important predictor of eventual device performance. Figure 8D
depicts LNG concentrations in cervical tissues collected at day 28
or day 90. Some samples in the 10 mm groups were below the
limit of quantification (0.75 ng LNG/g tissue), which hindered a
detailed analysis of the data. However, the median value differed
two-fold between the 10 and 20 mm groups on day 28 (4.01 vs.
2.02 ng/g), providing further evidence of dose-dependent PK.
Also, LNG levels did not differ significantly between tissues taken
on day 28 or day 90 (p= 0.10, two-tailed, heteroscedastic t-test),
confirming near-zero-order LNG release in vivo following the burst.
The rabbit model is useful for early in vivo testing of vaginal
delivery systems [27,41], although rabbit vaginal histology varies
greatly from that of the human vaginal vault. Furthermore, the
exact magnitude of the plasma profile is likely of little significance
as LNG pharmacokinetics will vary between species [46].
However, this study confirmed that near zero-order behavior
was achieved in vivo following the burst period, and that two
biologically distinct LNG doses were in fact achieved from the
10 mm and 20 mm length devices.
Conclusions
Multi-purpose drug delivery systems will need to deliver a
physically and chemically diverse set of molecules to target an
equally diverse set of indications. Accordingly, there is a need for
polymeric materials with a range of properties that are equally
chemically diverse. Through successful use of HPEU and PEU in
the same device, we have demonstrated that biomedical polyure-
thanes have potential to fulfill this need for many multi-functional
IVR formulations. We have described the design and engineering
Figure 7. IVR extension testing. (A,B) Extension testing of a full TFV/LNG IVR to 101 mm extension and 145 N (32.6 lbf) load. (C) Extension and (D)
load at TFV/LNG IVR both before (‘‘dry’’) and after (‘‘hydrated’’) 31 day in vitro release testing (N= 15 IVR per group). Nine of the 15 IVR in the dry
group did not fail below the upper test limit (UTL, ,330 mm extension).
doi:10.1371/journal.pone.0088509.g007
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of a two-segment, dual-reservoir TFV/LNG IVR, with focus on
the LNG segment, its incorporation into the full device, and the
evaluation of its performance using a combination of in silico, in
vitro and in vivo methodologies. Our two-stage, mechanistic drug
release model provides an improvement to existing models of
cylindrical reservoirs with dissolved drug in the literature and
enabled the rational design of the long duration LNG segment.
We demonstrated the near-zero-order release of LNG at clinically
relevant levels both in vitro and in vivo. We have also presented
design challenges specific to this system, including the prevention
of drug diffusion between compartments during long-term storage.
Through extension testing we have shown the IVR to be
mechanically sound in both the dry and hydrated states. This
IVR is the first long-acting multifunctional drug delivery system in
clinical development and may prove to be an important
advancement for women to control their reproductive health.
The co-delivery of two drugs as physicochemically diverse as TFV
and LNG and at such different release rates, sustained for 90 days,
demonstrates the adaptability of this dual-reservoir polyurethane
technology. The platform is easily configured to deliver other
drugs [12] and a wide range of doses or combinations for other
women’s heath challenges.
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Drug Release Model Validation Using Finite-Element Simulation
In order to assess the validity of the two-stage drug release model for solid reservoirs presented 
in Equation 11, we also performed graphical finite element simulations of drug release in 
COMSOL Multiphysics 4. The "Transport of Diluted Species Package" was used to solve Fick's 
Second Law on a free triangular mesh applied to two-dimensional, circular cross-sections of 
cylindrical reservoirs (an example is shown in Figure S1A). Identically to Equation 11, a uniform 
initial condition (c0 = 42 mol/m3) was applied to the entire cross-section and a sink boundary 
(c(ro) = 0) was applied to the outer edges of the cross-section. Core drug diffusivity was fixed at 
5 x 10-9 cm2/s (not considered in our analytical model as long as it is much larger than the 
membrane diffusivity). Four different configurations were solved with varying D, ro and ri (see 
Table S1). Simulations were carried out for 90 days, and area integrals were taken of the cross-
section at each time-point to determine drug concentration per unit length as a function of time. 
These integrals were converted to LNG mass units and multiplied by a fixed length of 20 mm. 
Equation 11 was evaluated for each of the configurations listed in Table S1, and daily release 
rates of both the finite-element simulation and analytical solutions were calculated by 
subtraction. The two data sets were then compared by computing the coefficient of 




























Figure S1: An example (A) finite-element mesh and (B) final concentration profile result from 
the finite-element drug release simulation, with highest concentration represented by dark red 
and lowest concentration by purple. (Configuration 'A' shown, see Table S1)
Table S1: Values of outer radius (ro), inner radius (ri) and drug polymer diffusivity in the outer 








ro (mm) Ri (mm) D (10-11
cm2/s)
A 5.5 90 2.75 2.66 5.0
B 8.0 90 4.00 3.91 1.0
C 3.0 200 1.50 1.30 5.0
D 5.5 200 2.75 2.55 10.0
An example concentration profile at the end of the finite-element simulations is shown in Figure 
S1B, and comparisons of daily release rate profiles from the finite-element simulations and 
computed using Equation 11 are shown in Figure S2. Equation 11 generally agreed with the 
simulations with two exceptions. First, the predicted drug release on day 1 was always 




























discontinuity exists on the outer boundary (ro) at t=0, there is bound to be some difficulty in 
accurately predicting the actual day 1 release using a numerical method. Second, two models 
generally disagreed during the changeover between the burst and steady state regimes of drug 
release. As noted during the derivation, our model treats this changeover as an instantaneous 
switch occurring at (tb), during which drug fluxes are likely to be underestimated while the 
concentration profile adjusts to the constraint of the inner boundary at ri. The models generally 
agree after this point, except for configuration C, where Equation 11 continued to under-predict 
the results of the simulation by an average of 18% during the predicted reservoir-stage (from 
day 19 onward). Based on the configurations that were simulated, the adjustment between the 
matrix and reservoir concentration profiles likely takes longer for proportionally thicker RCM 
(higher values of ri/ro). This may be due to the first-term approximation used to predict matrix-
stage release (Equation 11a), that is increasingly inaccurate for higher values of cumulative 
release, and only to be used for the first 20-30% of release (13% is released in the matrix-stage 
in configuration C). As mentioned in the manuscript, this model will be the most accurate for 
thinner membranes, and a higher order approximation would need to be used to predict matrix-
stage release for proportionally thicker membranes, as well as a re-calculation of the burst 
duration (tb). Nonetheless, day 2 to day 90 R2 values were greater than 0.90 for all four 
configurations, confirming that this is a sufficiently accurate predictor of drug diffusion in 
cylindrical reservoirs and useful for device design and optimization. Also interesting is that the 
core does not appear to be completely well mixed in Figure S1B as per our assumption, even 
with core and membrane diffusivity values that were 100-fold different. However, based on 




























Figure S2: Comparison of a finite-element diffusion model and our analytical model (Equation 
11) for drug release from cylindrical reservoirs. Panels A, B, C and D correspond to the 
"Configuration" column in Table S1.
Gradient HPLC methods for quantification of LNG in in vitro release samples
Two gradient HPLC methods were used to quantify LNG in in vitro release samples. In both 
cases a 1200 Series HPLC with a quaternary pump and diode array detector (Agilent 
Technologies, Santa Clara, California) and a 4.6 x 250 mm, 5 μm Zorbax ODS column (also 
Agilent Technologies) were used. For samples from LNG segment tests a 7-minute gradient of 
H2O and acetonitrile (ACN) was used (Table S2), whereas for samples from full TFV/LNG IVR 
tests an 18-minute gradient of 0.1% formic acid in H2O and 0.1% formic acid in ACN was used 




























Table S2: HPLC gradient profile for detection of LNG 
alone in in vitro release samples. Line A: H2O, Line B: 
ACN. A flow rate of 1.1 mL/min was applied throughout 
the method.







Table S3: HPLC gradient profile for  LNG in TFV/LNG 
IVR in vitro release samples. Line A: 0.1% formic acid in 
H2O, Line B: 0.1% formic acid in ACN. A flow rate of 1.0 
mL/min was applied throughout the method.

































Figure S3: Manufacturing flow diagram for the TFV/LNG IVR.




























Extraction of LNG from rabbit plasma samples and quantification by LC-MS/MS
LNG was quantified in rabbit plasma samples by LC-MS/MS during the PK study described in 
the manuscript. Blood samples were first thawed to room temperature, vortexed briefly and 
centrifuged at 4000 rpm for 10 minutes at 5°C. 250 μL of each sample was added to a 96-well 
plate. Also to each well were added 400 μL H2O and 50 μL of an internal standard containing 
levonorgestrel-d6 (LNG-d6) (TLC PharmaChem, Inc., Vaughan, Ontario, Canada). In parallel, 
an Oasis HLB 96-well solid phase extraction (SPE) plate (Waters, Milford, Massachusetts) was 
conditioned by passing 800 μL MeOH followed by 800 H2O, another 800 μL MeOH and finally 
800 μL dichloromethane (DCM) under minimal vacuum. Sample mixtures were then transferred 
to the conditioned SPE plate under minimal vacuum (as needed). 800 μL H2O, followed by 800 
μL 40:60 MeOH/H2O under minimal vacuum was passed through the wells to waste, followed by 
5 minutes under high vacuum to dry the SPE beds. 800 μL DCM then was passed through the 
SPE wells to a 96-well collection plate. High vacuum was again applied to the plate until the 
SPE beds were visually dry. The DCM eluent was then evaporated under N2 at 40°C, and 
reconstituted with 100 μL 50:50 MeOH/H2O. The entire plate was then vortexed for 1 minute, 
and samples were again centrifuged at 4000 rpm for 5 minutes at 5°C. 
LNG was then quantified in the reconstituted extractants using an 1100 Series HPLC (Agilent 
Technologies) and a API 5000 mass spectrometer (MS) (AB SCIEX, Framingham, 
Massachusetts). The HPLC was equipped with a chilled autosampler (set to 5°C), as well as 
two binary solvent pumps and a 6-port switching valve. Two Betasil C18 100 x 2.1 mm, 5 μm 
columns (Thermo Scientific, West Palm Beach, Florida) were used, one as the loading column 
and one as the analytical column. Gradients of H2O and ACN (both with 0.1% formic acid) were 
run on both columns. Pump profiles are shown in Table S4 and the column switching profile is 
shown in Table S5. Positive daughter ions of LNG and LNG-d6 (245.2 and 251.2 m/z) were 




























Table S4: HPLC pump profiles for the plasma LC-MS/MS method. Line A: 0.1% formic acid in 
H2O, Line B: 0.1% formic acid in ACN.









% Line A % Line B
0 0.3 35 65 0.0 0.6 35 65
2.5 0.3 35 65 1.0 0.6 35 65
2.6 0.6 0 100 1.1 0.3 35 65
4.6 0.6 0 100 5.4 0.3 35 65
4.7 0.6 35 65 5.5 0.6 0 100
10.0 0.6 35 65 6.5 0.6 0 100
6.6 0.6 35 65
10.0 0.6 35 65
Table S5: HPLC switching profile for the plasma analysis method. Position A: Pump 1 -
autosampler - Column 1 - waste; Pump 2 - Column 2 - MS, Position B: Pump 2 - Column 1 -





Extraction of LNG from rabbit cervical tissue samples and quantification by LC-MS/MS
Rabbit cervical tissue samples were ground with dry ice in a small blade homogenizer to make a 
finely ground sample. Samples were then stored overnight at -20°C to allow the dry ice to 
sublime. The ground tissues were then diluted with 80:20 MeOH/H2O at 100 mg tissue/mL and 
sonicated for 5 minutes in an ice water bath. Samples were stored at -80°C until analysis could 
be performed. Samples were again thawed, vortexed and centrifuged at 4500 rpm and 4°C for 
10 minutes. The supernatants were transferred to fresh containers prior to aliquoting into 96-
well filter plates. To each well, 600 μL ACN, 50 μL of LNG-d6 internal standard and 250 μL of 
sample were added. Plates were allowed to stand for approximately 5 minutes before applying 










reconstituted, vortexed and centrifuged as described for plasma extractants above prior to 
analyzing by LC-MS/MS. 
For analysis of tissue extractants, the same LC-MS/MS instrument as above was used except a 
single-pump, single-column set-up was employed. A 7-minute gradient of 0.1% formic acid in 
H2O and 0.1% formic acid in ACN was run through a Betasil C18 100 x 2.1 mm, 5 μm column. 
The pump profile is described in Table S6. The same positive daughter ions as above, (245.2 
and 251.2) were detected for LNG and LNG-d6 at approximately 2.2 minutes.
Table S6: HPLC gradient profile for LNG detection in  
cervical tissue using LC-MS/MS. Line A: 0.1% formic acid 
in H2O, Line B: 0.1% formic acid in ACN. A flow rate of 
0.3 mL/min was applied throughout the method.
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 Women in the developing world desperately need reliable methods to prevent 
HIV infection and unintended pregnancy.  Herein we describe the pharmacokinetic and 
stability evaluation of a dual-segment reservoir IVR that delivers the anti-HIV drug 
tenofovir and the progestin contraceptive levonorgestrel at near-constant rates for 90 
days. The stability of tenofovir and levonorgestrel, as well as their release rate profiles in 
vitro, were evaluated for up to 5 months at 30°C and 40°C. The sheep model was used for 
pharmacokinetic testing due to the anatomical similarity between the human and sheep 
vaginal tract. TFV and LNG were stable in the IVR formulation for up to 5 months at 
40°C. Release rates of TFV decreased gradually with storage due to the rearrangement of 
the hydrophilic polyurethane used to manufacture the TFV-releasing segment, plateauing 
in the 5-6 mg per day range. Release rates of LNG were stable over 90 days with the 
exception of an increased burst release due to gradual diffusion of LNG in the outer 
membrane of the LNG-releasing segment. Rings releasing 8-9 mg TFV per day in vitro 
resulted in sustained TFV levels in sheep vaginal fluid (~105 to 106 ng/g) and tissue (~103 
to 104 ng/g) for 90 days following a short lag measured at the 8-hour time-point. Two 
ring prototypes, releasing 9 or 23 µg LNG per day in vitro, resulted in sustained levels of 
LNG in the cervical tissue (~2 to 20 ng/g) over 90 days. These results demonstrate the 
potential of the TFV/LNG IVR to become the first long-acting multipurpose prevention 
device and warrant a clinical investigation. 
 
4.2 Introduction 
 Although three decades have passed since the discovery of HIV, 35 million 





infections and 1.6 million deaths occurring annually [1]. The HIV/AIDS pandemic 
continues to disproportionately affect young women in low-income areas. For example, 
an estimated 4.3% of women aged 15–24 in Sub-Saharan Africa are living with HIV, 
compared with 1.5% of men of same age-group. Efforts to encourage safe sex in these 
populations have experienced limited success due to the unwillingness of men to use 
condoms [2]. The CAPRISA 004 [3-5] clinical study recently proved the concept of HIV 
pre-exposure prophylaxis (PrEP), whereby antiretroviral (ARV) drugs are administered 
either topically or orally prior to sexual exposure to prevent sexual transmission. Women 
in the CAPRISA 004 study were 39% less likely to become infected with HIV when 
using a vaginal gel containing the HIV reverse transcriptase inhibitor tenofovir (TFV), 
both before and after sex. Although the success of CAPRISA 004 was modest, the 
Partner's PrEP study demonstrated a 75% reduction in HIV transmission between 
serodiscordant couples when the HIV-negative partner was administered an oral 
formulation (Truvada) containing a TFV prodrug [6]. Furthermore, several recent studies 
demonstrated the ability of ARV-containing gels [7, 8] and ARV-releasing intravaginal 
rings (IVR) [9, 10] to prevent SHIV transmission in nonhuman primates, confirming that 
PrEP may yet show promise in attenuating the spread of the virus.  Unfortunately, the 
HIV prevention field endured a setback when the VOICE (MTN-003) study failed to 
demonstrate any statistically significant reduction in HIV transmission across multiple 
study arms testing the once-daily administration of TFV gel and TFV-containing oral 
formulations [11]. By measuring TFV levels in plasma, researchers were able to 
determine that the participants adhered poorly to these once-daily dosing regimen, 





independent, once-daily dosing framework. In total, these successes and failures highlight 
the need to identify and develop of PrEP products that are most desirable to women 
needing to protect themselves against HIV infection [12].  
 There is a strong regional correlation between high incidence of HIV infection 
and unintended pregnancy. Worldwide, 40 % of pregnancies are unintended, resulting in 
staggering rates of material death in low-income populations [13]. Furthermore, it has 
been posited that inclusion of a contraceptive component may increase user demand, and 
subsequently adherence to PrEP products. Accordingly there is an imperative for the 
rapid development of long-acting, multipurpose prevention technologies (MPT) that 
simultaneously prevent HIV transmission (and/or other sexually transmitted infections) 
and unintended pregnancy. IVR have been identified as leading candidates for long-
acting MPT products based on the demonstrated acceptability of the contraceptive 
Nuvaring [14, 15], and the potential for IVR to provide sustained levels of ARV to 
potential sites of HIV infection for several months [16]. IVR leverage the advantages of 
local drug delivery (e.g. achieving appropriate drug levels at the site of action while 
minimizing systemic exposure) while avoiding the messiness and/or inconvenience of 
other frequently-administered topical vaginal delivery systems (e.g. gels, films, tablets) 
[17, 18].  
 We recently reported a dual-reservoir polyurethane IVR for simultaneous delivery 
of tenofovir (TFV) and the widely-used progestin contraceptive levonorgestrel (LNG) for 
up to 3 months [19]. This IVR demonstrated release of both TFV and LNG at near 
constant rates for up to 90 days in vitro. We targeted release rates of approximately 10 





TFV-releasing technology and the TFV gel. However, we targeted much lower release 
rates for LNG, either 10 or 20 µg per day based on release rates from LNG-releasing 
intrauterine systems (IUS) (Mirena® and Skyla®) and the discontinued LNG-releasing 
silicone IVR [20, 21]. Long-term vaginal administration of a progestin, such as LNG, is 
an appropriate contraceptive method for incorporation in an MPT due to the remarkably 
high effectiveness observed with LNG-releasing IUS, which achieve reliable 
contraception primarily via local effects and without unnecessary systemic hormone 
exposure.  
 PK testing of both component segments of the TFV/LNG IVR have been 
reported: the TFV segment in the sheep PK comparison with TFV gel mentioned above 
[16], and the LNG segment in the rabbit model [19]. Near zero-order local PK were 
observed in both studies, motivating the investigation of the full dual-indication device in 
the sheep model. This manuscript will describe two major efforts in the continued 
preclinical development of the TFV/LNG IVR: 1) accelerated physical and chemical 
stability testing and 2) a 90-day PK evaluation in the sheep model. The results herein 
further demonstrate that our first-in-class long-acting contraceptive/PrEP product has 
potential to make a significant impact on the reproductive health of women in the 
developing world. 
 
4.3 Materials and Methods 
4.3.1 Materials 
 As in our previous paper [19], two sets of biomedical PEU were used for the 
fabrication of TFV/LNG IVR. For stability testing, Tecophilic HP-100A-60 (HP-100A-





Lubrizol Advanced Materials (Wickliffe, Ohio). For PK testing, a custom-designed 
hydrophilic aliphatic polyether urethane  (HPEU-35), and two hydrophobic aliphatic 
polyether urethane  (PEU-1 and PEU-2) with shore hardness of 78A, 73A-77A and 59D, 
respectively, were obtained from DSM Biomedical (Berkeley, CA). Tenofovir (TFV) was 
supplied by Gilead Sciences (Foster City, CA) and micronized LNG was obtained from 
Industriale Chemica (Saronno, Italy) or Haorui Pharma-Chem Inc. (Edison, New Jersey). 
USP grade glycerol and water were purchased from Spectrum Chemical (New 
Brunswick, NJ). All water used was either USP grade or double de-ionized (DDI). All 
other solvents and reagents were HPLC or ACS grade, unless otherwise mentioned. 
Phosphate buffered saline (PBS) was obtained from Life Technologies (Carlsbad, CA). 
 
4.3.2  IVR Fabrication 
 TFV/LNG IVR were fabricated as described previously [16] [19]. Briefly, for the 
TFV-releasing segment, HPEU-35 or HP-100A-60 pellets were formed by hot-melt 
extrusion into hollow tubes with approximately 5.5 mm cross-sectional diameter and 0.7 
mm wall thickness. HPEU tubing was cut to two different lengths, 145 mm or 155 mm, 
for IVR prototypes I and II, respectively (Figure 4.1). Tubes were filled with a 
TFV/glycerol/water paste (62-65% TFV) using a high-pressure back-filler (Dymax, 
Torrington, CT) and sealed using a bonding-die induction welder (PlasticWeld Systems, 
Newfane, NY), resulting in segments with final lengths of 121 or 131 mm, respectively. 
For the LNG segment, LNG-loaded PEU-1 or EG-85A pellets were first fabricated by 
roll-coating with LNG powder, hot-melt extrusion, pelletization, and bag mixing. LNG-





EG-65D in a two extruder, co-axial hot melt extrusion set-up. Reservoir strands were 
approximately 5.5 mm in diameter with approximately 0.1 mm PEU-2/EG-65D rate-
controlling membrane (RCM) thickness. For IVRs used in PK testing, LNG-loaded co-
axial strands were heat treated for 14 days to mitigate the lag time required for steady 
state release. Strands were cut to either 20 or 10 mm (for IVR prototypes I and II, 
respectively) and end-capped using 2 mm length, 5.5 mm diameter PEU-2 or EG-65D 
polymer discs to prevent LNG diffusion into the TFV segment [19]. Prior to any melt 
processing, all PEU or HPEU resins were dried overnight in a CAFM series compressed 
air dryer (Dri-Air, East Windsor, Connecticut) to less than 0.05% H2O (w/w) as 
determined using a C30 Coulometric Karl Fischer Titrator (Mettler-Toledo, Columbus, 
Ohio).    
 TFV segments and end-capped LNG segments were joined using a split-die 
induction welder (PlasticWeld Systems, Inc., Newfane, NY). For IVR Prototype I, a 121 
mm TFV segment was joined to a 20 mm (24 mm after end-capping) segment, while for 
Prototype II, a 131 mm TFV segment was joined to a 10 mm (14 mm after end-capping) 
segment. IVR were annealed in custom-made aluminum molds for 65°C for 10 to 15 
minutes to obtain a more circular shape. IVRs used in stability testing were heat treated 
for 14 days at 40°C in heat-sealed aluminum pouches to simultaneously eliminate the lag-
time required to achieve steady state LNG release [19] and stabilize TFV release rates by 








4.3.3 HPLC Quantification of TFV and LNG in Drug Release 
and Extraction Samples 
 TFV and LNG were quantified in in vitro release samples using an Agilent (Santa 
Clara, CA) 1200 series HPLC equipped with a diode array detector. TFV was quantified 
at 260 nm using a 15-minute gradient of potassium phosphate buffer (pH 6.0) and 
acetonitrile (ACN) described previously [16]. LNG was quantified using a 4.6 x 250 mm 
Zorbax C18 5 µm column (Agilent, Santa Clara, CA) and 240 nm. For polymer 
extraction samples, a 5-minute isocratic run of 80:20 ACN:water was used, while a 18-
minute gradient of 0.1% formic acid in water and 0.1% formic acid in ACN was used to 
quantify LNG in in vitro release samples, both as described previously [19]. 
 
4.3.4 In Vitro Drug Release Testing 
 The release kinetics of TFV/LNG IVR were evaluated in vitro under sink 
conditions as previously described [19]. For IVR undergoing stability evaluation, 
Prototype I samples were placed in glass jars and immersed in 25 mM sodium acetate 
buffer (pH 4.2) in an incubated shaker cabinet set to 37°C and 80 rpm. IVR Prototypes I 
and II were similarly evaluated in parallel to the sheep PK study, except that acetate 
buffer was replaced with 1X phosphate buffered saline (PBS) (pH 7.4) to mimic the 
neutral pH of the sheep vaginal tract. Media volumes were selected and modified as 
needed to ensure that sink conditions (drug concentrations not exceeding 20% of their 
solubility) were maintained. Release media were changed daily, and aliquots were 





media by HPLC as described above. Time-averaged release rates for each IVR were 
determined using a trapezoidal numerical integration for comparison to in vivo data. 
 
4.3.5 Extraction and Quantification of TFV and LNG from IVR 
 Drug extractions were performed on TFV/LNG IVR were performed as part of 
the stability and pharmacokinetic studies described below. First, IVR were dissected with 
a razor blade between the TFV segment plugs and the LNG segment end-caps. TFV 
extraction from TFV segments were performed as described previously for the TFV-only 
IVR [16]. Briefly, segments were dissected into several pieces (approximately 5-8 mm in 
length) and placed into glass jars containing 100 mM sodium phosphate buffer (pH 7.4), 
which were shaken overnight on a High Capacity Mixer (Glas-Col, Terre Haute, IN) to 
completely dissolve all TFV present in the ring. For IVR evaluated following in vivo 
testing, TFV segments were first placed at -80°C to avoid spilling of core contents during 
dissection. Following complete dissolution, the supernatant and multiple rinses of the 
remaining HPEU tubing fragments were transferred to a 50 mL volumetric flask, which 
was filled to volume with additional sodium phosphate buffer and agitated briefly. The 
resulting solution was then volumetrically diluted 100-fold in the same buffer using 100 
µL a calibrated glass syringe (Hamilton Company, Reno, Nevada) and a 10 mL 
volumetric flask. TFV was quantified in the resulting solution by HPLC as described 
above. Similar extractions were performed on the source TFV-containing paste for each 
ring lot to estimate the initial average TFV load for each ring. 
 LNG was extracted from in LNG segments using a dissolution and precipitation 





pieces (approximately 2-3 mm in length), all of which were transferred to a 25 mL 
volumetric flask, which was filled with approximately 15 mL of dichloromethane (DCM) 
before undergoing vigorous shaking on the same High Capacity Mixer. Following 
overnight shaking, flasks were filled to volume with DCM and vortexed vigorously. A 1 
mL aliquot of the DCM solution was transferred to a 10 mL volumetric flask, which was 
filled to volume with ACN to dissolve the LNG present while precipitating the PEU. The 
supernatant was then subjected to HPLC analysis for LNG quantification as described 
above. 
 
4.3.6 Stability Evaluation of TFV/LNG IVR 
 TFV/LNG IVR were stored individually in heat-sealed VF42 Vapor-Flex flat 
barrier bags (LPS Industries, Moonachie, NJ) and stored at either 30°C/65% relative 
humidity (RH) or 40°C/75% RH for up to 5 months. Chemical stability was assessed at 
multiple pull points using the extraction methods described above. For TFV, the total 
mass extracted was compared at each point to a t=0 baseline, while for LNG, the initial 
mass of the segment (prior to end-capping) was used to normalize each extracted mass 
value for a baseline comparison due to the higher dimensional variability observed in the 
co-axial strands. In vitro release testing was performed at each time and temperature for 
28 days as described above. We used similarity factors (f2) to quantitatively assess the 
stability in vitro release profiles. It was first necessary to estimate the cumulative release 
profile of both TFV and LNG, which was performed by simple summation (for regions of 
the profile where continuous collection points were available) or by trapezoidal 





for days 21 and 28). Similarity factors are typically calculated using cumulative release 
expressed as a percentage of total drug load in the device [25]. However, since these in 
vitro release tests were not designed to test IVR to exhaustion, we expressed cumulative 
release as a percentage of the drug released by day 28 in the t=0 group. Similarity factors 
were then calculated by the following equation: 




∗ 100ൡ (4.1) 
where n is the total number of points on the release profile and R and T are the reference 
and test profiles to be compared. The FDA considers two release profiles to be similar if 
f2≥50. 
 We assessed the physical stability of LNG in the co-axially extruded strands and 
full IVR both visually and using polarized light microscopy to examine the surface of the 
LNG segment for LNG recrystallization at some time-points. 
 
4.3.7 Pharmacokinetic Evaluation of TFV/LNG IVR in Sheep 
 Pharmacokinetic studies were carried out at MPI Research (Mattawan, MI) which 
is accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International (AAALAC International). IVR Prototypes I and II were evaluated in 
2- to 5-year-old and 65-80 kg Dorset Crossbred sheep purchased from Buckham’s sheep 
farm (Kalamazoo, MI). Animals were treated under a protocol reviewed and approved by 
Institutional Animal Care and Use Committee (IACUC) at MPI Research. The sheep 
were housed in separate indoor pens under fluorescent light provided for approximately 
12 hours daily and interrupted for study related activities if required. Animals were 





periods and water was provided ad libitum. Sixteen animals were divided into two groups 
of 8, one receiving Prototypes I and the other receiving Prototype II. IVR were inserted 
continuously for 90 days. Prior to insertion, each IVRs was fitted with a medical grade 
suture thread to allow for easy removal. The exterior of the vagina was treated with 
chlorhexidine solution and IVR were inserted using gloved hands and a small amount of 
medical-grade lubricant. Strings fitted to the IVRs were left hanging outside the vagina to 
visually that samples had not been expelled. Correct ring placement was confirmed by 
visual examination with the aid of a speculum. Animals were examined daily to confirm 
that rings had remained in place. Following ring administration, vaginal fluid sponges, 
vaginal and cervical tissue biopsies, and blood samples were collected periodically for 
drug content analysis. Preweighed Weck-Cel® sponges (Beaver-Visitec International, 
Inc., Waltham, MA) were used to collect vaginal fluid from each animal, 8 hours after 
removal and on days 1, 2, 3, 7, 14, 28, 60, and 90. Samples were also taken on days 91, 
92, and 93 (1, 2, and 3 days following IVR removal). Vaginal fluid sponges were 
collected from proximal vagina (5 to 7 cm from the introitus) and distal vagina (2 to 4 cm 
from the introitus). Sponges were pressed against the vaginal wall for 1 minute to allow 
for fluid absorption. The mass absorbed was determined by reweighing sponges 
following collection and comparing to the initial mass. Kevorkian-Younge biopsy forceps 
(Miltex, York, PA) were used to collect vaginal and cervical biopsies 8 hours after 
removal and on days 14, 28, 60, 90, and 93. Prior to all biopsy procedures, animals were 
anesthetized and the exterior vagina was cleaned using chlorhexidine solution. Tissue 
samples (approximately 50 mg) were biopsied alternatively from the left or right side 





was applied with gauze (with or without thrombin), and local analgesic was administered. 
Approximately 2 mL of blood was collected via the jugular vein at all time points and 
stored in K3EDTA-containing tubes and tubes were stored in wet ice until centrifuged.  
Blood samples were centrifuged at 4°C and the supernatant was collected. Sponges, 
biopsies, and blood supernatants were stored at -70°C until further bioanalysis could be 
performed. Animals that expelled rings during the study were immediately administered a 
fresh ring, with ring treatment continuing to a total of 90 days. PK and drug extraction 
data obtained from these animals were excluded from analysis (except for one animal that 
had a ring replaced after 1 hour that was retained for the remainder of the study). A total 
of 7 and 6 animals retained an IVR for the full 90 days in the Prototype I and II groups, 
respectively. At study's end, IVR were retrieved from the vaginal tract using the attached 
suture thread. TFV and LNG were extracted from returned IVR as described above, and 
time-averaged release rates were determined for each animal by dividing the difference in 
initial and extracted drug mass by the duration of insertion. For TFV, the initial mass was 
estimated by multiplying the TFV-containing paste fill mass by the average TFV loading 
in the paste batch used for the ring lot. For LNG, the initial mass was estimated by 
multiplying the segment mass (prior to end-capping) by the average LNG weight fraction 
determined by LNG segment extractions from the same ring batch.  
 TFV was quantified in vaginal fluid swabs, vaginal tissue biopsies, and plasma 
samples by extraction and LC-MS/MS procedures described previously [16]. LNG was 
also quantified in cervical biopsies and plasma samples by extraction and LC-MS/MS 







4.4.1 TFV and LNG Chemical Stability 
 Results of the TFV/LNG IVR chemical stability evaluation are shown in Figure 
4.2. TFV and LNG recovery did not significantly decrease during 147 days storage at 
either 30°C/65% RH or 40°C/75% RH compared to a baseline control. Initially, 1.40 ± 
0.03 g TFV was recovered from TFV/LNG IVR, compared to 1.37 ± 0.03 (p=0.06, 
heteroscedastic t-test) and 1.41 ± 0.04 g (p=0.75) recovered from IVR stored at 
30°C/65% RH or 40°C/75% RH, respectively (all N=5, mean ± SD). LNG loadings were 
1.12 ± 0.03 % LNG (w/w) at baseline compared to 1.17 ± 0.01 % (p=0.02, but higher) 
and 1.16 ± 0.07 % (p=0.29) at 30°C/65% RH or 40°C/75% RH, respectively (all N=5, 
mean ± SD). 
 
4.4.2 TFV and LNG Release Rate Stability 
 Release kinetics of TFV and LNG were evaluated following 31, 92, and 150 days 
storage at 30°C/65% RH and 40°C/75% RH. These results are shown in Figure 4.3. 
Following a lag on day 1 and a slight burst on day 2, average TFV was released from 
IVR at nearly constant rates over 28 days at each time-point as expected [16, 22]. Mean 
TFV release rates between day 3 and day 28 (N=5) ranged from 5.4 to 7.8 mg/d, 6.5 to 
7.9 mg/d, 5.6 to 7.2 mg/d, and 4.7 to 6.8 mg/d following 0, 31, 92, and 150 days storage 
at 40°C/75% RH, respectively (Figure 4.3C). Release rates generally showed a slight 
downward trend during increased storage time; however, the 150-day group released 
more than the 92-day group at 3 collection points (days 14, 21, and 28) and more than the 
t=0 group on day 21. On average, release rates decreased 22% during 150 days storage at 





days storage at 30°C, with the maximal drop (30%) also occurring on day 7. LNG release 
also occurred at near constant rates over 28 days at each pull point. LNG release rates 
varied across the various pull-points, but with no clear trend preserved across the entire 
kinetic curve. An increase in the initial LNG burst release was observed over the first 3 to 
4 days, with the largest change occurring between the t=0 and the 31-day groups at 40°C, 
but between the 31- and 92-day groups at 30°C. A dip in the release rate profile was 
observed in the t=0 group but not at any other of the time-points at either temperature. 
From day 5 onward, mean LNG release rates (N=5) ranged from 13 to 22 µg/d (17 to 22 
µg/d discarding day 7 through 9), 22 to 25 µg/d, 18 to 24 µg/d, and 19 to 24 µg/d 
following 0, 31, 92, and 150 days storage at 40°C/75% RH, respectively. At certain 
points in the kinetic profile, LNG release was the highest in the 150-day storage group 
(day 1 and day 21) while on day 21, release was the lowest in the 150-day storage group. 
 In comparison to the t=0 release rate profile, TFV similarity factors were 
determined to be 85.5, 62.5, and 53.3 following 31, 92, or 150 days at 40°C, respectively. 
In comparison to the 31-day profile, TFV similarity factors were determined to be 95.2 
and 91.4 following 92 or 150 days at 40°C, respectively. For LNG, similarity factors 
were determined to be 44.3, 50.1, and 48.6 in comparison to the t=0 group, and 65.7 and 
77.2 in comparison to the 31-day group. 
 
4.4.3 TFV and LNG Physical Stability 
 Both LNG-loaded co-axial reservoir strands and TFV/LNG IVR were monitored 
visually and by polarized light microscopy for LNG surface recrystallization [23]. 





observed following 30 and 38 days at 40°C, 30°C on EG-85A/EG-65D strands stored in 
sealed pouches (approximate LNG loading 1.3% w/w). However, crystallization kinetics 
were different for TFV/LNG IVR, also stored in sealed aluminum pouches. As shown in 
Figure 4.4, no LNG surface crystallization was detectable by polarized light microscopy 
following 150 days storage at 40°C (164 days total, including heat treatment), which is in 
direct contrast to the data presented above for LNG strands. 
 
4.4.4 Comparison of TFV and LNG Release Rates In Vitro and In Vivo 
 In vitro drug release profiles for TFV and LNG from TFV/LNG IVR (both 
prototypes I and II) used in the sheep PK study are shown in Figures 4.5A and 4.5B, 
respectively. Similarly to the data presented above, TFV was released in a zero-order 
fashion for 90 days following a short lag period on day 1. TFV release rates from 
Prototype I were consistently lower than prototype II (except on day 21), which was 
expected as Prototype I contained a 10 mm shorter TFV segment. Time-averaged release 
rates were 7.7 ± 0.2 and 8.1 ± 0.2 mg/d from Prototypes I and II, respectively (N=5 time-
averaged IVR release profiles, mean ± SD). LNG release proceeded in a near zero-order 
fashion similarly to above, with a short burst period occurring for Prototype I but not for 
Prototype II. LNG release rates were between 1.9-fold and 3.6-fold higher at individual 
time-points from Prototype I in comparison to Prototype II, with the highest of these 
occurring on day 2. Time-averaged release rates were 23 ± 1 and 9.3 ± 0.5 µg/d from 
Prototypes I and II, respectively (N=5 time-averaged IVR release profiles, mean ± SD), 





 A comparison of time-averaged TFV and LNG release rates in vitro and in vivo 
from IVR prototypes I and II is displayed in Figure 4.5C. All data below describe only 
IVR that remained in for the full 90 day duration (N=7 for Prototype I and N=6 for 
Prototype II). Extraction of residual TFV from recovered IVR revealed average rates of 
12.0 ± 1.7 and 12.6 ± 1.5 mg/d (90.4 ± 12.6 % and  86.4 ± 10.2 % cumulative release, 
mean ± SD) from Prototypes I and II, respectively. Even though the standard deviation 
for the Prototype I group extended beyond 100%, all rings had quantifiable TFV 
remaining. In vivo TFV release was 56% higher than that observed in vitro for both 
Prototypes I and II, which is similar to our previous observations of the TFV-only HPEU 
reservoir ring [24]. LNG release rates were 31 ± 3 and 14 ± 1 µg/d (44 ± 4 % and 40 ± 3 
% cumulative release, mean ± SD) from IVR prototypes I and II over 90 days, 
respectively. In vivo LNG release rates were 38% and 49% higher than those observed in 
vitro for Prototypes I and II, respectively. 
 
4.4.5 Pharmacokinetic Evaluation of TFV/LNG IVR in Sheep 
 TFV vaginal fluid concentrations during 90-day insertions of IVR Prototypes I 
and II in sheep are shown in Figures 4.6A and 4.6B. In all cases, vaginal fluid levels were 
relatively steady from day 1 (24 hours) onward, following a short lag observed at the 8-
hour time-point, when all mean readings ranged between 1-3 x 104 ng/g (both proximal 
and distal, prototypes I and II. From day 1 to day 90, mean TFV concentrations ranged 
from 1.2 x 105 to 1.4 x 106 ng/g (proximal) and 1.4 x 105  to 8.1 x 105 ng/g (distal) for 
sheep treated with Prototype I (N=7), and from 3.3 x 105  to 1.9 x 106 ng/g (proximal) 





Mean TFV concentration was generally higher in proximal swabs than distally, for both 
Prototypes with some exceptions (days 1 and 14 for Prototype I and days 2, 3, and 92 for 
Prototype II). Although TFV release was slightly higher from Prototype II than from 
Prototype I, the two datasets were relatively indistinguishable for both proximal and 
distal swabs. The ratio of mean TFV concentrations between animals treated with 
Prototype II over Prototype I ranged from 0.3 to 5.2 proximally and from 0.3 to 6.2 
distally from day 1 to day 90. The minimum concentrations in any single animal 
observed between day 1 and day 90 were 2.0 x 103 ng/g (proximal, but with the next 
highest being 1.6 x 104) and 1.5 x 103 ng/g (distal) for Prototype I, and 1.3 x 103 ng/g 
(proximal, but with the next highest being 2.5 x 104) and 2.8 x 104 ng/g (distal). With the 
exceptions of some samples below limit of quantification (LOQ), TFV fluid 
concentrations were maintained for 3 days beyond ring removal in the 102-104 ng/g 
range. Since the lower and upper limits of quantification depended on the individual 
uptake mass of each swab, samples below LOQ (only samples after ring removal, see 
Figures 4.6A and 4.6B) or above LOQ (only one proximal swab on day 2 for Prototype I) 
were excluded from analysis, and mean values are not reported for those time-points. An 
attempt was made to quantify LNG in vaginal fluid swabs, but most readings beyond day 
3 were below our limit of quantification for both swab locations and Prototypes, 
preventing any meaningful analysis.      
 TFV concentrations in vaginal tissue biopsies were also sustained throughout the 
90-day sheep study, as demonstrated in Figures 4.6C and 4.6D. Again a lag was observed 
at the 8-hour time-point, and as no collections were taken between this and the 14-day 





elucidate from these data. From day 14 to day 90, mean TFV concentrations in vaginal 
tissue ranged from 5.8 x 103 to 3.1 x 104 ng/g (proximal) and 2.6 x 103 to 1.4 x 104 ng/g 
(distal) for sheep treated with Prototype I (N=7), and from 3.3 x 103 to 2.5 x 104 ng/g 
(proximal) and from 2.2 x 103 to 5.7 x 103 ng/g (distal) for sheep treated with Prototype II 
(N=6). TFV was still detected in most samples on day 93 (3 days postremoval), with 
mean TFV concentrations of 120 ng/g (proximal) and 200 ng/g (distal) for Prototype I 
and 170 ng/g (proximal) and 75 ng/g (distal) for Prototype II. Samples below LOQ were 
assigned the value of LOQ/2 (10 ng/g) for the calculation of mean values [10]. Mean 
TFV concentration was always higher in proximal biopsies than in distal biopsies 
between days 14 and 90, except at day 14 for prototype II, and again the datasets of the 
two Prototypes were relatively indistinguishable at both biopsy locations. All individual 
animal readings were above 390 ng/g between days 14 and 90 for both Prototypes and 
biopsy locations.   
 LNG concentrations profiles in cervical tissue biopsies are shown in Figure 4.6E. 
Some samples were below the LOQ for this assay (0.75 ng/g), and were assigned the 
value of LOQ/2 (0.375 ng/g) for the calculation of mean values [10]. LNG levels were 
steady from the 8-hour time-point through day 90, and did not exhibit the lag observed in 
the TFV. Mean LNG concentrations ranged from 2.9 to 14 ng/g in sheep treated with 
Prototype I (N=7) and 2.4 to 4.9 ng/g in sheep treated with Prototype II (N=6). With the 
exception of day 90, mean LNG concentrations were higher in sheep treated with 
Prototype I (N=7) vs. Prototype II (N=6), which was expected as the former was 
designed to give a 2-fold higher release rate of LNG. In fact, the ratios between mean 





and day 28, respectively, clearly indicating that the 2.5-fold doses achieved in vitro were 
also achieved in vivo. LNG levels were steady over the 90-day period with the exception 
of the spike observed at day 60 in the Prototype I group, likely resulting from the 
unusually high value of 65 ng/g achieved in 1 animal. When this value is removed, the 
mean LNG concentration decreases to 5.6 ng/g, and a Prototype I vs. II ratio of 1.9 is 
obtained. All readings were below LOQ on day 93 (3 days following ring removal). 
 TFV was also quantified in blood plasma samples during the 90-day PK study. 
All readings were below LOQ (1 ng/mL) in plasma 8 hours postinsertion, but TFV was 
quantified in all samples from day 1 to day 90, with the exceptions of 1 animal in each 
ring group on day 1 and 2 animals in the Prototype I group on day 90 (again these values 
were assigned LOQ/2, or 0.5 ng/mL, for statistical calculations).  Mean TFV plasma 
concentrations at day 1 through day 90 ranged between 2.3 and 18 ng/mL for prototype I 
and between 1.7 and 27 ng/mL for prototype II. Cmax occurred on day 14 and day 60 for 
Prototypes I and II, respectively. In both cases, a sharp drop was observed from day 60 to 
day 90: 12 ± 6 to 5.5 ± 5.5 ng/mL for prototype I and 27 ± 16 to 8.2 ± 3.6 ng/mL for 
prototype II (all mean ± SD). TFV was not detected in plasma after 1, 2, or 3 days 
postremoval for either group.  
 Generally, LNG concentrations in plasma were below our LOQ (25 pg/mL). For 
the higher-dose Prototype I group, LNG was detected in plasma for all animals on at the 
8-hour time-point, 5 of 7 animals on day 1 and 1 of 7 animals on day 2 with all samples 
below LOQ thereafter. In the lower-dose Prototype II group, LNG was below LOQ in all 






4.5 Discussion  
4.5.1 IVR Stability 
 TFV and LNG proved chemically stable in the IVR formulation for up to 5 
months under accelerated conditions. No loss of TFV or LNG was observed after storing 
rings for 147 days at either 30°C or 40°C. Stability testing of TFV/LNG IVR will 
eventually continue out to at least 2 years at these temperatures to determine the actual 
shelf life of the product. 
 TFV and LNG release kinetic profiles remained zero-order or near-zero order 
throughout the stability evaluation; however, some differences were observed. The 
average TFV release rate decreased gradually over time. HPEU, such as those used to 
manufacture the tubing of the swellable TFV segment, undergo gradual microphase 
separation following extrusion. This physical change results in a reduction of free water 
in the fluid-filled pores that facilitate transport of TFV through the wall, resulting in a 
decreased effective diffusivity, and resulting flux of TFV from the reservoir (manuscript 
in preparation). Ultimately, the TFV release rate is likely to plateau over time as the 
physical arrangement of the HPEU approaches an equilibrium state. As described in the 
methods, a 14-day heat treatment was applied to IVR before the start of the stability 
study. This was done both to drive this HPEU rearrangement toward completion, as well 
to facilitate LNG diffusion into the membrane of the LNG reservoir segment, as 
described below. The decay in release rate is greatly enhanced in the presence of the 
TFV/glycerol/water formulation (data not shown), leading us to hypothesize that glycerol 
may act as a plasticizer to aid in the migration of polymer chains following its permeation 
into the tubing wall. Regardless of this gradual migration of the release rate, it should not 





flux provides a sufficient concentration of TFV in the vaginal tissue to prevent HIV 
infection from occurring. A more vigorous pretreatment step could be performed to the 
tubing (e.g., higher temperature or longer time) prior to IVR manufacturing to ensure that 
the HPEU reaches its equilibrium state, resulting in a more stable release rate. Even 
though a drop in release rate was noticed, the similarity factor analysis revealed that TFV 
release rate profiles were quantitatively similar (f2≥50) at all time-points when compared 
to the t=0 data. 
 The two stage nature of drug release from solid reservoir devices is discussed in 
detail in a previous manuscript [19]. During the initial matrix-phase, which appeared to 
last 3 or 4 days, LNG burst release increased in magnitude during IVR storage, but 
appeared to level off in the 40°C group, meaning that the LNG concentration had likely 
equilibrated in the wall. However, the burst release on day 1 was well below that 
predicted by our model [19] for the Prototype I configuration (~100 µg), suggesting that 
the presence of glycerol on the surface of rings following storage may slightly attenuate 
the burst. This is a positive result, as the change in burst following 14-day heat treatment 
(resulting an initial concentration profile similar to that at the beginning of the reservoir 
phase), to the final equilibrium state was much less than anticipated. Following the 
matrix-stage, LNG release rates were relatively stable on storage at both temperatures. 
This result indicates that the microphase separation discussed above, likely also to occur 
in PEU due to their chemical similarity to HPEU, did not have an effect on diffusion of 
dissolved LNG molecules through the outer polymer membrane. Based on similarity 
factor analysis, the 31- and 150-day (40°C) LNG release profiles were slightly dissimilar 





similar (65.8 and 77.2) to the 31-day profile, quantitatively confirming that the LNG 
release behavior had reached equilibrium following the initial 31-day storage.   
 Based on the ability of LNG to crystallize on the surface of reservoir segments, 
LNG likely exists as a supersaturated solution in the outer rate-controlling PEU at our 
target LNG loading (~1.2% LNG w/w). At some point during the RCM loading process, 
possibly even before 14-day heat treatment is completed, the concentration of LNG in the 
outer interfacial layer of the RCM will become super-saturated and immediately create a 
chemical potential gradient for recrystallization across the interface. This phenomenon is 
also encountered with the super-saturated solution of etonogestrel present in NuvaRing® 
[26], and is the reason for cold-chain storage of the product. Extensive drug surface 
crystallization is undesirable for any drug delivery system as it may result in an additional 
burst release of drug and a corresponding reduction in the magnitude of the reservoir 
release profile in time, provided sufficient drug was allowed to escape from the device 
core. The presence of glycerol on the outer surface of IVR following storage appears to 
prevent surface recrystallization of LNG from the LNG segment. This phenomenon was 
consistent for all IVRs in the 40°C test group following 150 days storage (164 days total, 
including heat treatment). It is unclear if this 'self-coating' is a permanent solution for 
surface crystallization, but it is an encouraging improvement to the system and may 
eliminate the need for either cold-chain storage or application of a spray/dip coating, 








4.5.2 Sheep Pharmacokinetic Study 
 TFV release was 56% higher in vivo than in vitro for both Prototype I and II, 
similar to what we observed with our sheep PK study of the TFV-only IVR [16]. As we 
only measured the total release over 90 days, it is impossible to determine the exact in 
vivo profile for a head to head comparison with in vitro data. However, PK profiles in 
vaginal fluid swabs were relatively steady over the 90-day period, suggesting that a 
similar zero-order release profile of greater magnitude was achieved in vivo. For reservoir 
systems, drug release rates vary linearly with dissolved concentration. We hypothesize 
that the increased release rate may be due to the pH-dependent solubility of TFV. The 
HPEU tubing is a sempermeable membrane which will allow contents of the endogenous 
vaginal buffer that are sufficiently small to pass through, and eventually reach 
equilibrium across the membrane. Even though our parallel in vitro release studies were 
performed in a pH 7.4 buffer, it is possible that an increased buffering capacity of the 
vaginal buffer present inside the reservoir core during use allowed for more TFV to be 
dissolved, thus resulting in more rapid TFV flux across the wall. Ultimately, these IVR 
need to be tested in women to determine the actual in vitro/in vivo release rate 
relationship for this system, but encouraging is that the in vivo release rate variability was 
relatively low within each group (coefficients of variation of 14% and 12% for 
Prototypes I and II, respectively), indicating that although we may see a higher release 
rate in women than in vitro, the release rate obtained will likely be reproducible. LNG 
release rates were also higher in vivo than in vitro. In our previous rabbit PK evaluation 
of the LNG segment in rabbits [19], the comparison of data between 28-day and 90-day 





conclude that, although a higher burst was achieved in vivo, the resulting in vitro release 
rates were nearly identical. Again, we only have a single time-point to assess in vivo 
release, but this phenomenon is likely preserved because the LNG segments used in the 
sheep study IVR were made nearly identically to those used in the rabbit PK study. 
However, the concentration profile in cervical tissue does not support this assessment at 
first glance as it is steady with time from 8 hours to 90 days postinsertion. However, one 
would generally expect a lag (as is observed with the loading of vaginal tissues with 
TFV), and the presence of an in vivo LNG burst may be negated by this physiological lag. 
The variability in the cervical tissue data may also make the observation of this in vivo 
burst difficult. Regardless, of the presence/absence of this burst, the steady cervical tissue 
levels throughout the 90-day period are encouraging. 
 TFV vaginal fluid levels exceeded 104 ng/g in nearly all animals at all time-points 
from 24 hours postinsertion onward for both ring prototypes (with few exceptions in the 
103 ng/g range and many readings exceeding 106 ng/g). Mean values were all in the 105 
to 106 ng/g range, and trend slightly lower, but are comparable to those achieved from the 
TFV-only variant, which released 17 mg/d in vivo vs. the 12-13 mg/d achieved from 
these combination rings [16]. The partially effective TFV 1% gel has been observed to 
generate peak vaginal fluid levels in the 106 ng/g range in sheep, indicating that this IVR 
can generate clinically relevant TFV concentrations for extended duration. Furthermore, 
103 ng/g was identified as a lower cutoff for a higher efficacy group (74% reduction in 
HIV infection) in the CAPRISA 004 study of the TFV 1% Gel [4] and it is encouraging 
that all concentration readings in all animals were above this point during the study. 





efficacy, as it is unclear from the study reports how long after gel dosing those readings 
were obtained. 
 The vaginal tissue compartment is the eventual primary site of action for any 
product designed to interrupt sexual HIV transmission, and thus is the most important 
predictor of efficacy in preclinical PK evaluation. Our TFV tissue concentration results 
were encouraging. The EC99 of TFV has been estimated at 5 µM in cell culture, which 
equates to approximately 1 x 103 ng/g [27]. All mean TFV tissue concentrations from day 
14 to day 90 onward well exceeded this value, although some individual readings were 
lower. In total the TFV PK data obtained here again confirms that a TFV dose in the 10 
mg/d range in a sustained fashion from an IVR is clinically relevant and warrants clinical 
investigation. However, caution should be used when comparing PK results between 
women and sheep. Even though the sheep model anatomically approximates the human 
vaginal tract, in is not clear whether histological differences may result in disparities in 
drug transport, metabolism, and elimination between species. This principle is well 
illustrated below for LNG. 
 Topical microdose administration of progestins primarily achieves contraception 
through local effects (e.g. the thickening of cervical mucus to prevent sperm transport) 
[28], and thus our measurement of LNG in the cervical tissue over time during IVR 
administration is the primary indicator of efficacy in this study. As we noted in our PK 
assessment of  LNG in rabbits [19], the kinetics of the concentration profile are more 
important than the exact concentration magnitude. Delivery of 10-20 µg/d LNG locally is 
clinically known to achieve reliable contraception in women, most notably from the 





steady levels of LNG achieved over time, as well as the distinguishability of the two 
doses given by Prototype I and II at most time-points (not statistically, but through the 
comparison of averages nonetheless). We were not able to quantify LNG in plasma, 
except in the first few time-points in the study. Our LOQ was 25 pg/mL, well below the 
~150-300 pg/mL observed in women using the discontinued 20 µg/day LNG-releasing 
IVR [21]. This further illustrates that the PK properties of drugs in sheep are not well-
enough understood to make direct comparisons between species. 
 
4.6 Conclusions 
 The TFV/LNG IVR formulation proved to be stable when stored at 40°C for up to 
5 months, with the exception of some drift in the average TFV release rate and LNG 
burst release, both of which less than expected based on our previous investigations of 
the two phenomena. Our PK assessment in sheep confirmed that this system can achieve 
clinically-relevant doses of both TFV, which remains the only anti-HIV molecule with 
clinical efficacy data for HIV PrEP (including its prodrug TDF), and LNG, a long-studied 
molecule for topical microdose contraception. The TFV/LNG IVR and the TFV-only 
IVR have been transferred to GMP manufacturing and are currently slated for a Phase I 
clinical investigation. The TFV/LNG IVR is the first in a new class of exciting, long-
acting MPT, any of which may become critical tools in overcoming the PrEP adherence 
battle through their ability to provide simultaneous contraception and to provide 
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Figure 4.2: Recovery of (A) TFV and (B) LNG by residual extractions from TFV/LNG 
IVR (Prototype I) following storage at either 30°C/65% RH or 40°C/75% RH for up to 






























Figure 4.3: In vitro release rate profiles of TFV and LNG from TFV/LNG IVR 
(Prototype I) following storage following storage at either 30°C/65% RH (A, B) or 

































Figure 4.4: Prevention of LNG surface crystallization for 164 days (total) at 40°C by 
glycerol self-coating on a full TFV/LNG IVR (right), shown in comparison to (A, left) a 






































Figure 4.5: In vitro release of (A) TFV and (B) LNG under sink conditions from IVR 
Prototypes I and II. (C) In vivo release estimated from residual extractions of IVRs 
following 90-day insertion in sheep. Data represent mean ± SD, N=5 (in vitro), N=7 






























Figure 4.6: Individual animal results of the sheep pharmacokinetic study. Horizontal bars 
represent mean values. (A,B) TFV levels in vaginal fluid of sheep treated with IVR 
prototype I (A) or II (B) for 90 days. Some samples were below limit of quantification 
(BLOQ) during the 72-hour washout period (days 91-93), and mean values were not 
calculated for these points. Some samples were lost at the study site during days 91-93. 
(C,D) TFV levels in vaginal tissue biopsies from sheep treated with IVR Prototype I (C) 
or II (D) for 90 days and (E) LNG levels in cervical tissue biopsies. For tissue data, 
values below LOQ were plotted as LOQ/2 (10 ng/g TFV and 0.375 ng/g LNG) and 




















5.1 Research Summary and Context 
 Chapters 2 through 4 summarize a wide array of the research and preclinical 
development of the HPEU TFV IVR and the dual-segment TFV/LNG multipurpose IVR. 
In Chapter 2, the first-generation matrix-type injection-molded TFV HPEU IVR was 
presented as a case study for the rigorous engineering design of matrix-type IVR, with 
many of the concepts extending to cylindrical matrix-type drug delivery systems in 
general. Our explicit solution (Equation 2.4) to Roseman and W.I. Higuchi's classic 
model for cylindrical reservoirs [1, 2] allowed us to accurately extrapolate release rates 
from 7 out to 90 days, and the mechanical model (Equation 2.6) provided the first insight 
into the effects of IVR design choices on mechanical properties. Very interesting is the 
interplay between drug release and mechanical compressibility, which are intimately 
coupled for matrix devices containing large amounts of undissolved drug. The second-
generation of the TFV HPEU IVR, described in detail in the final chapters of the Ph.D. 
thesis of Todd Johnson (Department of Bioengineering, University of Utah), utilized a 
hollow reservoir design which allowed for constant drug release rates and mechanical 
properties over time. This technology was adapted for use in the TFV/LNG IVR. 
 Chapter 3 described the incorporation of a solid PEU reservoir into the second-
generation TFV IVR for the creation of the dual-segment TFV/LNG IVR, the first long-
acting system designed to simultaneously prevent HIV infection and unintended 
pregnancy. When the TFV/LNG IVR project was initiated, we desired to rigorously 
understand the two-stage nature of release from solid reservoir systems. This behavior 
was discussed in one of the NuvaRing development papers [3], but not mathematically 
described. Due to the higher cross-sectional area (i.e. diffusion path) of our reservoir 





importance, with burst durations of up to several days, whereas burst release of 
etonogestrel from NuvaRing typically occurs in 24 hours. We used a piecewise-approach, 
as well as a moving concentration boundary, to quantitatively address the knowledge gap 
in the description of reservoir-type IVR. We also, for the first time, illustrated the 
importance of drug loading in the rate-controlling membrane. Again, this is potentially 
more important for our system due to the increased diffusion path and its influence on the 
lag or burst behavior at early times from reservoir systems. These concepts are universal 
to any reservoir device, provided that the geometry is well understood and accounted for. 
Also remarkable is the utilization of an improved two-segment IVR for the simultaneous 
delivery of microdose progestin and a "macro-dose" of an NtRTI. Use of induction 
welding technology and the chemically diverse PEU elastomer class allowed us to create 
a ring that retained impressive mechanical integrity, even following the hydration at 
swelling of the TFV segment (at least 85% of the ring circumference), around the 
nonhydrating, rigid LNG segment. 
 In Chapter 4, we exposed the TFV/LNG IVR to the rigors of preclinical 
development. The formulation was remarkably stable throughout during 5 months under 
accelerated conditions, with the exception of some instabilities in the release kinetics of 
both drugs. However, these instabilities are well understood and were less prominent than 
expected for this system. During this work, we discovered the unexpected benefit of the 
glycerin present in the TFV segment leaching out into the packaging on storage and 
forming a protective coating around the ring, preventing LNG surface crystallization and 
potentially hindering the burst release. This eliminated the need for application of a 





the need for cold storage of the eventual product (also successfully investigated as a 
method for prevention of surface crystallization on the LNG segment), a desired trait for 
developing world-bound products such as these IVR. The TFV/LNG IVR performed well 
in a sheep PK study, although analytical limitations prevented us from a more complete 
compartmental PK description for LNG. Nonetheless, these two studies demonstrated the 
potential of the system to be sufficient for a clinical investigation. 
 
5.2 Discussion and Future Recommendations 
 In this dissertation, the reader has been exposed to the full range of IVR design 
and manufacturing complexity: from the monolithic, injection molded, matrix-type first 
generation TFV IVR in Chapter 2, to the dual-segment, dual-reservoir, dual-indication 
TFV/LNG IVR in Chapters 3 and 4. No future recommendations will be made regarding 
the design of the former, as it was replaced by the second-generation TFV reservoir 
platform [4]. However, some commentary is warranted regarding the theoretical aspects 
of the work. In this manuscript, we were the first to publish a mathematical model for 
drug delivery regarding the Lambert-W function [5] (Equation 2.4), and also the first to 
utilize the 40-year-old Roseman/Higuchi implicit solution for drug release from cylinders 
for analysis of drug release from an IVR. Higuchi's famous equation for thin films [6], 
which is the planar analog to Equation 2.4, is sometimes used in the context of drug 
delivery from IVR [7]. When deriving Equation 1.3/2.4, Roseman noted that the Higuchi 
equation was a valid approximation at early times, due to the low error in approximating 
the annulus outside the diffusion front as a thin plane of length equal to the IVR 





will result in a deviation from square-root-of-time behavior, necessitating the use of 
Equation 2.4. A similar phenomenon is encountered for Equation 1.2/3.2 (matrix cylinder 
diffusion-only model), where a first-term approximation also gives square-root-of-time 
dependence, but a second negative term, which must be considered after 20-30% of 
cumulative release, depends linearly on time. It is often acceptable to use simpler models 
to provide meaningful insight to the design of drug delivery systems, as long as the 
assumptions made (and some estimate of the resulting error) are understood. An attempt 
should always be made to construct drug diffusion models from first principles when 
possible, as the exercise will lead the researcher to a better understanding of the 
underlying mechanisms at work. Any students seeking to investigate this topic are 
referred to the review articles of Juergen Siepmann [8-12], including one in particular 
[13] that served as a catalyst for my Ph.D. work.  
 Although IVR are generally classified as drug products, they are also medical 
devices, meaning that concepts beyond typical pharmaceutical formulation need be 
understood, requiring some engineering expertise. If IVR are to be further investigated 
and utilized as drug delivery systems, an attempt should be made to couple the 
compression properties of IVR with the elastic properties of the vaginal wall. Our use of 
the load at 10% compression (F10) for comparison to existing rings should serve only as a 
first-order rough method for estimating IVR acceptability. It is thought that the excessive 
stiffness of the WHO LNG IVR caused vaginal tissue damage and that this was a major 
factor in the discontinuation of its development [14]. IVR also rely on sufficient retractile 





force balance with an inserted IVR would be an excellent project for a biomedical or 
mechanical engineering student. 
 There are several ways in which the TFV/LNG IVR could be improved before its 
full consideration as a clinical product. First, as evidenced by Figures 3.S3 and 3.S4, the 
manufacturing of this device is quite complex and may be difficult to scale into high-
volume manufacturing (e.g. 105-106 units per year). The main process impediment is 
likely the 6 induction welds required to fabricate the device. Furthermore, each of the two 
split-die welds used to assemble the final ring require a >1-minute heating cycle. If a 
single over-molding step could be used to both join the two segments and generate the 
PEU end-caps, this would eliminate 3 net process steps and greatly streamline the 
manufacturing. Such a process change may require the preannealing of the two extrudates 
(HPEU tubing and LNG-loaded PEU) to the correct curvature, which could cause 
problems with filling of the TFV-loaded paste. Also recommended is the use of milled 
(i.e. cryo-ground) PEU and a blending with LNG powder. This would likely eliminate the 
need for roll-coating and the first compounding extrusion prior to co-axial extrusion. We 
investigated this early our research but had difficulty in sufficiently drying PEU powders 
with our equipment due to their extremely high surface area and ability to readily adsorb 
and retain surface water. 
 The two-stage model for the LNG segment (Equation 3.11) accurately describes 
drug release solid reservoir where the entirety of the drug load is dissolved at t=0. 
However, as demonstrated in Figure 3.S2 (and experimentally in Figures 3.3A and 3.4D), 
there is some inaccuracy in the use of an instantaneous changeover between matrix and 





between the matrix and reservoir stages could be described, replacing the discontinuity at 
tb with a third, intermediate phase. During our research, Siepmann published a similar 
first-order diffusion-only, "nonconstant activity source" model for reservoir cylinders 
where drug is allowed to release in all directions [10]; however, in simplifying the model 
to only consider radial drug release (as occurs in IVR), we were able to elucidate a much 
simpler exponential time constant ('a'). Equation 3.11 also considers the change in mass 
of dissolved drug in the RCM (contrary to the model presented in Chapter 2), which 
increases accuracy. Although algebraically challenging, the time constant obtained when 
considering the RCM mass change was surprisingly simpler than when it was neglected.     
 It is not clear why a greater burst release was observed in vivo than in vitro from 
the LNG segment in the rabbit PK study (Figure 3.7), and also not clear from the 
available data whether this occurred in the sheep PK study of the full IVR (Figure 4.6). 
Adequate volumes were used to maintain sink conditions during in vitro, meaning it is 
nearly impossible for higher flux in vivo to occur by passive diffusion alone. LNG likely 
exhibits better solubility in vaginal fluid than the simple PBS solution used in parallel in 
vitro studies due to the presence of naturally-present solubilizing agents. Even though 
drug is molecularly dissolved in the rate-controlling PEU, there may be a small amount 
of LNG at the polymer-fluid interface that can be released by surface erosion, the rate of 
which would depend on the solubility of drug in media.  
 A criticism leveled at the hollow HPEU TFV reservoir system is the potential for 
a bacterial reservoir to form within the liquid core during IVR use, thus potentially being 
released in the event of a tubing wall failure and resulting in an acute bacterial infection. 





are currently under investigation by Kiser and colleagues. The effective pore size of a 
hydrated HPEU is likely many orders of magnitude smaller than the smallest dimension 
of any bacterium present in the vaginal milieu, meaning such bacterial infiltration would 
have to occur during manufacturing of the TFV segment, or through a tubing wall defect. 
As vaginal products are not typically manufactured under sterile conditions, there may be 
a need to quantify bacterial load during the manufacturing of the TFV segment. 
 A major limitation in the TFV/LNG IVR, and with all PrEP IVR to-date, is that 
the required prophylactic ARV dose for HIV prevention is not known. Any effective 
PrEP IVR must result in effective levels at all potential sites of infection throughout the 
duration of use [15]. As an estimate of potential efficacy, most PK studies to date have 
quantified ARV levels in large vaginal tissue biopsies and have attempted to compare 
these data to in vitro estimates of efficacy. While these large biopsies can be taken in 
various longitudinal and circumferential positions in the tract, they represent a depth-
average of drug concentration, and do not necessarily represent the exact concentration at 
the three-dimensional location of an HIV target cell. Further complicating this assessment 
for TFV is that its active by product,  TFV diphosphate (TFV-DP), is formed in cells 
[16], and thus TFV concentration never represents the true efficacy of a TFV delivery 
system. We have investigated the measurement of drug TFV concentration as a function 
of depth in rabbit vaginal tissue cross-sections using MALDI-MS/MS. This type of 
measurement, coupled with a detailed three-dimensional PK simulation of drug delivery 
from an IVR, could become a powerful tool to estimate necessary drug release rates for 
HIV prevention. Geonnotti and Katz performed a vaginal drug transport simulation on a 





as a starting point for these efforts [17]. In the Appendix, the reader will find a proposed 
strategy for modeling drug and virus transport in the vaginal tract following drug release 
from an IVR. This proposal was written into an NIH grant proposal, which was 
ultimately funded. The PK modeling effort will be undertaken by Patrick Kiser, Igal 
Szleifer, and colleagues at Northwestern University. 
 In summary, this dissertation should illustrate the necessity of incorporating a 
fundamental physical understanding in a rigorous engineering approach during the 
conception and design of IVR, and drug/device combinations in general. 
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PROPOSED SPATIAL PK MODEL FOR PREDICTION OF DRUG  






 The following text was adapted from an eventually-funded NIH multiproject 
program grant (U19), specifically, from one of three specific aims of the "Research 
Design and Methods" section of a project entitled "Pharmacokinetics and Biodistribution 
of Antiretrovirals and HIV-1 in Macaques". The two remaining aims, not discussed here, 
proposed the design and manufacturing of new IVR prototypes and the spatial mapping 
of drug concentrations following their testing in the pig-tailed macaque (PTM) model, as 
well as the localization of fluorescently labeled HIV pseudovirions in pig-tailed 
macaques. The original text was conceived and authored by Justin T. Clark, Igal G. 
Szleifer, and Patrick F. Kiser.  
 
A.2 Rationale 
 One of the most significant knowledge gaps in the topical PrEP field has been the 
lack of a quantitative mechanistic description of drug PK and virus distribution in the 
vaginal tissue. An experimentally validated model which couples drug release to complex 
mass transport processes occurring in the FGT and surrounding tissue, as well as with the 
existing PD data available for ARVs, could become an invaluable tool in the future 
design of effective microbicide products. We propose to model ARV transport in the 
FGT using a multiscaled approach. Microscopic, molecular dynamics simulations will be 
constructed to determine drug and virus mobility in various compartments. Continuum-
scale models, based primarily on linear transport theory and MRI of the PTM FGT, will 
be used to describe bulk ARV transport and determine effective tissue concentrations of 
drugs and their metabolites as a function of spatial position, time, and release rate from 





equations (PDE) that describe both diffusive and convective drug transport, as well as 
chemical reactions and elimination, we will utilize COMSOL or in-house software to 
numerically resolve ARV concentration profiles within MRI-derived, CAD-generated 
renderings of the PTM FGT. An array of physiologically relevant constants will be 
required for the continuum-scale model, including vaginal fluid velocity, effective drug 
diffusivities through the vaginal epithelium and lamina propria, and rate constants for 
first-order drug elimination from the tissues into the plasma compartment. These 
parameters will be obtained by detailed simulations of the molecular dynamics of ARV 
mobility at the microscale, results of which will be compared to experimental data. We 
will use a similar multiscaled approach to describe the transport of HIV into the tissue. 
 
A.3 Microscale Molecular Dynamics Simulations 
 To determine ARV and virus mobility in various FGT domains (i.e. vaginal 
epithelium, lamina propria), we will construct microscopic models, results from which 
can be used as inputs into the continuum-scale transport model. We have performed 
preliminary molecular dynamics simulations on a simple model system. Figure A.1 
shows the paracellular distribution of a model drug (A) and virus (B) in a simplified 
structure mimicking epithelial tissue. It is clear from the graphics shown that there are 
differences in the mobility and resulting distribution of the model drug as compared to 
virus. We expect that such mobility modeling within structures derived from histological 
examination will be instrumental in providing exquisite information as to the microscopic 
nature of drug and virus distributions within tissues, as well as their effective tissue 





A.4 Continuum-scale Transport Model 
 Using MRI scans  generated at the University of Washington we will generate 3D 
representations of PTM FGT, which will ultimately be rendered in the CAD software 
package SolidWorks. The continuum-scale model will consist of four principal 
compartments: (1) drug delivery system (25 mm OD macaque IVR), (2) vaginal lumen, 
(3) vaginal epithelium, and (4) lamina propria. Additional tissues such as ectocervix will 
also be included if drug loss into these compartments is determined to have a large 
impact on model outcomes. This 3D CAD representation of PTM FGT will be imported 
into COMSOL or custom software for model construction. In general, time-dependent 
effective bulk transport in biological tissue can be approximated by PDE in the form of 
Equation A.1 [1], a modified form of the linear transport equation (see Figure A.2 for all 
equations in this Appendix). 
 
A.5 Establishing the Device/Lumen Boundary 
 Solutions to the vaginal transport model will depend heavily on drug/virus input 
boundaries. In the case of water-soluble drugs, it is likely that an effective sink is 
maintained in vivo (see Chapter 4). In this case, we will first estimate the in vivo drug 
release profile, by a combination of residual drug analysis from removed devices and 
analysis of drug release in vitro. We will then introduce a drug-generating torus in the 
luminal compartment of the rendered FGT, whereby the outer surface is assigned as a 
steady flux boundary, whose magnitude will be defined as the estimated in vivo release 
rate divided by the outer surface area of the IVR. In previous studies, we have observed 
that in vivo release of hydrophobic ARV may be limited by its solubility in the 





release rate determination, and in vivo fluxes need be approximated by residual drug in 
IVRs following PTM studies. Modulation of model in vivo fluxes can aid in the 
determination of optimal ARV release rates from IVR. For virus, we will introduce a sub-
domain in the fluid compartment that simulates the volume of viral suspension added in 
PTM experiments. The PTM vaginal fluid velocity, also measured in these experiments, 
will then be applied in the longitudinal direction in the luminal compartment. Although 
advection is thought to be the primary driving force for luminal transport [4], diffusion 
may also be important in this compartment, especially for circumferential distribution of 
drug molecules after they are released from the device. It may be necessary to estimate 
the effective diffusivities of ARVs and HIV in the vaginal fluid layer. Since these 
diffusivities will likely not be transport-limiting, it may be sufficient to estimate them 
using the Stokes-Einstein equation and appropriate molecular shape factors [5]. We also 
plan to study the specific nature of molecular dynamics in the fluid layer to obtain a 
microscopic understanding of the process. Especially, we expect mucus structure and 
specific solute-mucus interactions to play a role in viral transport, whereas they may not 
impact ARV mobility. 
 
A.6 Modeling Transport in the Tissue Compartments 
 Fluid-tissue partition coefficients and effective tissue diffusivities will be 
estimated experimentally and using microscopic simulations as described above. Through 
such measurements we will estimate if there is a difference in partitioning and effective 
diffusivity between the epithelial layer and the lamina propria. Partition coefficients at 
the lumen-epithelium boundary will be applied as jump conditions across the rendered 





epithelium may be described purely by effective diffusivity Equation A.3. In the lamina 
propria, a fraction of particle concentration at any given point in the tissue will be 
eliminated per unit time, yielding Equation A.4 [1]. We will estimate the effective tissue 
elimination rate constant (k12) for each drug using Equation A.5 upon zero-order delivery 
from an IVR (assuming mass-balance in the plasma compartment), where, cLP is the 
average steady-state concentration in the lamina propria estimated by biopsy extraction 
and MALDI-MS/MS imaging, K is the terminal elimination rate constant, which can be 
estimated for PTM, and Cp is the observed steady-state plasma concentration in PTM. It 
may be possible to describe the transport, cellular uptake, and elimination of HIV in a 
similar fashion as in Equation A.1. However, experimental determination of rate 
constants will be more difficult to obtain and results from microscopic simulations will 
be required. Effective diffusivities of HIV in tissues have been estimated experimentally 
by methods previously described [6]. Furthermore, molecular dynamics studies will 
enable us to assess if the effective diffusivity assumption is valid. It may be determined 
that position-dependent diffusivities need be used to properly describe the bulk motion of 
ARV and virus. If so, these quantities will be estimated from microscopic simulations. 
 
A.7 Outer Model Boundaries 
 There will be several types of outer model boundaries employed. The pelvic floor 
will likely be modeled as an impermeable boundary, although the introitus to the vaginal 
canal will be modeled as an outflow boundary. Some modeling and experiment will need 
to be performed to determine the nature of the outer radial boundary. If MALDI imaging 
and initial model estimates reveal that drug concentrations at a certain depth into the 





from the tract. In analytically approximating one-dimensional steady-state vaginal 
delivery, Saltzman imposed a semi-infinite boundary condition, which is an equivalent 
approach [7]. 
 
A.8 Conversion of TFV Prodrugs and Formation of TFV-DP 
 Effective rates of conversion for TFV prodrugs (e.g. TDF) to TFV can be 
estimated from published data [8]. This will result in a system of equations for 
simultaneous transport of the two compounds. The system for TDF transport in the 
lamina propria is shown as an example in Equation A.6a and A.6b. We propose that the 
relatively small amounts of the active TFV metabolite, TFV diphosphate (TFV-DP), 
formed in cells will not affect bulk transport of either TFV or its prodrugs. Thus, the 
average intracellular concentration of TFV-DP at any point can be estimated by probing 
the model as in Equation A.7 where keq are the effective equilibrium constants estimated 
from cell culture experiments. The cellular scale multicomponent mass transfer of the 
prodrug/TFV/TFV-DP system can be modeled in detail in one or more microscopic 
simulations, results of which will be used to determine the appropriateness of applying 
Equation A.7 at the continuum-scale. 
 
A.9 Experimental Model Validation and Further Study 
 Solutions to 3D concentration profiles for drugs and virions from models outlined 
above will be compared to data obtained from tissue sections and MALDI experiments. 
This comparison will provide an opportunity to assess the sensitivity of model outputs to 
the biological variability of various physiological parameters and to assess the physical 





validation are successful, the effects of varying ARV dose regimen, drug properties, and 
biological variability can be further studied in silico. PTM finite element models could 
also be reconstructed at the human scale to enhance the clinical relevance of this work. 
 
A.10 Expected Outcomes and Potential Pitfalls 
 Upon completion of this work, we expect to construct a mathematical model 
capable of quantitatively describing experimental vaginal drug and virus distribution 
data. If experimental validation is successful, we will be able to estimate the ARV release 
rates necessary to achieve protective ARV concentrations where HIV and CD4+ cells are 
present. There will likely be high variability in the in vivo data, the range of which may 
have a large impact on model predictions that may limit the utility of the integrated 
model. In equilibrium constants proposed for TFV-DP formation are embedded cell 
volume fractions, cellular uptake equilibria, and intracellular phosphorylation rates. If, 
through comparison of microscopic and continuum-scale modeling, as well as 
experimental data, this is found not to be a representative approximation of TFV-DP 
formation, we can further expand this part of the model. This may include a 
representation of distinct cellular structures and ARV uptake rates in the continuum 
model to replace the basic representation of the tissue as a spatially averaged 
homogeneous medium. We will likely find that cycle phase is important in drug and virus 
transport and drug metabolism. Our data will allow us to construct simulations 
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Figure A.1: Distribution of model drug (A) and virus (B) that arise from molecular 
dynamics simulations of a source (upper part of slab) and a model tissue. Molecular 

















Figure A.2: Continuum model for tenofovir. Compartmental description of continuum-
scale mass transport in the vaginal epithelium. Shown is a generic linear transport PDE 
(A.1) describing convection, diffusion, chemical reactions, and elimination, along with 
reduced forms for the vaginal fluid/mucus (A.2), vaginal epithelium (A.3), and lamina 
propria (A.4). (A.5) is a simple mass balance argument for the blood compartment 
following steady state administration. TDF conversion to TFV during transport can be 
modeled by a coupled system of PDEs (A.6) (an example is shown for the lamina propria 
compartment). An equilibrium assumption (A.7) may be used to probe the model at any 
point in space-time to estimate average TFV-DP concentration in tissue.  
